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Characterisation of a Novel Leukocyte Receptor Complex-encoded
Receptor TARM1
Valeria Radjabova
Cellular immune responses are orchestrated by an intricate balance of activating and
inhibitory signals transmitted by cell surface receptors. Perturbations in this balance by
overamplified or dysregulated signalling underlie many severe immunopathologies such
as sepsis and cancer. In this work I describe the identification and characterisation of
a novel, evolutionarily conserved immunoreceptor encoded within the human leukocyte
receptor complex and syntenic region of mouse chromosome 7, named T cell–interacting,
activating receptor on myeloid cells-1 (TARM1). The transmembrane region of TARM1
contained a conserved arginine residue, consistent with association with a signalling
adaptor. Co-immunoprecipitation experiments confirmed that TARM1 associated with
the ITAM adaptor FcRγ but not with DAP10 or DAP12. Flow cytometric screening of
cells and tissues from pathogen-free mice showed that the TARM1 protein was constitu-
tively expressed on the cell surface of mature and immature CD11b+Gr-1+ neutrophils
isolated from bone marrow but not at peripheral sites. Following ip LPS treatment
or systemic bacterial challenge, TARM1 protein expression was upregulated by myelo-
cytes, mature neutrophils and inflammatory monocytes and TARM1+ cells were rapidly
recruited to sites of inflammation. TARM1 expression was also upregulated by bone
marrow–derived macrophages and dendritic cells following stimulation with TLR ago-
nists in vitro. Ligation of the TARM1 receptor with specific antibody in the presence
of TLR ligands, such as LPS, enhanced the secretion of proinflammatory cytokines by
bone marrow–derived macrophages and primary mouse neutrophils, whereas TARM1
stimulation alone had no effect. Finally, an immobilised TARM1 Fc fusion protein sup-
pressed CD4+ T cell activation and proliferation in vitro. These results suggest that
a putative T cell ligand can interact with TARM1 receptor, resulting in bidirectional
signalling and raising the T cell activation threshold while costimulating the release of
proinflammatory cytokines by macrophages and neutrophils.
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Research aims
Previous work by Dr. Alex Barrow and Dr. Bernard de Bono resulted in the identifica-
tion of the TARM1 gene, a novel member of IgSF encoded within the human LRC. I set
out to perform a complete characterisation of TARM1 including genomics, phylogenetics
and protein function. The work pursued the following aspects of TARM1 biology.
• Genomics of TARM1 The starting step was to perform an extensive bioinfor-
matic study of TARM1 gene structure and expression using databases of expressed
sequence tags and to establish a predicted amino-acid sequence of the full-length
protein.
• Phylogenetics of TARM1 It was of interest to elucidate the phylogenetic rela-
tionship of the predicted TARM1 DNA and amino-acid sequences to other mem-
bers of IgSF within the LRC of the mouse and human as well as to establish
whether TARM1 is present in the genomes of other species.
• Expression of TARM1 mRNA in cells and tissues The next step was to
identify the cells and tissues with constitutive and/or inducible TARM1 gene ex-
pression and to validate the predicted TARM1 DNA sequence.
• Generation of soluble TARM1 Fc proteins and the development of mon-
oclonal anti-TARM1 antibodies Once the full-length transcripts of the human
and mouse TARM1 were identified, it was necessary to develop monoclonal anti-
bodies to enable the study of TARM1 protein. I generated secreted human and
mouse TARM1 Fc fusion proteins to serve as immunogens. Several cell lines ex-
pressing full-length FLAG- or HA-tagged TARM1 protein were also established to
facilitate further biochemical analysis.
xix
Research aims
• Biochemical analysis of TARM1 protein I investigated the glycosylation sta-
tus of human and mouse TARM1 proteins as well as their ability to associate with
signalling adaptor molecules DAP10, DAP12 and the FcRγ.
• Characterisation of TARM1 protein expression in vivo during inflam-
matory responses. Based on the finding that TARM1 expression was induced
by TLR signalling, I characterised the expression of TARM1 in mice during LPS-
induced inflammatory response and during infection with live Salmonella typhimurim.
• Characterisation of TARM1 protein function In the final chapter I addressed
the question of whether TARM1 protein could function as a bona fide receptor ei-
ther by signalling through as yet unidentified ligand or by transducing intracellular
signals that modulate the function of TARM1-expressing cells. I generated 2B4-
TARM1-CD3ζ-NFAT-GFP reporter cell lines to screen for TARM1 ligand. I also
used TARM1 Fc fusion protein to study the effects of TARM1 ectodomain on
activation and proliferation of primary T cells. And established whether TARM1-




Cellular function, in particular that of immune cells, is tightly controlled through the
integration of signals from a large array of cell surface receptors. Therefore, the search
for and characterisation of as yet unidentified immune receptors encoded within our
genomes is a prerequisite for understanding immune cell function and genetic diseases.
The present work adds a new member to the growing family of immune regulators
belonging to the Immunoglobulin Superfamily (IgSF).
The IgSF is the largest and most functionally diverse protein family in the human
genome. Ancestral genes for IgSF proteins existed more than 300 million years ago,
before the divergence of birds and mammals. The evolution of the Ig-like fold can be
traced back all the way to nematodes, as evidenced by the presence of large number of
IgSF members (80 validated) in C. elegans (Vogel, Teichmann, and Chothia 2003) and
in every multicellular eukaryote studied to date.
The majority of IgSF proteins are cell surface receptors with diverse tissue and cellular
distributions, although secreted forms such as immunoglobulins, β2m and a number of
other soluble molecules represent rare exceptions. Despite their functional diversity, the
common feature of all IgSF members is the presence of at least one or more structurally
conserved Ig-like fold in their extracellular domains.
1
2 Chapter 1. Introduction
1.1 IgSF domain structure
The signature domain of the IgSF proteins, the Ig-like fold, is formed by approximately
one hundred amino acid residues arranged into two anti-parallel amphipathic β-sheets,
whose hydrophobic sides face each other. This arrangement is often stabilised by a
disulphide bond between two conserved cysteines in the centre of each β-sheet. The
stretches of amino acids joining the two β-sheets are not structurally constrained and
loop outward which allows them to accommodate a high variety of sequence composi-
tions. These intervening loops are the main sites that determine ligand specificity and
allow for a large ligand diversity of IgSF proteins without compromising their conserved
structural domains (A. Williams and Barclay 1988).
Although the emergence of the Ig fold long predates the evolutionary events that gave
rise to its role in the adaptive immune system of jawed vertebrates (Agrawal, East-
man, and Schatz 1998), the IgSF domains are classified into four distinct sets based on
their structural similarity to the immunoglobulin constant and variable domains. Thus,
the IgSF fold where the number of the β strands and their relative position resemble
immunoglobulin variable or constant region is termed the V-set, the C1 or C2-set, re-
spectively. An intermediate structure between the V-set and the C-set is termed the
I-set and is suggested to represent the ancestral Ig domain family (A. Williams and
Barclay 1988; Harpaz, Chothia, et al. 1994).
Domains from the same set are more phylogenetically and structurally related to each
other than to members of a different set (Teichmann and Chothia 2000) and form distinct
clades on a phylogenetic tree. Different sets are variously represented among organisms,
with the I-set being the most prevalent in lower organisms (Harpaz, Chothia, et al.
1994). C and V-sets dominate the structural repertoire of immune receptors in higher
vertebrates.
The next section discusses the evolutionary origin of the LRC and describes the IgSF
members comprising the human LRC.
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1.2 Signaling by immune receptors through tyrosine-based
activation, inhibition and switch motifs ITAMs, ITIMs
and ITSMs.
The initiation and resolution of immune responses are orchestrated through a complex
interplay between activating and inhibitory signals transmitted by an array of cell sur-
face receptors. The immune system has co-opted a large number of such cell surface
receptors belonging to the IgSF. Two distinct, evolutionarily conserved signalling motifs
encoded within the cytoplasmic domains of many of these receptors are responsible for
the initiation of inhibitory or activating signalling cascades.
The inhibitory class of immune cell receptors contains long cytoplasmic domains bearing
one or more immunoreceptor tyrosine-based inhibition motifs (ITIM) with a consensus
sequence defined as I/V/L/SxYxxL/V (where x denotes any amino acid) (Ravetch and
Lewis L Lanier 2000). Ligand engagement of ITIM-bearing receptors results in tyrosine
phosphorylation of the ITIM by Src kinase. Phosphorylated ITIM sequences are the
docking sites for SH2 domain-containing lipid or protein-tyrosine phosphatases (PTPs)
such as SHP-1 (Src homology region 2 domain-containing phosphatase 1), SHP-2, or the
inositol-5’-phosphatase SHIP.
ITIM-recruited phosphatases SHP-1 or SHP-2 dephosphorylate key signalling compo-
nents of activating receptors positioned in close proximity to the inhibitory ITIM-
containing receptor leading to the dampening of cellular responses (Ravetch and Lewis
L Lanier 2000). SHIP acts by translocating to the cell membrane and hydrolysing the
phosphatidylinositol-3-kinase (PI3K)-generated second messenger PI-3,4,5-P3 (PIP3) to
PI-3,4-P2 (PIP2) resulting in the suppression of cell proliferation and survival (Sly et al.
2007).
Immunoreceptor tyrosine-based switch motif (ITSM) is an ITIM-like motif with the
consensus sequence TxYxxV/I (where x denotes any amino acid) that can mediate both
inhibitory and activating signals depending on the associated signalling components
(Cannons, Tangye, and Schwartzberg 2011). It was initially characterised in cell-surface
receptors belonging to the signalling lymphocyte activation molecule family (SLAMF)
with a broad expression in immune cells. Each member of the family contains one or
more ITSM motifs in the cytoplasmic domain, which, when phosphorylated in humans,
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serve as docking sites for SH2 domain-containing small adaptor molecules SAP and
EAT-2 and enzymes such as Src-related protein tyrosine kinase (PTK), phosphatases
SHP-2, SHP-1, SHIP and the inhibitory kinase Csk (Latour et al. 2003; Chemnitz et al.
2004; Feng, Garrity, et al. 2005; Eissmann et al. 2005).
2B4, a SLAM family member, is expressed on T cells and NK cells and contains four
consecutive ITSMs in its cytoplasmic tail. Ligation of 2B4 on NK cell leads to the phos-
phorylation of tyrosines within ITSMs and the recruitment of SAP adaptor that initiates
an activating signalling cascade resulting in triggering of cytolytic activity and cytokine
release. However, in the absence of SAP, as seen in patients suffering from X-linked
lymphoproliferative disease, the phosphorylated ITSMs recruit the inositol phosphatase
SHIP-1, which inhibits signalling by activating ITAM adaptor-associated receptors (Eiss-
mann et al. 2005).
The ITSM motifs have been identified in other receptors such as programmed death
1 (PD-1), a critical co-inhibitory receptor on T cells. The cytoplasmic tail of PD-
1 contains an ITIM followed by a single ITSM (Chemnitz et al. 2004). ITIM and
ITSM were shown to perform distinct but overlapping functions in PD-1 signalling.
Mutagenesis of the tyrosines in these motifs indicated that ITSM is indespensable for
PD-1 mediated inhibition of T cell activation (Sheppard et al. 2004; Chemnitz et al.
2004). PD-1 engagement leads to ITSM tyrosine phosphorylation and the recruitment
of phosphatases SHP-1 or SHP-2 enabling the receptor to signal in an inhibitory manner
(Chemnitz et al. 2004).
As opposed to the inhibitory receptors whose signalling motif-containing domain is lo-
cated on the same polypeptide as the ligand-binding domain, the activating receptors
usually have a modular architecture where several protein subunits with distinct roles
are associated non-covalently into a functional receptor. The ligand-binding subunits
have short cytoplasmic portions and are incapable of independent signal transduction.
Instead, they encode a charged amino acid in the transmembrane (TM) domain, usually
an arginine or a lysine, that facilitates the association with a dimeric signalling sub-
unit of the receptor via a complementary charged TM residue. The signalling subunits
contain a cytoplasmic Immunoreceptor Tyrosine-based Activation Motif (ITAM).
Two main ITAM-bearing adaptors, the FcεR common γ chain (FcRγ) and the DNAX
activation protein 12 (DAP12) are shared by numerous immunoreceptors expressed on
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NK and myeloid cells. Signalling cascades initiated by the ITAM motif have been studied
extensively since its identification by Reth et al. over two decades ago. ITAM sequences
contain two conserved tyrosines according to the consensus YxxL/I-(x)6-8-YxxL/I (where
x represents any residue) (Reth 1989) where the tyrosines are phosphorylated by Src
family kinases upon the engagement of the ligand-binding subunit. The phosphorylated
tyrosines become a docking site for a number of kinases which initiate an activating
cascade culminating in, among others, calcium flux and the activation of transcription
factor NF-κB (J. A. Hamerman and Lewis L Lanier 2006).
The paradigm of ITAM as a transducer of activating signals originated from studies of
ITAM signalling properties in the context of high-avidity antibody cross-linking of the
associated antigen receptors. Under these conditions a strong induction of the NF-κB
and MAP kinases leading to cell activation was observed. Mounting evidence suggests,
however, that the functional outcome of ITAM mediated signalling is strongly influenced
by the cellular and molecular context and can result in either activation or inhibition of
cellular responses as discussed below.
This functional ITAM heterogeneity provides an explanation for the behaviour of the
IgA. The IgA receptor FcαRI associates with an ITAM-bearing adaptor FcRγ and can
elicit cellular activation but can also suppresses cytokine secretion (Wolf et al. 1994)
and signalling by a variety of activating receptors such as TLRs, cytokine receptors and
TNF receptors (Pasquier et al. 2005; Kanamaru et al. 2008). Ligation of the FcαRI
by a monomeric IgA in the absence of an antigen or by an anti-FcαRI Fab delivers an
inhibitory signal and can attenuate a plethora of cellular functions such as phagocytosis,
oxidative burst and cytokine secretion (Nikolova and Russell 1995; Pasquier et al. 2005;
Kanamaru et al. 2008). Conversely, co-aggregation of FcαRI by multimeric IgA immune
complexes initiates an activating signalling cascade (Kanamaru et al. 2008; Pasquier
et al. 2005).
Bifunctional signalling is also described for a number of DAP12-associated receptors.
DAP12 was initially identified as a signalling subunit of several activating NK cell re-
ceptors in humans and mice (Lewis L Lanier et al. 1998; K. M. Smith et al. 1998).
Several recent studies described DAP12 associated receptors including triggering recep-
tor expressed on myeloid cells (TREM)-2 (J. Hamerman et al. 2006; Turnbull et al.
2006), NKp44 (Fuchs et al. 2005) and Siglec-H (Blasius et al. 2006) where DAP12 was
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involved in an inhibitory pathway and where the absence of DAP12 led to enhanced
cellular responses to TLR ligands (J. A. Hamerman, Tchao, et al. 2005).
For example, ligation of Siglec-H, a sialic acid-binding Ig-like lectin, expressed on in-
terferon producing cells (IPCs), was shown to reduce IFN-α secretion in response to
TLR9 agonist (Blasius et al. 2006). A similar outcome was shown for NKp44 ligation
on IPCs. NKp44, an IgSF member, that was originally identified on human activated
NK cells, where it triggered the release of IFN-γ and cytotoxicity against tumour and
virus-infected cells (Vitale et al. 1998; Arnon et al. 2001), was shown to suppress TLR9
signalling and production of IFN-α (Fuchs et al. 2005). Macrophage activation by TLR
ligation can be inhibited by DAP-12 associated TREM-2. Macrophages in which TREM-
2 was knocked down with shRNA construct secreted more TNF in response to TLR
ligands (J. Hamerman et al. 2006). This phenotype is reproduced in DAP-12 deficient
macrophages that produce higher concentrations of proinflammatory cytokines TNF, IL-
6 and IL-12 p40 in response to TLR stimulation than wild type cells (J. A. Hamerman,
Tchao, et al. 2005).
The signalling dichotomy of the ITAM motif led to the adoption of the term inhibitory
ITAM (ITAMi).
1.2.1 Inhibitory ITAM
The molecular mechanism responsible for the dual action of ITAMs is only beginning
to be unravelled. In the classical model of ITAM signalling, the dually phosphorylated
tyrosines in the ITAM recruit kinases spleen tyrosine kinase (Syk) and/or Zap-70 which
bind doubly phosphorylated ITAMs through their tandem SH2 domains, leading to
cellular activation (J. A. Hamerman and Lewis L Lanier 2006). However, suboptimal
activation of ITAM adaptor as in the case of monovalent antibodies and low-avidity
ligands results in an inhibitory ITAM signalling (Pasquier et al. 2005; Kanamaru et al.
2008).
The study of the FcαRI inhibitory signalling revealed that a suboptimal receptor liga-
tion, with either monovalent IgA or an anti-FcαRI Fab, results in ITAM phosphorylation
on one of the two tyrosines and leads to the preferential recruitment of SHP-1 phos-
phatase instead of Syk (Kanamaru et al. 2008; Ganesan et al. 2003; Pfirsch-Maisonnas
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et al. 2011). Syk is nevertheless important in the inhibitory signalling pathway as demon-
strated in Syk deficient macrophages. In the absence of Syk macrophages exhibit identi-
cal phenotype to DAP-12 deficiency and are more sensitive to activation by TLR ligation
(J. A. Hamerman, Tchao, et al. 2005).
In addition to FcαRI, TREM2, NKp44 and Siglec-H, ITAMi is described for a large
number of immunoreceptors among which are FcγRIII (Da Silva et al. 2007), LILRA
(D. J. Lee et al. 2007), ILT7 (Cao et al. 2006), MHC class II (Liang et al. 2008) and
others, that will act as inhibitors of cellular activation in certain contexts.
It was also found that pathogens such as E. coli can exploit ITAMi to achieve immune
evasion during infection. For example, non-opsonised E. coli can evade phagocytosis
through macrophage class A scavenger receptor MARCO by binding with low avidity
to the FcγRIII. Under these conditions, the tyrosines in the FcγRIII associated ITAM
adaptor Fcγ are not fully phosphorylated which leads to a strong recruitment of the
phosphatase SHP1. In turn, SHP1 proceeds to dephosphorylate downstream signalling
mediators such as PI3 kinase and inhibits phagocytosis (Da Silva et al. 2007).
1.3 Regulation of T cell responses
T cell populations act both as powerful effectors of immune function and as a safeguard
against inappropriate immune activation thus ensuring tolerance. Maintenance of this
balance is the result of a delicate interplay between a plethora of co-stimulatory and
co-inhibitory signals transduced by T cell receptors. Continuous integration of these
signals determines the functional outcome of T cell responses.
This section reviews the immunoregulatory mechanisms that shape T cell function and
fate during immune homeostasis and disease.
1.3.1 Families of T cell co-signalling IgSF molecules
Our understanding of T cell activation originates from the early findings that led to the
development of a two-signal model of B and T cell activation (Lafferty and Cunningham
1975). The first signal in the T cell activation requires the engagement of the T cell
receptor (TCR) by a specific ligand-bound MHC. This interaction is highly sensitive and
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requires only a few MHC molecules (Sykulev et al. 1996). The second signal, delivered
by a co-stimulatory receptor, is required for a productive initiation of T cell responses.
CD28 was identified as one of the most effective constitutively expressed co-stimulatory
receptors on T cells. Engagement of CD28 by its ligands B7-1 (CD80) or B7-2 (CD86)
expressed on antigen presenting cells (APCs) simultaneously with TCR engagement
provides the necessary second stimulus. In the absence of CD28 ligation, T cells enter
a state of anergy characterised by hyporesponsiveness to subsequent activating stimuli
or undergo apoptosis (Harding, Gross, et al. 1992). As our understanding of T cell
regulation is improving and more co-signalling receptors are being characterised, the
two-signal paradigm of B7-CD28 is being expanded.
A majority of co-signalling receptors characterised to date belong to the IgSF and tu-
mour necrosis factor receptor families. Within the IgSF, several subfamilies have been
identified. The most well-characterised are the CD28 and B7 families. With some excep-
tions, B7 related receptors interact with receptors related to CD28. Exceptions include
the receptor B and T lymphocyte attenuator (BTLA), a negative regulator of lympho-
cytes that interacts with a member of the tumour necrosis factor receptor family and
herpes virus entry mediator (HVEM) (Sedy et al. 2005). HVEM has a broad expression
pattern and is present on T cells. Although numerous studies implicated HVEM as a co-
stimulatory molecule, T cells isolated from HVEM deficient animals are hyper-reactive
to activating stimuli and the animals are more susceptible to autoimmune conditions
(Yang Wang et al. 2005). Recently, the interaction of HVEM on T cells with BTLA-
expressing DCs was shown to drive the conversion to Foxp3+ T regulatory cells and the
establishment of tolerance (A. Jones et al. 2016).
Butyrophilin (BTN) and BTN-like (BTNL) family molecules resemble B7 family mem-
bers in their extracellular domains and carry a B30.2 domain in the cytoplasmic tails.
BTN and BTNL proteins have a complex tissue and cell expression patterns and their
function and the mechanism of action are only beginning to be understood. In vitro
assays have demonstrated that some BTN proteins inhibit T cell activation and prolif-
eration via an unidentified ligand on T cells (I. A. Smith et al. 2010). The isoforms of
BTN3 have been shown to play a critical role in the activation of γδ TCR by phospho-
antigens via a novel antigen presentation mechanism (Vavassori et al. 2013; Sandstrom
et al. 2014).
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Inducible co-stimulator (ICOS) is another important co-stimulating member of IgSF
related to CD28 (Hutloff et al. 1999). As the name indicates, ICOS expression is induced
on the surface of CD4 and CD8 T cells following antigen-specific TCR signalling and/or
CD28 co-stimulation (Hutloff et al. 1999). Similarly to its homologue CD28, ICOS binds
to a B7-like ligand expressed predominantly by B cells, macrophages and DCs but also
by some endothelial cells (Yoshinaga et al. 1999; Aicher et al. 2000; Khayyamian et al.
2002). Early studies in ICOS and ICOS ligand (ICOSL) deficient mice indicated that
ICOS is involved in thymus dependent antibody responses and regulates various T helper
cell subsets in the context of infection, mainly by promoting or inhibiting Th1 and Th2
responses. More recently, ICOS signalling was found to play a role in controlling the
responses of germinal centres by directing functional differentiation and maintenance of
follicular helper T cells and follicular regulatory T cells (Leavenworth et al. 2015).
One of the most critical and well-studied negative co-regulators of T cells is CTLA-4.
CTLA-4 expression is upregulated on conventional T cells following activation, where it
competes with CD28 for binding to CD80 and CD86 on APCs. This interaction leads
to inhibition of T cell activation and safeguards against T cell hyperactivation (Walunas
et al. 1994). The critical role of CTLA-4 in maintaining T cell homeostasis is illustrated
by the fact that a genetic disruption resulting in the loss of CTLA-4 expression is fatal
within weeks after birth due to a severe autoimmune organ failure (Tivol et al. 1995).
PD-1 is another important co-inhibitory receptor that regulates the balance between
T cell activation and tolerance (Keir et al. 2008). PD-1 is a member of the IgSF and
contains an ITIM and ITSM in its intracellular domain. PD-1 expression is not detected
on resting T cells but can be induced by TCR ligation and T cell activation. PD-1
ligands, PD-L1 and PD-L2 are related to the B7 family members and are expressed on
lymphoid and nonlymphoid tissue. PD-L1 expression is observed on activated T cells
and there is evidence for a bi-directional signalling for PD-L1. T cell expressed PD-
L1 has been shown to bind B7-1 (CD80) with affinity intermediate to B7-1 interaction
with CTLA-4 and CD28. B7-1/PD-L1 binding inhibits T cell activation and cytokine
secretion (Butte et al. 2007).
ITMS of PD-1 can associate with both SHP-1 and SHP-2 following T cell stimulation,
although, the ligation of PD-1 by its ligand favours the recruitment of SHP-2 (Chemnitz
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et al. 2004). During TCR engagement by an APC, PD-1 accumulates at the immuno-
logical synapse (Pentcheva-Hoang et al. 2007). Engagement of PD-1 in proximity to
the antigen receptor complex and the recruitment of SHP-2 results in the preferential
dephosphorylation of the CD28 (Hui et al. 2017; Kamphorst et al. 2017) and potentially
TCR (Bennett et al. 2003; Sheppard et al. 2004) signalling intermediates. The effective-
ness of PD-1 mediated inhibition is inversely related to the extent of T cell activation
and can be overcome by CD28 engagement or high exogenous IL-2 (Bennett et al. 2003).
PD-1 and CTLA-4 inhibit T cell activation through distinct and potentially synergis-
tic pathways. CTLA-4 acts primarily at the very early stages of T cell activation and
regulates the magnitude of the response by competing with the co-stimulatory CD28
molecule and by transducing an inhibitory signal to the T cell. PD-1 regulates ongoing
immune responses and is responsible for T cell exhaustion during chronic viral infections
(Kaufmann and Walker 2009) and in the tumour microenvironment (R. H. Thompson et
al. 2007). High levels of PD-L1 expression are seen on a variety of tumours and on many
tumour-associated APCs and T cells. PD-L1 expression is induced and maintained by
a number of pro-inflammatory cytokines. It is thought that tumour-associated effector
T cell-derived IFN-γ is partially responsible for high expression levels of PD-L1 in this
setting, which contributes to the establishment of an immunosuppressive microenviron-
ment and tumour immune-evasion (Curiel et al. 2003; Ghebeh et al. 2006; Kuang, Zhao,
Peng, et al. 2009; Taube et al. 2012). PD-1/PD-L1 pathway blockage has shown varied
success in reversing tumour immune-suppression in a number of clinical trials and a
variety of solid and hematologic malignancies. Current clinical data indicates that PD-
1 pathway blockade resulted in significant antitumor activity in patients with, among
others, advanced melanoma and metastatic bladder cancer (Hamid et al. 2013; Powles
et al. 2014).
Many T cell co-regulatory receptors have been identified in recent years. As our knowl-
edge and understanding of the complexity of their interplay increases, every receptor
with immunomodulatory function may represent a potential target for therapeutic in-
tervention.
Besides adaptive immune cells, such as T- and B-lymphocytes, coactivating and coin-
hibitory IgSF receptors are expressed on innate cells e.g. monocytes, macrophages,
neutrophils and dendritic cells, innate lymphoid cells (ILCs), Natural Killer cells, and
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Figure 1.1: Human LRC located on chromosome 19q13.4
even on non-classical immune cells, such as platelets and osteoclasts, where they are
predicted to play critical immunoregulatory roles during tissue homeostasis and disease.
Many of such coactivating and coinhibitory receptors that typify this broad expression
profile on innate and adaptive immune cells are encoded in a large conserved cluster
present in all mammalian genomes termed the leucocyte receptor complex (LRC). The
LRC is particularly important since many of the receptors encoded within this region
recognise MHC class I molecules strongly associated with disease. This region also
contains other IgSF members critical for osteoclastogenesis (e. g. OSCAR) and platelet
function (e. g. GPVI).
1.4 The LRC and its genes
In humans, the LRC is located on chromosome 19q13.4 (Fig. 1.1). A number of key
findings point to the origin of the LRC in the distant evolutionary past, before the
divergence of mammalian and avian lineages. Syntenic LRC regions have been iden-
tified in every mammalian genome studied so far, with many LRC-encoded genes well
conserved across species. The notion of a single evolutionary origin of the LRC genes
is also supported by the identification of a number of homologous Ig-like sequences in
chickens (Dennis, Kubagawa, and Cooper 2000; Nikolaidis, J. Klein, and M. Nei 2005),
amphibians (Guselnikov et al. 2010) and teleosts (Stafford et al. 2006; Yoder et al. 2001).
The LRC region in humans spans roughly 1Mb of genomic DNA and, until recently,
the boundaries for the canonical LRC region were set at osteoclast-associated receptor
(OSCAR) on the centromeric side and glycoprotein VI (GPVI) on the telomeric side.
The work in our group and by Steevels et al (Steevels, Lebbink, et al. 2010) led to the
identification and characterisation of additional genes encoding Ig-like receptorsTARM1
and SIRL-1 located at the centromeric side of the LRC adjacent and related to OSCAR.
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These genes mark the new centromeric boundary of and are likely the last remaining
Ig-like immunoreceptors in the LRC.
1.4.1 OSCAR
OSCAR is a key costimulatory receptor expressed on osteoclasts where it regulates
osteoclastogenesis in human and mouse (A. Barrow, N. Raynal, et al. 2011). In mouse
OSCAR expression is restricted to osteoclasts, in human, OSCAR is also expressed on
monocytes, macrophages, neutrophils and dendritic cells where it plays a role in innate
immune responses by supporting cell activation and differentiation, antigen presentation
and the release of pro-inflammatory mediators (Merck, Gaillard, Scuiller, et al. 2006;
Merck, Gaillard, Gorman, et al. 2004).
The function of OSCAR on monocytes has been addressed by several groups showing
that ligation of OSCAR by cross-linking antibodies promoted cell survival and induced
the release of multiple chemokines, while cross-linking of OSCAR in conjunction with
TLR stimulation, enhanced the secretion of TLR-induced proinflammatory cytokines
(Merck, Gaillard, Scuiller, et al. 2006). Barrow et al. demonstrated that collagens
(Col) I, II and III (A. Barrow, N. Raynal, et al. 2011) and the collagenous protein
Surfactant Protein D (SP-D)(A. D. Barrow et al. 2015) are the physiological ligands for
OSCAR. In vitro treatment of human peripheral blood monocytes or monocyte-derived
DCs with ColII promoted their survival in the absence of growth factors and the effect
was dependent on OSCAR signalling (Schultz, Nitze, et al. 2015; Schultz, L. Guo, et
al. 2016). OSCAR-ColII interaction on monocytes induced upregulation of activation
markers and secretion of 14 proinflammatory mediators including TNF-α, IL-8, IL-1β
and MIP-1α (Schultz, L. Guo, et al. 2016). OSCAR-Col interaction has been implicated
in the pathogenesis of rheumatoid arthritis (RA). Fragments of ColII are present in
the synovial fluid of RA patients with ongoing disease. Monocytes of these patients
express elevated levels of OSCAR, have activated phenotype and infiltrate the synovium
inflamed joints. Schultz et al. hypothesize that OSCAR signalling on monocytes may
contribute to the sustained inflammation and joint damage in RA patients (Schultz,
L. Guo, et al. 2016). Barrow et al. also showed that OSCAR is expressed on the cell
surface of inflammatory interstitial lung and blood CCR2+ monocytes from patients with
chronic obstructive pulmonary disease. Engagement of OSCAR on these cells by SP-D,
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a secreted product of alveolar epithelial cells, induced TNF-α release (A. D. Barrow
et al. 2015).
Telomeric to OSCAR is the Leukocyte Ig-Like Receptors (LILR) comprised of 13 mem-
bers, that, due to an inverted duplication (Wende, Volz, and Ziegler 2000), are separated
into two clusters flanking the Leukocyte-Associated Ig-like Receptors (LAIR)-1 and -2,
LENG (an unrelated, non IgSF encoding gene) and the KIR3DX1 gene.
1.4.2 LILRs
LILRs are expressed on the surface of cells in the lymphoid and myelomonocytic lin-
eages. Ligation of these receptors has been shown to have profound immunomodulatory
effects such as regulation of classical and non-classical HLA class I (Marco Colonna,
Navarro, et al. 1997; Allan et al. 1999; Lepin et al. 2000; Navarro et al. 1999; Shiroishi,
Tsumoto, et al. 2003; Marco Colonna, Samaridis, et al. 1998). LILRs are grouped into
two functional categories; the inhibitory receptors, termed LILRB, and the activating
variants, denoted LILRA. The importance of LILR immunomodulatory capacity came
to prominence when Chang et al. demonstrated that LILRB2 and LILRB3 lie at the
heart of DC functional plasticity by providing the inhibitory signalling necessary for the
acquisition of tolerogenic properties by immature DCs(C.-C. Chang et al. 2002).
Moreover, the activating LILRA1 was shown to bind to a β2m-free HLA-B27 allele,
while the inhibitory LILRB2 can engage both the unfolded, β2m-free HLA-B27 and the
non-classical HLA-G (Shiroishi, Kuroki, et al. 2006; Allen, Raine, et al. 2001).
Classical HLA molecules are highly polymorphic and a recent comprehensive analysis
of LILR binding to over 90 HLA class I antigens demonstrated that the binding affinity
was strongly influenced by the HLA allelic variation (D. C. Jones et al. 2011). This
represents a significant finding as unfolded HLA is a hallmark of activated lymphocytes
(Schnabl et al. 1990; Allen, O’Callaghan, et al. 1999; Madrigal et al. 1991), thus certain
HLA genotypes may underlie the perturbations in the balance between the activating
and inhibitory LILR signalling and may influence disease outcomes. This scenario is
exemplified by recent findings pointing to an important role for LILRs in the progression
of HIV-1 infection. LILRB2 interaction with HLA in patients was found to correlate with
the ability of the immune system to control the virus (Lichterfeld and G. Y. Xu 2012;
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Bashirova et al. 2014). A recent study found a novel function for an orphan activating
receptor LILRA2. Hirayasu et al. showed that LILRA2 acts as innate immune receptor
that detects microbially cleaved immunoglobulins associated with bacterial infections
(Hirayasu et al. 2016).
1.4.3 Leukocyte-associated immunoglobulin-like receptor I and II
(LAIR-I and -II)
LAIR-I and -II are located in the middle of the LILR cluster and contain a single C2-
type Ig-like domain. The characterisation of LAIRs revealed a previously unrecognised
immunoregulatory mechanism effected through binding to collagen in the extracellular
matrix (Lebbink, Nicolas Raynal, et al. 2009) and to the collagenous C-type lectin
surfactant protein D (SP-D) present at mucosal surfaces where it is involved in host
defense against infections (Nordkamp et al. 2014). LAIR-I is an inhibitory receptor
constitutively expressed by the majority of peripheral blood mononuclear leukocytes
(Linde Meyaard, Adema, et al. 1997) and during early osteoclast development. LAIR-II
is its soluble counterpart that acts as a LAIR-I antagonist by competing for the collagen
binding sites (Lebbink, Berg, et al. 2008; L. Meyaard 2008).
Although the precise nature of LAIR-I mediated immune regulation in vivo remains
poorly defined, numerous studies using antibodies cross-linking LAIR-I showed its ability
to inhibit the function of many immune cells in vitro such as NK (Linde Meyaard,
Adema, et al. 1997), T cells (Maasho et al. 2005; Linde Meyaard, Hurenkamp, et al.
1999), plasmacytoid DC (Bonaccorsi et al. 2010) and the differentiation of hematopoietic
progenitors (Poggi et al. 1998).
For instance, heterogeneous expression of LAIR-I has been reported for T cells, where
naive T cells express the highest level. Crosslinking of LAIR-I on human peripheral blood
naive (Maasho et al. 2005) or cytotoxic T effector cells (Linde Meyaard, Hurenkamp,
et al. 1999) attenuates T cell function such as TCR signalling and cytotoxic responses
suggesting LAIR-I signalling may provide an important regulatory input during both
the very early T cell activation and later at the effector stage.
Similarly, LAIR-I, highly expressed on plasmacytoid dendritic cells, was found to inhibit
IFN-α production in response to TLR stimulation (Bonaccorsi et al. 2010).
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1.4.4 Killer cell immunoglobulin–like receptors (KIRs)
KIRs are a large family of highly polymorphic receptors that have been intensively stud-
ied over the past decades. KIRs are thought to represent a relatively recent evolutionary
development as no KIR homologues have as yet been identified in non-mammalian ver-
tebrates. The KIR receptors are expressed on natural killer (NK) cells and cytotoxic
T cells and have been implicated as major players in the regulation of a wide range
of cell functions, from anti-tumour activity to human reproduction (Parham and Mof-
fett 2013). KIRs exhibit a striking haplotype and gene copy number diversity as well
as a high degree of allelic polymorphism and have been shown to recognise HLA class
I molecules with each KIR exhibiting strong preference for a specific HLA-C allotype
(Yawata et al. 2008). Some KIRs containing three Ig-like domains bind certain HLA-A
and -B alleles (L. Moretta and A. Moretta 2004).
Binding of the inhibitory KIRs expressed by NK cells to cognate HLA class I ligands on
target cells safeguards against non-specific NK cell-mediated cytotoxicity against healthy
cells and is the fundamental principle behind missing self recognition. Many pathogenic
states are characterised by the downregulation of HLA class I expression on the cell
surface as seen during viral infections or cancer. This serves to relieve the inhibitory
signals normally conferred by the KIR receptors and primes NK cells for cytotoxic killing
of target cells. Several classes of stimulatory receptors expressed by NK cells can then
either recognise virally encoded epitopes or stress ligands expressed by diseased cells and
initiate NK cytotoxic responses (Raulet 2006).
KIR genes are comprised of two functional haplotype groups, A and B, and are present
in all human populations at varying frequencies. KIR A haplotypes encode alleles that
are strongly inhibitory in the presence of HLA-C2 and alleles that are weakly inhibitory
HLA-C1 receptors. In contrast, KIR B haplotypes encode weak inhibitory HLA-C2
receptors and strong inhibitory HLA-C1 receptors (Yawata et al. 2008). Numerous
studies have demonstrated that the different possible combinations of KIRs and HLA and
the high degree of polymorphism within both molecules is associated with susceptibility
or resistance to disease such as viral infections, autoimmunity and cancer (Purdy and
Campbell 2009). Moreover, the mismatch between the maternal KIR genotype and fetal
HLA-C has been shown to influence the risk of developing pre-eclampsia and affect the
reproductive success (Hiby et al. 2004).
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1.4.5 FcaR, NCR1 and GpVI
Telomeric to the KIR gene cluster are the Fc receptor for IgA (FCAR), the natural
cytotoxicity receptor (NCR1, also known as Nkp46 receptor in humans), and the platelet
collagen receptor, Glycoprotein VI (GpVI) (A. Barrow and J. Trowsdale 2008). NCR1 is
an activating member of the IgSF with two C2-type Ig-like domains in the extracellular
portion, a short cytoplasmic tail and a charged arginine in the transmembrane domain.
NCR1 is well-conserved in mammals and is expressed on the surface of all mature NK
cells where it mediates NK cytotoxic activity against target cells by recruiting ITAM-
bearing adaptors (Walzer et al. 2007).
GpVI is a major signalling receptor for collagen expressed by platelets (Kehrel et al.
1998). It is triggered by binding to collagen present in the exposed extracellular matrix
in the context of blood vessel injury. The interaction leads to a rapid platelet activa-
tion and the formation of platelet plug followed by coagulation cascade. Similarly to
other activating members of the LRC, GPVI recruits ITAM-bearing adaptor for signal
transduction (Nieswandt and Watson 2003).
1.4.6 SIRL-1
A new immune receptor, Signal Inhibitory Receptor on Leukocytes-1 (also known as
VSTM-1), was recently identified at the telomeric boundary of the LRC. SIRL-1 contains
a single Ig-like V-set domain and encodes two ITIMs in the cytoplasmic tail. Steevels
et al showed that it is highly expressed on human neutrophils and monocytes where
it plays a role in the negative regulation of cell functions such as oxidative burst and
release of neutrophil extracellular traps (NETs) (Steevels, Lebbink, et al. 2010; Steevels,
Avondt, et al. 2013; Van Avondt et al. 2013). Numerous recent findings suggest a role for
neutrophils in the regulation of adaptive immune responses and implicate dysregulation
of neutrophil function in a variety of autoimmune conditions such as Systemic lupus
erythematosus (SLE) (Lande et al. 2011). SLE is characterised by the presence of
antibodies to self-antigens such as double-stranded DNA. Abberant NET formation by
neutrophils is thought to contribute to the disease pathogenesis by exposing nuclear
DNA within the NETs to self-reactive B cells leading to production of autoantibodies
(Lande et al. 2011). Cross-linking of SIRL-1 on neutrophils from SLE patients was shown
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to inhibit NETs formation and can represent a target for therapeutic intervention in the
treatment SLE (Steevels, Lebbink, et al. 2010; Steevels, Avondt, et al. 2013; Van Avondt
et al. 2013).
1.5 Neutrophil-mediated immune regulation
Neutrophils have long been viewed as short-lived, terminally differentiated, innate ef-
fector cells specialised for antimicrobial responses. Evidence accumulated over the past
two decades puts into question this long-standing view and tells a new fascinating story
of this underappreciated cell type.
It is now clear that under certain conditions the neutrophil life-span is extended and new
neutrophil subsets are generated through hematopoietic proliferation or recruited from
the pool of tissue-resident neutrophils. These cells can then actively modulate innate
and adaptive immune responses by engaging in complex bi-directional interactions with
a variety of immune cells (Mantovani et al. 2011; Pelletier et al. 2010). Another aspect
that has recently emerged from studies of various immune pathologies is the presence
of heterogeneous neutrophil populations composed of mature and immature cells with
distinct, and often opposing, functions. It has proven extremely difficult to study this
heterogeneity due to the lack of unique markers that would define discrete neutrophil
subsets and their functions. The matter is further complicated by the fact that different
neutrophil populations emerge under different pathological states. It is, however, now
firmly accepted that neutrophils play an important role in conditions ranging from sepsis
and autoimmunity to cancer.
Neutrophil cross-talk with immune cells The ability of neutrophils to interact with
other immune cells, whether through cell-to-cell contact or through soluble mediators,
has been demonstrated in multiple studies of ex vivo cells. For instance, ex vivo culture
of human or murine neutrophils in the presence of IFN-γ, GM-CSF and IL-3 causes
neutrophils to acquire a DC-like phenotype, become less susceptible to apoptosis and to
be able to prime antigen-specific T cell responses (Brach, Gruss, Herrmann, et al. 1992;
Colotta et al. 1992; Gosselin et al. 1993; Fanger et al. 1997; Oehler et al. 1998). Other
studies show that even in the absence of exogenous cytokines, antigen-pulsed neutrophils
can present in an MHC II-dependent manner to antigen-specific T cells and induce their
18 Chapter 1. Introduction
polarisation towards a proinflammatory Th1 or Th17 phenotype (Abdallah et al. 2011;
Radsak et al. 2000).
In vivo, neutrophils were found to traffic antigens or live bacilli to draining lymph nodes
(Abadie et al. 2005; Chtanova et al. 2008) and cross-present to prime naive CD8+ T cells
(Tvinnereim, S. E. Hamilton, and Harty 2004; Beauvillain et al. 2007). Neutrophil-DC
cross-talk was shown to either enhance or inhibit the function and survival of both cell
types depending on the tissue localisation and the immune status. This interaction was
found to be mediated through direct cell contact (Gisbergen, Sanchez-Hernandez, et al.
2005; Gisbergen, Ludwig, et al. 2005) and/or through the release of immune mediators.
Activated neutrophils are known to release reactive oxygen species, cytokines, chemokines
and extracellular vesicles containing immunoregulatory factors that are chemotactic for
other immune cells and regulate their responses. For instance, in vitro stimulated neu-
trophils enhance DC maturation and their ability to stimulate T cell proliferation and
polarisation through the release of TNF-α and direct cell contact (Gisbergen, Sanchez-
Hernandez, et al. 2005; Gisbergen, Ludwig, et al. 2005). In co-culture, DCs upregulate
CD40, CD86 and HLA-DR and acquire antigens from live neutrophils in a cell-contact
dependent manner (Megiovanni et al. 2006). In vitro findings have been corroborated
in vivo where inflammatory sites in the colonic mucosa of Crohn’s disease patients were
found to contain neutrophils interacting with DCs (Gisbergen, Sanchez-Hernandez, et
al. 2005). Neutrophil-DC interactions have been implicated in the pathogenesis of other
autoimmune and inflammatory diseases such as SLE (Lande et al. 2011), RA (Khandpur
et al. 2013) and T1D (Diana et al. 2013). In the context of autoimmune conditions, ac-
tivated neutrophils were found to be more prone to undergo NETosis, a process whereby
neutrophils extrude large quantities of nuclear DNA bound to a variety of autoanti-
gens in the form of web-like structures called neutrophil extracellular traps (NETs).
This self-DNA-autoantigen complexes were found to activate plasmacytoid DC (pDC)
to produce type I interferons and to trigger aberrant adaptive immune responses, such
as activation of autoreactive B cells, culminating in the production of autoantibodies to
both the self-DNA and the autoantigen peptides present within the NETs (Lande et al.
2011; Khandpur et al. 2013).
Numerous studies have also demonstrated neutrophil-mediated regulation of other im-
mune cells. In recent years research interest has focused on the neutrophil-mediated
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regulation of T cells particularly during tumourigenesis and sepsis. Cytotoxic T cells
are the major effector cells in the anti-tumour immunity but are rendered non-functional
by the suppressive tumour microenvironment. In murine models of cancer and later in
human patients, neutrophils were shown to infiltrate the tumour mass, pre-metastatic
and metastatic tissues where they took an active part in either limiting tumour growth
through the release of soluble factors and by supporting anti-tumour immune responses
or promoting tumourigenesis by enhancing tumour-driven inflammation, angiogenesis
and contributing to T cell suppression (Tazzyman, Lewis, and Murdoch 2009; Fridlen-
der et al. 2009).
Neutrophils with T cell regulatory properties are often referred to as granulocytic myeloid-
derived suppressor cells (G-MDSC). Initially, MDCSs were described in murine models of
cancer and characterised as a heterogeneous population of mainly immature neutrophils
and monocytes capable of T cell suppression. This population has since been described
in late stage human cancers and is associated with unfavourable prognosis.
Conflicting data on the role of neutrophils in cancer comes from studies of murine models
and human patients. This stems from the great phenotypic and functional heterogeneity
of neutrophils and the differences in murine and human pathologies. Mouse tumours
are routinely induced using aggressive, rapidly growing tumour cell lines that, most
likely, represent advanced stages of tumour development in humans where the immune-
suppressive microenvironment is fully established. In contrast, human tumours develop
very slowly while undergoing repeated rounds of immune selection (Eruslanov 2017).
Although the majority of research on neutrophils in human cancer uses peripheral blood,
a few recent high quality studies using human early-stage lung tumour tissue provide fas-
cinating insight into the role of tumour associated neutrophils (TANs). In these studies,
small, early-stage tumours showed infiltration with immature neutrophils that differen-
tiated into a hybrid cell population exhibiting characteristics of canonical neutrophils
and APCs (APC-like hybrid TANs). The differentiation was driven by low amounts of
tumour-derived IFNγ and GM-CSF. The APC-like hybrid TANs acquired new functions
such as the ability to augment or directly stimulate antigen-dependent and independent
memory and effector T cell responses, and capture and cross-present tumour antigens.
This cell subset was only found in small early-stage tumours and was not present in
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larger, more advanced tumours (Eruslanov et al. 2014; Singhal et al. 2016). These find-
ings are in agreement with previous data reported by other groups showing that both
mouse and human neutrophils can be induced to acquire APC-like functions when cul-
tured in the presence of IFN-γ, GM-CSF and IL-3 (Gosselin et al. 1993; Fanger et al.
1997; Oehler et al. 1998; Abdallah et al. 2011; Radsak et al. 2000).
In contrast to human data, a recent study of murine model of invasive breast cancer
demonstrated that early in the malignant conversion, tumour-secreted G-CSF triggers
myeloid expansion in the bone marrow and drives the hematopoietic cells towards an
alternative differentiation generating T cell suppressive neutrophils (Casbon et al. 2015).
Neutrophils were shown to modulate T cell function in other contexts such as transplan-
tation and acute systemic inflammatory reactions. Acute inflammation is known to be
associated with a rapid mobilisation of mature and immature neutrophils. Pillay et al
identified a unique population of mature human neutrophils that are released into the
circulation in patients with severe injury or following intravenous (iv) LPS challenge in
healthy volunteers. These cells showed a hypersegmented nuclear morphology charac-
teristic of more mature neutrophils, were CD62Ldim and were able to strongly suppress
T cell proliferation in vitro. This suppression was mediated by a localised release of
H2O2 into the immunological synapse between neutrophils and T cells. The synapse
formation depended on the integrin Mac-1 and the suppression could be relieved with
blocking anti-Mac-1 antibodies (Pillay et al. 2012). Peripheral blood neutrophils from
healthy donors could not be induced to acquire suppressive phenotype in vitro suggest-
ing that the mature suppressive population is recruited from the tissues under particular
conditions of systemic inflammation (Pillay et al. 2012).
It is now beyond any doubt that neutrophils are important players in shaping both innate
and adaptive immune responses. Our understanding of the mechanisms employed by the
variety of neutrophil/G-MDSC and the specific conditions that lead to the emergence
of the functional heterogeneity is still rudimentary.
The work presented in this dissertation describes the identification and characterisation
of TARM1, a novel IgSF member expressed by activated neutrophils/G-MDSC. TARM1
expressing cells are mobilised during acute inflammatory responses and TARM1 protein
is capable of suppressing T cell activation and proliferation in vitro. TARM1 may
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2.1.1 Novel gene identification
The TARM1 gene was identified in the NCBI human genome database (NCBI 2009) us-
ing the Hidden Markov Model (HMM) designed by Dr Bernard de Bono in collaboration
with Dr Alexander Barrow. The algorithm parameters were adjusted to identify novel
IgSF members that contained the following elements: a) a leader peptide sequence for
surface expression, b) at least one immunoglobulin-like domain, and c) either a charged
transmembrane residue and/or one of the following signaling motifs in the cytoplasmic
tail: an immunoreceptor tyrosine-based inhibition motif (ITIM), proline rich repeats
(PRR) or an immunoreceptor tyrosine-based switch motif (ITSM). This approach was
successful in identifying a number of novel genes among which was VSTM1 (also known
as SIRL-1) encoding a single Ig-like fold, a transmembrane domain and an ITIM contain-
ing cytoplasmic tail. Further search for homologous genes using the VSTM1 nucleotide
sequence revealed a closely related gene,TARM1, encoded in close vicinity to VSTM1
on the human chromosome 19.
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2.1.2 Genomics and Sequence analysis
Full-length human and mouse TARM1 nucleotide sequences were predicted by analysing
the database of expressed sequence tags (ESTs). NCBI Position-Specific Iterated (PSI)-
BLAST and tBLASTn search methods were used to search the High Throughput Ge-
nomic Sequences (HTG) database with the putative TARM1 consensus sequences. A
tBLASTn search enables a comparison of the query protein sequence to the six-frame
translation of a nucleotide sequence database such as EST or to an unannotated draft
genome sequence such as HTG and thus allows the identification of homologous protein
coding regions. PCR primers were designed to verify TARM1 gene expression in human
and mouse tissues and to confirm the nucleotide sequence (as described in 2.2.1). Vali-
dated TARM1 nucleotide and amino-acid sequences were analysed using bioinformatics
software resources (see Table 2.1 below) available from the Expasy proteomics server
(www.expasy.org)
Prediction type Software Reference
N-glycosylation NetNGlyc www.cbs.dtu.dk/services/NetNGlyc/
O-glycosylation NetOGlyc www.cbs.dtu.dk/services/NetOGlyc/
Signal peptide SignalIP www.cbs.dtu.dk/services/SignalP/
Transmembrane region Phobius http://phobius.sbc.su.se/
Molecular weight Compute pI/Mw http://web.expasy.org/compute pi/
Structure, homology HHpred http://toolkit.tuebingen.mpg.de/hhpred
Table 2.1: Expasy bioinformatics software resources used for TARM1 sequence anal-
ysis
2.1.3 Phylogenetic analysis
To establish the molecular evolutionary relationship of TARM1 gene to other members of
the LRC, amino acid sequences encoding Ig-like domain 1 and 2 were aligned separately
and the phylogenetic tree was constructed using the neighbour-joining (NJ) method with
the p-distance. All multiple sequence alignments were conducted at the amino acid level
using CLC Main Workbench software (CLC Bio, Qiagen) and ClustalW (J. Thompson,
Higgins, and Gibson 1994). All resulting alignments were inspected by eye to ensure
best accuracy. MEGA v5.0 (Tamura et al. 2011) was used to construct phylogenetic
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trees based on the NJ method with the p-distance. Bootstrap analysis was performed
on 1000 runs and bootstrap values are indicated for each node. The multiple sequence
alignment parameters set in the ClustalW are outlined in the table 2.2 below. The p-
distance method was chosen as it generates small standard errors and is thus considered
to produce a good resolution of branching topology (M. Nei and S. Kumar 2000).
Parameter Setting
Gap Open Penalty 10.0
Gap Extension Penalty 0.1
Weight Matrix Blosum
Clustering type NJ
Table 2.2: ClustalW parameters used for multiple sequence alignments
2.2 Molecular biological methods
2.2.1 Primer design for molecular cloning and TARM1 gene expression
studies
Predicted DNA sequences were initially used to design forward and reverse primers to
amplify the full-length human and mouse TARM1 transcripts for cloning into pCR2.1-
TOPO vector (Invitrogen). All primers were designed using the Primer3 (Untergasser et
al. 2012) software taking into account self-complementarity, 3’ stability, internal repeats,
GC content (40-60%) and a theoretical annealing temperature of 62-65 ℃. qPCR primers
were designed to span an exon-exon junction to prevent genomic DNA amplification.
The specificity of primer pairs was validated by performing a Primer-BLAST search
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) on the mouse or human reference
genome databases. Primers used for cloning were designed to contain a restriction
enzyme cite preceded by three additional nucleotides to allow the formation of a stable
DNA restriction enzyme complex. The integrity of the resulting open reading frame
was validated using CLC Main Workbench software (CLC Bio, Qiagen). Sequences of





















Primer ID, F / R Target Forward Reverse Amplicon
HA01233987 / HA01089345 mTARM1 full-length AGACCTGCTGAAGACCTTTG TTCAACCAGGAAGCCTCCCACTATTA 864 bp
full-F1 / full-R2 hTARM1 full-length GAGCCATCATGATCCCTAAG AGCCCCGGTTCAAGATGGAG 844 bp
HA03927386 / full-R2 hTARM1 exons 2-5 CACAAGGGGAGATGGGTCAC AGCCCCGGTTCAAGATGGAG 780 bp
HA01286330 / HA01286331 mGapdh GCAGTGCCAGCCTCGTCC TGAGGTCAATGAAGGGGTCGT 143 bp
HA01252576 / HA01252577 hGapdh GAAGGTGAAGGTCGGAGTC CATCACGCCACAGTTTCCC 590 bp
HA00778803 hTARM1 XhoI GCCCTCGAGTCACTCTGGTTTGAAG
HA00778802 mTARM1 XhoI GCCCTCGAGTTACCAGGGTTTATTTGG
HA04544210 / HA04544216 mTARM1 qPCR TCTGTGATAGACAACCATCTGCCTC ACACCGACCCGGATGAGATT
HA01782199 / HA01782200 hTARM1 qPCR TTCACAGCGCAGTGACGTCCTT ATTGGTCTCGCTTCTGGCACTG 131 bp
Table 2.3: Sequences of primers used for TARM1 gene expression studies and molecular cloning. Nucleotide sequences are given in a 5’ to 3’
orientation. Restriction sites are in bold font. Amplicon size produced by each primer pair is given in base pairs (bp). h, human; m, mouse
26 Chapter 2. Materials and methods
2.2.2 Polymerase chain reaction (PCR) and quantitative PCR (qPCR)
Colony PCR Routine PCR screening of transformed DH5α E. coli was performed in
10 µl reactions using GoTaq Flexi (Promega) according to the setup in Table 2.5. The
reaction mix was inoculated with bacterial colony of interest and overlaid with 10 µl
PCR-grade mineral oil. Template amplification was carried out after a ”hot start” of 2
min at 95 ℃ and then followed by 30 cycles of denaturation at 94 ℃ for 30 sec, annealing
at 60 ℃ for 30 sec and extension at 72 ℃ for 1 min with a final extension step of 72 ℃
for 5 min. The resulting PCR product was resolved by electrophoresis on 1% agarose
gel and visualised under UV light.
RT-PCR analysis of TARM1 mRNA expression in tissues Mouse tissue total
RNA panel was prepared in-house as follows. Total RNA was extracted from tissues
of 8-10 week old C57BL/6 female mice with TRIzol reagent (Invitrogen) following the
manufacturer’s instructions. cDNA was synthesised from 2 µg total RNA using oligo
dT primer and Superscript III (Invitrogen). PCR screening was performed using primer
pairs that amplified a full-length TARM1 and are listed in Table 2.3. Forward primer
HA01233987 was specific to 5’ UTR region and reverse primer HA01089345 was specific
to exon 6. Mouse Gapdh was used as a reference gene using primer pair HA01286330
and HA01286331.
Human total RNA Master Panel II was purchased from Clontech (cat. 636643). cDNA
was synthesised from 2 µg total RNA using oligo-dT primer and Superscript III (In-
vitrogen). Forward primer HA03927386 was specific to the junction of exons 2 and 3.
Reverse primer full-R2 was specific to exon 5. Human GAPDH was used as a reference
gene with the primer pair HA01252576 HA01252577 (see Table 2.3). RT-PCR reaction
was carried out using GoTaq Flexi RT-PCR kit (Promega) as shown in Table 2.4.
Quantitative PCR analysis of tissue mTARM1 expression following Salmonella
infection Mouse tissues were harvested at indicated time points following Salmonella
infection and stored in RNAlater (Qiagen) at -20 ℃ until further processing. Total RNA
was extracted using RNeasy kit (Qiagen) and cDNA was synthesised from 2.5 µg total
RNA using oligo dT primer and Superscript III (Invitrogen). qPCR was performed using
GoTaq qPCR Master Mix (Promega), according to the manufacturer’s instructions on
an ABI 7500 Fast Real-Time PCR System. Forward primer HA04544210 was designed
to span the junction of exons 4 and 5. Reverse primer HA04544216 was specific for
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exon 6 (see Table 2.3). Gapdh was used as a reference gene using Gapdh QuantiTect
156 Primer mix (Qiagen, cat QT01658692). Primer amplification efficiencies (E=1.9
for both TARM1 and Gapdh) were calculated from the slope of a standard curve pre-
pared with a 2-fold serial dilution of splenic cDNA. TARM1 gene expression levels were
calculated as fold change over the levels detected in control animals using fold change=2-
∆∆CT method. Primer specificity was verified by melt curve analysis of the product
and amplicon sequencing.
2.2.3 Molecular cloning
The DNA sequences of interest were amplified by PCR using primer pairs containing
appropriate restriction sites and the products were purified using QIAquick PCR Pu-
rification Kit (Qiagen) according to the manufacturer’s instructions.
Restriction digestion of DNA All DNA digestion reactions were performed with
restriction enzymes from New England Biolabs (NEB) according to the manufacturer’s
instructions. In brief, the reactions were set up in a volume of 50 µl in 0.25 ml PCR
tubes using 1-2 units of appropriate enzymes per 1 µg of DNA substrate in a compatible
buffer. The reactions were allowed to proceed for 4 hours at 37 ℃ with a final inactivation
step of 20 min at 85 ℃. Following restriction digest, PCR products were purified using
QIAquick PCR Purification Kit (Qiagen). For restriction digest of plasmids 2-5 µg
DNA were used. To purify the digested plasmid DNA, the reaction was mixed with gel
loading buffer and separated on 1.5% agarose gel in 1xTBE buffer. 1 kb DNA ladder
(Promega) was used as DNA size reference marker. The band corresponding to the
linearised plasmid was excised and the DNA was extracted as described below.
Gel extraction DNA fragments to be gel-extracted were visualised with long-wavelength
UV light and excised with a scalpel blade. Agarose slices were either extracted imme-
diately using the QIAquick Gel Extraction kit (Qiagen) or stored in 1.5 ml eppendorf
tubes at -20 ℃ until extraction. The concentration of the purified DNA was determined
on Nanodrop 1000 apparatus.
Ligation reactions 50 ng of linearised plasmid DNA was ligated to a four fold molar
excess of insert DNA with compatible ends in the presence of 1 unit of T4 DNA Ligase
(NEB) and manufacturer’s buffer in a final volume of 20 µl for 15 min at RT. The
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ligation reaction product was either used immediately to transform competent E. coli
or stored at -20 ℃.
2.2.4 Transformation of competent E. coli
Subcloning efficiency DH5α competent E.coli (Invitrogen) were transformed with liga-
tion product according to manufacturer’s instructions. Briefly, competent E.coli were
thawed on ice, ligation product was added and the cells were incubated for 30 min on
ice. Following incubation, the bacteria were heat-shocked at 42 ℃ for 30 s and allowed
to cool on ice for 2 min. Pre-warmed SOC medium was added and the cells were al-
lowed to recover on a shaking heat-block at 37 ℃ for 1 hour. To select for successfully
transformed bacteria, the cells were streaked onto LB agar plates containing 100 µg/ml
ampicillin and incubated at 37 ℃ overnight. Single cell colonies were screened by PCR
as described in section 2.2.2 for the presence of plasmid with the insert of expected size.
Several clones were picked for sequencing of the transformed DNA.
2.2.5 Plasmid DNA extraction from E. coli
Small and large-scale plasmid DNA extractions were performed using the Qiagen Plas-
mid Mini or Maxi kits, respectively, following the manufacturer’s protocol. Briefly, LB
broth supplemented with ampicillin (100 µg/ml ) was inoculated with a single bacterial
colony that was previously confirmed to contain the cloned DNA sequence. The bac-
terial culture was expanded overnight at 37 ℃ in a shaking incubator. To extract the
DNA plasmid, the bacterial culture was centrifuged at 4000 × g for 20 min, LB broth
was discarded and the pelleted cells were lysed.
2.2.6 Transient transfection
All transient transfections were carried out in 6-well plates using either FugeneHD
(Promega) or jetPEI™ (Polyplus). Cells were seeded at optimal densities into 6-well
plates the day before transfection and allowed to adhere. Immediately prior to the
transfection, growth medium was changed to 1 ml/well of either serum-free, antibiotics-
free medium for FugeneHD or complete medium for jetPEI transfection. 2 µg of plasmid
DNA was used per well for transfection according to the manufacturer’s protocol. Cells
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x1 reaction (µl)
5x Green buffer 4
MgCl2 (25 mM) 1.2








Table 2.4: Composition of PCR
master mix
x1 reaction (µl)
5x Green buffer 2
MgCl2 (25 mM) 1
dNTP (10 mM) 0.2
Forward primer 0.5
Reverse primer 0.5




Table 2.5: Composition of PCR
master mix for colony PCR
were then incubated for 6 h to overnight and the medium was exchanged to normal
growth medium. The expression of transfected construct was assayed 48 h following the
transfection.
2.2.7 Stable transfections to generate TARM1-Fc fusion protein
DNA sequences encoding the extracellular portions of murine (aa 16-255) and human
(aa 16-233) TARM1 were cloned into the mammalian expression vector Signal pIg Plus
(R&D Systems) carrying a neomycin resistance gene, CD33 signal sequence and a hu-
man IgG1 Fc tail. For stable transfections, the vector was linearised to facilitate the
integration into genomic DNA. HEK293 cells were prepared in the same manner as for
the transient transfections (see section 2.2.6) and transfected with 2 µg of plasmid DNA
using FugeneHD according to the manufacturer’s protocol. The cells were passaged un-
der G418 selection (1 mg/ml) until stable cell lines secreting soluble TARM1-Fc fusion
protein were established.
30 Chapter 2. Materials and methods
2.3 Protein biochemistry
2.3.1 SDS-PAGE
The mini-Protean3 system (BioRad) was used to perform all SDS-PAGE. The gels were
prepared to contain a 10% resolving and 4% stacking layers. Samples were mixed with
reducing sample buffer containing DTT and denatured at 90 ℃ for 5 min, vortexed and
allowed to cool prior to loading. Prestained SDS-PAGE molecular weight standard was
loaded alongside the samples and the gel was run at 100 V in Tris-glycine buffer (see
section 2.3.6). Protein bands were visualised by either coomassie stain or western blot.
2.3.2 Coomassie staining
Proteins resolved on the SDS-PAGE gels were visualised by incubation with Coomassie
blue stain for 1 h and cleared in a de-stain solution (see section 2.3.6 on page 32 for
recipes).
2.3.3 Western blotting
Proteins were resolved on a 10% SDS-PAGE gel and wet transferred in Towbin buffer
(see section 2.3.6) onto a methanol-activated PVDF membrane (Immobilon-P, Millipore)
for 1 h at 100 V on a BioRad Mini Transblot system (BioRad). Following transfer,
the membrane was blocked in 5% milk, 0.05% Tween-20 (Sigma) for 1 h at RT on
a rocking platform. After the blocking step, primary antibody diluted in PBS-T 5%
milk was added to the membrane and incubated for 1 h at RT on a rocking platform.
Thereafter, the membrane was washed 5 min × 5 times in PBS-T and the secondary
HRP-conjugated antibody diluted in PBS-T 5% milk was added and incubated for 1 h
at RT on a rocking platform. The membrane was washed 5 min × 5 times in PBS-T
then soaked in chemiluminescent ECL™ Detection Reagents (GE Healthcare) and the
protein bands were visualised by exposing an X-ray film (GE Healthcare). The X-ray
film was developed on a Kodak compact X4 X-ray developer (Kodak).
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2.3.4 PNGase F and Endo H treatment of TARM1
Hek293T cells were transiently transfected with full-length FLAG-tagged TARM1 using
FugeneHD (Promega). Two days post transfection total cell lysates were prepared in
ice-cold Nonidet P-40 (NP-40) lysis buffer for 20 min on ice. Insoluble cell fragments
were removed by centrifugation at 14,000 × g for 15 min. Proteins were denatured at
90 ℃ for 5 min and the samples were treated with either Endo H or PNGase F (both
from NEB) for 4 h at 37 ℃. Control samples were incubated without the addition of
enzymes. All samples were stored at -80 ℃ until further analysis by Western blotting.
2.3.5 Co-immunoprecipitation
Hek293 cells stably expressing HA-tagged ITAM-adaptors Dap10, Dap12 and FcRγ were
transiently transfected with full-length Flag-tagged human TARM1 and cells were lysed
in 1% Triton X-100 lysis buffer (see section 2.3.6) for 25 min on ice. Lysates were
centrifuged at 10,000 × g and 4 ℃ for 5 min to remove debris. Supernatants were
collected and incubated with monoclonal anti-TARM1 antibody or isotype control for 1
h at 4 ℃ on a rotor. Washed protein A agarose FastFlow beads (Sigma) were added to
the samples and incubated on a rotor for 1 h at 4 ℃. The agarose beads were then washed
three times in lysis buffer and two times in TBS. Proteins were eluted from the beads by
heating at 70 ℃ for 10 min in lithium dodecyl sulphate (LDS) (Invitrogen) sample buffer
and separated by SDS-PAGE. Co-immunoprecipitated proteins were resolved on a 10%
agarose gel and analysed by Western blotting. The membrane was probed with anti-HA
monoclonal antibody (Roche) to detect the co-immunoprecipitated adaptor protein.
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2.3.6 Recipes
Name Composition
PBS-T 1 ml Tween-20
1 L PBS
NP-40 lysis buffer 50 mM Tris-HCl pH 8.0
150 mM NaCl
1% NP-40
1.0 mM AEBSF (Sigma)
Co-IP lysis buffer 20 mM Tris-HCl pH 8.0
150 mM NaCl
1% Triton X-100
0.5 mM AEBSF (Sigma)
ProteoBlock (Fermentas)
Laemmli sample buffer×2 4% SDS
0.125 M Tris-HCl pH 6.8
0.004% Bromophenol blue
20% Glycerol
0.7 M DTT added prior to use
dH2O
Tris-glycine buffer×10 0.25 M Tris
1.92 M Glycine (pH 8.6)
1% SDS
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dH2O
Towbin transfer buffer×10 0.25 M Tris












2.4 Confocal microscopy of spleen sections
Spleen fragments from control or Salmonella-infected mice were harvested at 2 wpi
and fixed in 4% paraformaldehyde, paraffin-embedded and stored until analysis. Tissue
sections were deparaffinised, and heat-induced epitope retrieval was performed in citrate
buffer pH 5.5. Sections were blocked with goat serum and sequentially stained with
rat anti-mouse TARM1 and goat F(ab’)2 anti-rat FITC (AbD Serotec) secondary Ab.
Nuclei were visualised with DAPI. Multiple images of each section were taken to ensure
accurate representation.
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2.4.1 Flow cytometric cell-surface phenotyping
For flow cytometric cell phenotyping, 0.5 - 1.0 × 106 cells were stained per well. Flow
cytometry was performed on BD FACScan with CyTek DxP three laser setup (Table 2.7)
and data analysis was carried out using FlowJo 10 software (Tree Star).
Laser Excitation (nm) Fluorochrome conjugates
Blue argon 488 Fitc
Red diode 635 Alexa Fluor647
Green-Yellow 561 Pe
Table 2.7: Lasers and optical configuration
Unless otherwise stated, all incubation steps were performed on ice and all commercial
antibodies were diluted to working concentrations in FACS buffer. FACS buffer was also
used for all washing steps. All immunostaining was performed in v-bottomed 96-well
plates (Sterilin).
• Fc receptors were blocked by resuspending cell pellets in 40 µl of 5% normal mouse
serum and incubated for 20 min.
• 20 µl of anti-TARM1 monoclonal antibody-containing hybridoma supernatant or
isotype control were added to appropriate wells and incubated for 1 h.
• Cells were washed twice and fluorochrome conjugated anti-Rat secondary antibody
was added to the wells and incubated for 1 h.
• Cells were washed twice and unbound anti-Rat antibodies were blocked with 50 µl
of 5% normal rat serum for 25 min.
• Rat serum was removed and appropriately diluted antibodies to lineage markers
were added to the wells and incubated for 1 h.
• Cells were washed twice, fixed in 2% paraformaldehyde solution and stored at 4
℃ over night.
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2.5 Generation and purification of TARM1-Fc fusion pro-
teins
2.5.1 Collection of TARM1-Fc containing supernatants
Hek293 cells stably transfected with TARM1-Fc construct (see section 2.2.7) were main-
tained in DMEM supplemented with 2 mM L-Glutamine, 100 U/ml penicillin/strep-
tomycin, 2% ultra-low IgG FCS (Invitrogen) and 1 mg/ml G418. TARM1-Fc fusion
protein secretion was assessed by Western blotting and ELISA assays. The culture su-
pernatant containing the fusion proteins was collected every four days and exchanged
for fresh medium until 5 L of each fusion-containing supernatant were collected. The
supernatants were stored at 4 ℃ until further processing. For storage, the medium was
clarified by centrifugation, Tris buffer was added to adjust the pH to 8 and 1 mM phenyl-
methane sulfonyl fluoride (PMSF) was added to inhibit proteolytic protein degradation.
2.5.2 Purification of TARM1-Fc fusion proteins
TARM1-Fc fusions were purified by affinity chromatography over protein-A agarose
FastFlow (Sigma-Aldrich) packed columns. Glass columns (Millipore) were packed with
2 ml of 50% protein-A agarose slurry and washed with 0.1 M Tris-HCl pH8. The
column assembly was kept at 4℃ during the entire purification process. TARM1-Fc
containing supernatants were allowed to enter the column by gravity flow. The columns
were washed with 50 ml 0.1 M Tris-HCl pH8 and then with 20 ml 0.1 M Citrate buffer
pH5.5. Thereafter, the fusion proteins were eluted from the columns with 0.1 M Glycine
at pH2.5. The eluate was collected into tubes containing 2.0 M Tris-HCl pH8. The
eluted Fc fusion proteins were concentrated using Amicon Ultra-0.5 mL Centrifugal
Filters (Millipore) with a molecular weight cutoff of 10 kDa. The concentrated solutions
were filter-sterilised and the protein concentration was measured on a Nanodrop 1000
spectrophotometer (Fisher Scientific). Aliquots of TARM1-Fc fusion proteins (1 mg/ml)
were stored at -80 ℃.
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2.6 Generation of TARM1 reporter lines
2.6.1 Retroviral transduction
2B4-NFAT-GFP T cell lymphoma cell line was retrovirally transduced with chimeric
TARM1 construct bearing the extracellular portion of TARM1 fused to the transmem-
brane domain of PDGFR and the cytoplasmic tail of human CD3ζ.
Phoenix™-E ecotropic retroviral packaging system was used to stably transduce 2B4-
NFAT-GFP cell line following previously published protocol (Pear et al. 1993). Pack-
aging cells were seeded into 6-well plate and transiently transfected with 3 µg pMXs-
TARM1 vector DNA per well using FugeneHD reagent (Promega). 24 h post transfection
the cells were transferred to 32 ℃ for additional 2 days to increase the stability of se-
creted viral particles. On day 3 post transfection, retroviral supernatants were harvested
and applied to 2B4-NFAT-GFP cells in the presence of 4 µg/ml of Polybrene (Sigma-
Aldrich). The cells were then placed a six-well plate and centrifuged at 1200 times g
at 32 ℃ for 1 h. Following the spin, the cells were incubated at 32 ℃ overnight. The
medium was then exchanged for normal growth medium and grown at 37 ℃. 72 h fol-
lowing transduction the expression of TARM1 was analysed by flow cytometry using
anti-HA monoclonal antibody.
2.7 Antibodies
2.7.1 Generation and screening of anti-TARM1 monoclonal antibodies
mAb production
Monoclonal mouse anti-humanTARM1 and rat anti-mouse TARM1 Abs were raised
against the ectodomain of mouse and human TARM1 proteins using TARM1-Fc as
immunogens. The work was performed by the laboratory of Professor Karsten Skjødt
(Dept. Cancer & Inflammation, Institute for Molecular Medicine, University of Southern
Denmark).
mAb screening
To eliminate the clones specific for the IgG1 Fc tail, hybridoma supernatants were
screened by ELISA using the TARM1-Fc fusion proteins whereby the mouse anti-human
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TARM1 clones were screened against mouse TARM1-Fc fusion, and the rat anti-mouse
TARM1 clones were screened against the human TARM1-Fc fusion protein. The per-
formance and specificity of monoclonal anti-TARM1 Ab clones selected by ELISA were
further evaluated by flow cytometry and Western blot against transfected and primary
cells.
2.7.2 Antibodies used in this work
Antibody Clone Isotype Supplier
Ly6C APC HK1.4 Rat IgG2c, κ BioLegend
Ly6G FITC 1A8 Rat IgG2a, κ BioLegend
Gr-1 FICT RB6-85C Rat IgG2b, κ eBioscience
CD19 APC 1D3 Rat IgG2a, κ eBioscience
CD11c FITC N418 Armenian hamster IgG eBioscience
CD11b APC M1/70 Rat IgG2b, κ eBioscience
CD69 PE H1.2F3 Armenian hamster IgG eBioscience
CD62L PE-Cy5 MEL-14 Rat IgG2a, κ eBioscience
CD3 FITC 145-2C11 Armenian hamster IgG eBioscience
CD4 APC GK1.5 Rat IgG2b eBioscience
CD25 APC PC61.5 Rat IgG1, λ eBioscience
Annexin V FITC - - BD Pharmingen
Secondary
anti-Rt IgG (H+L) PE Polyclonal Goat Ig Southern Biotech
anti-Ms Alexa Fluor 647 Polyclonal Goat Ig Molecular Probes
Continues on next page
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Table 2.8 – continued from previous page
Antibody Clone Isotype Supplier
Western blot
anti-Rt HRP ms-ads Polyclonal Goat Ig Southern Biotech
anti-Hu IgG (Fc) HRP Polyclonal Goat Ig Sigma-Aldrich
anti-HA HRP 3F10 Rat IgG1 Roche
anti-FLAG HRP M2 Mouse IgG1 Sigma-Aldrich
Cell activation
anti-CD3 145-2C11 Armenian hamster IgG eBioscience
anti-CD28 37.51 Syrian Hamster IgG Miltenyi
anti-human IgG (Fc) GtxHu-004-D Goat Ig ImmunoReagents
2.8 Cell isolation, manipulation and culture
2.8.1 General tissue culture
All cell lines were maintained in either RPMI-1640 or Dulbecco’s Modified Eagle medium
(DMEM, both from Gibco) supplemented with 10% heat inactivated fetal calf serum
(FCS), 2 mM L-glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin (all from
PAA). Primary cells were maintained in RPMI-1640 supplemented with all the above
plus 50 µM 2-Mercaptoethanol. For cryopreservation, cells were resuspended in 10%
dimethylsulfoxide (DMSO) diluted in FCS and stored in liquid nitrogen.
2.8.2 Preparation of primary murine cells
Mice were sacrificed and tissues collected into ice-cold RPMI supplemented with 10%
FCS. Single cell suspensions of liver, spleen and lymph nodes were prepared by gently
forcing the tissues through a 70 µm nylon cell strainer.
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Splenocytes The resulting cell suspension was pelleted by centrifugation at 400 × g for
10 min at 4 ℃ and resuspended in 2 ml of ammonium chloride buffer per spleen to lyse
red blood cells. The lysis was allowed to proceed for 20 seconds on ice with occasional
swirling. Thereafter, 40 ml FACS buffer was added to the cell suspension to stop the
reaction and cells were washed twice.
Liver mononuclear cells (MNC) Cells were pelleted by centrifugation at 400 × g,
resuspended in 10 ml of Percoll (GE Healthcare) 33% (vol/vol) and centrifuged at 800
× g for 20 min at RT. MNC were collected and washed once with FACS buffer.
Bone marrow (BM) Femur and tibia of both legs were thoroughly cleaned from
surrounding tissue, epiphyses were cut and bone marrow was flushed with ice-cold FACS
buffer using a 24 gauge needle attached to a syringe. Cellular aggregates were dissociated
by pipetting and the cells were then passed through 70 µm nylon cell strainer, pelleted
by centrifugation and red blood cells were lysed with ammonium chloride buffer as
described above.
2.8.3 Isolation of peripheral blood mononuclear cells (PBMC)
Blood samples were collected from healthy adult volunteers into heparin containing tubes
(Sarsted) and processed immediately. PBMC were isolated by density centrifugation
over Histopaque-1077 (Sigma) according to the manufacturer’s instructions. Briefly, 20
ml freshly drawn blood was diluted 1:1 in PBS and overlaid onto Histopaque-1077 in 50
ml Falcon tubes equilibrated to RT. The samples were centrifuged at 700 × g with low
acceleration and no breaks for 20 min at RT. The PBMC layer was transferred into a
fresh 50 ml tube and washed in PBS 2 mM EDTA once at 700 × g 10 min and once at
300 × g 10 min.
2.8.4 Isolation of human peripheral blood neutrophils
Peripheral blood was collected from healthy volunteers and circulating neutrophils were
purified using Dextran sedimentation and discontinuous plasma-Percoll gradients as pre-
viously described (Haslett et al. 1985). Briefly, 40 ml of blood was collected into 50 ml
tubes (containing 4 ml 3.8% (w/v) sodium citrate) using a 19 gauge needle, and cen-
trifuged for 20 minutes at 300 × g. Platelet-rich plasma upper layer was removed for
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later use. Red blood cells were removed from the leukocyte/erythrocyte pellet by dex-
tran sedimentation. The upper leukocyte-rich layer was collected and centrifuged at
275 × g for 5 minutes. The cell pellet was resuspended in platelet-poor plasma and
neutrophils were isolated by discontinuous plasma-Percoll gradient centrifugation. Neu-
trophil purity as determined by cytospins was routinely greater than 95% using this
method.
2.8.5 Immunomagnetic T cell isolation
Spleen and lymph nodes of 6-8 week old mice were pooled and single cell suspension was
prepared by gentle mechanical disruption through a 70 µ nylon cell strainer. Total T
cell population was isolated by immunomagnetic selection with either negative selection
Mouse T Cell Enrichment Kit (StemCell Technologies) or EasySep CD4 positive selection
magnetic beads (StemCell Technologies) in accordance with the manufacturer’s protocol.
The purity of isolated T cells was assessed by staining with fluorescently labelled anti-
CD3 antibody and flow cytometric analysis. The purities were routinely at or above
96%.
2.8.6 Plates for T cell stimulation inhibition assay with TARM1-Fc
96-well flat-bottomed plates were coated in two layers. First layer was the anti-human
IgG Fc-specific antibody 10 µg/ml (ImmunoReagents) and 1 µg/ml anti-CD3 (clone
145-2C11, eBioscience) together with 0.25 µg/ml anti-CD28 (clone 37.51, Miltenyi) over
night at 4 ℃. The plates were then washed with PBS and coated with a second layer
of mouse TARM1-Fc or human IgG1 control both at 10 µg/ml for 2 h at 37 ℃ washed
with complete growth medium and used in either CFSE dilution assay or MTT metabolic
assay of T cell proliferation (see section 2.8.7).
2.8.7 T cell proliferation assays
CFSE For CFSE dilution assay CD4+ T cells were purified from naive NOD female mice
using EasySep positive selection magnetic beads (StemCell Technologies) to 95–98%
purity as determined by flow cytometric analysis. Cells were loaded with 1 µM CFSE
(Molecular Probes) in PBS for 15 min at 37 ℃ washed three times in complete growth
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medium and seeded into a 96-well plate coated as described in 2.8.6. A total of 1.5 ×
105 T cells were added to each well in a volume of 200 µl RPMI-1640 supplemented with
10% FCS, penicillin/streptomycin and 50 µM 2-mercaptoethanol. CFSE dilution was
assessed after 90 h of culture.
MTT For metabolic MTT assay, CD4+ T cells were purified using EasySep negative
selection magnetic beads (StemCell Technologies) and activated in precoated plates as
described above in section 2.8.6, but omitting the anti-CD28 antibody. Cells were cul-
tured for 20 h, 40 h and 80 h. Two hours prior to each time point, MTT (Sigma) stock
solution was added directly to the wells to give 500 µg/ml final concentration and follow-
ing 2 h incubation at 37 ℃, DMSO was used to dissolve formazan crystals. Absorbance
(570 nm) was measured on a Synergy HT plate reader. Human T cells were isolated
from peripheral blood of healthy donors (n=2) using CD4 positive selection magnetic
beads (Miltenyi) to 95-98% purity and activated with plate-bound anti-CD3 (1.2 µg/ml,
clone OKT3) in the presence of plate-bound human TARM1-Fc (10 µg/ml) or hIgG1
(10 µg/ml). Recombinant human IL-2 (50 U/ml) was added to some wells as indicated.
T cells were cultured for 3 days and the expression of CD25 and CD69 was analysed by
flow cytometry.
2.8.8 Generation of bone marrow-derived dendritic cells and macrophages
Bone marrow was isolated as described in section 2.8.2. Single cell suspension was pre-
pared in IMDM supplemented with 10% FCS, 2 mM L-glutamine, 50 U/ml Penicillin,
50 µg/ml Streptomycin (all from PAA) and 50 µM 2-Mercaptoethanol and transferred
into tissue culture dishes. For bone marrow-derived dendritic cell (BMDC) differentioa-
tion cells were allowed to adhere for 30 min at 37 ℃ and the nonadherent cells were
reseeded into new plates in IMDM complete growth medium supplemented with GM-
CSF (20 ng/ml, Peprotech) and IL-4 (10 ng/ml, Peprotech). For bone marrow-derived
macrophage (BMM) differentiation the medium was supplemented with 10% L-cell con-
ditioned medium as a source of M-CSF. On day 10 (BMDC) or on day 5-6 (BMM)
non-adherent cells were washed out from the plates with PBS, adherent cells were de-
tached non-enzymatically and the cellular phenotype was confirmed by flow cytometry
using CD11b and F4/80 markers for BMMs and CD11c and CD80 for BMDCs.
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TLR Agonist Final concentration
TLR1/2 Pam3CSK4 100 ng/ml
TLR3 Poly(I:C) 50 µg/ml
TLR4 LPS Ultrapure from E. coli R515 100 ng/ml
TLR5 Flagellin from S. Typhimurium 50 ng/ml
TLR2/6 MALP-2 80 ng/ml
TLR7 Imiquimod 1 µg/ml
TLR9 CpG ODN 1585 2 µg/ml
TLR11 Profilin from Toxoplasma gondii 250 ng/ml
Table 2.9: TLR agonists and their final concentrations used for cell stimulation.
2.8.9 TLR stimulation and measurement of cytokine secretion
For the analysis of TARM1 cell-surface expression, BMM and BMDC were stimulated
for 24h with the TLR agonists (all from Apotech) listed in Table 2.9. For analysis of
cytokine secretion, 1 × 105 of BMM or 1.3 × 105 sorted neutrophils were cultured in
96-well tissue culture plates coated with goat anti-rat capture Ab and rat anti-TARM1
crosslinking Ab or a rat IgG2a isotype control Ab (all at 10 µg/ml). Neutrophils were
stimulated in the presence or absence of 10 ng/ml Ultrapure LPS from E. coli K12
(InvivoGen) for 8 h at 37 ℃. BMM were stimulated in the presence or absence of either
0.5 µg/ml Pam3CSK4, 0.5 µg/ml PolyI:C, 1 ng/ml LPS, or 10 µM Imiquimod for 16 h
at 37 ℃. Tissue culture supernatants were collected and cytokine production determined
using the Cytometric Bead Array mouse inflammation kit (Becton Dickinson).
DuoSet sandwich ELISA (R&D) was used in accordance with manufacturer’s protocol
to determine IL-2 secretion by stimulated mouse T cells.
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2.9 Induction of sterile inflammation and Salmonella in-
fection
2.9.1 Sterile inflammation and S. Typhimurium infection
To induce sterile inflammation, 8-10 week old C57BL/6 mice were injected with 3 mg per
mouse of ultrapure LPS (InvivoGen) intraperitoneally (ip), and tissues were harvested
for immunophenotyping 24 h later. Systemic infection was induced with an aroA atten-
uated strain of Salmonella enterica serovar Typhimurium, SL3261. Bacteria were grown
overnight in Luria–Bertani (LB) broth until stationary phase and C57BL/6 mice were
injected into a lateral tail vein with 1 × 106 CFU diluted in PBS. At indicated times
following infection, mice were euthanised and TARM1 expression in cells and tissues
was analysed by flow cytometry, qPCR, and confocal microscopy.
2.9.2 Enumeration of bacterial load within organ homogenates
Inocula were enumerated by pour-plating in LB agar as follows. Mice were euthanised
by cervical dislocation one week post infection, spleens and livers were removed and
homogenised in 5 ml of sterile water in a Stomacher 80 Lab System (Seward). The
resulting homogenate was 10-fold serially diluted in PBS and pour-plated in LB agar.




3.1 TARM1 gene-structure analysis
The human TARM1 gene maps to chromosome 19q13.42, at the centromeric portion
of the LRC, in the identical position to the mouse gene within the syntenic region of
chromosome 7A1 (Fig. 3.1). Using the data on the genomic location of predicted TARM1
open reading frame (ORF) I validated its exon-intron structure and investigated the
existence of alternative splice variants and homologs in human and mouse using the
bioinformatics tools described below.
Prediction of gene structure from genomic sequence is a computationally challenging
problem. The most reliable results are achieved by aligning a spliced cDNA sequence
of the gene of interest to the genomic sequence. In the absence of cDNA sequence,
computational analysis of expressed sequence tags (EST) can be used as a starting point
for the gene structure prediction. ESTs are short, single-pass sequencing products that
represent partial cDNAs. Aligning EST sequences to the genomic DNA is complicated
due to the short length and inherently low quality of the EST sequence, which often
contains abundant deletions and chimerism. The analysis could be further confounded
by the presence of non-canonical splice site, very short exons (∼20 bp), paralogous genes
and/or complex patterns of alternative splicing (Brendel, Xing, and W. Zhu 2004) . A
number of computational tools have been developed to address this problem.
Unlike other species, human and mouse GenBank EST databases have a large sampling
of sequences. I was able to retrieve ESTs that originated within the genomic region of
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Figure 3.1: TARM1 and TARM1-related genes are encoded at the centromeric bound-
ary of the LRC in mouse and human. Genomic organisation of the human LRC (top)
on chromosome 19q.13.42 and the syntenic mouse LRC (bottom) on chromosome 7A1.
Gene orientation is indicated by arrows. Black - transcriptionally active genes. Grey -
pseudogenes. Centr - centromeric.
Tarm1 and that had at least ≥ 90% sequence identity with Tarm1 nucleotide sequence.
I used the Geneseqer software (Brendel, Xing, and W. Zhu 2004) to perform EST align-
ment to the genomic DNA and to establish the initial exon structure. Although the
availability of high-identity sequences meant the prediction was relatively accurate, the
existence of splice variants could not be established using this method. Hence, it was nec-
essary to adopt a more direct experimental approach. To this end, I cloned a full-length
Tarm1 cDNA from a total RNA of mouse bone marrow and human spleen (purchased
from ClonTech) and the nucleotide sequence was aligned using GeneSeqer to the cor-
responding genomic region alongside previously retrieved ESTs. Resulting alignments
were checked by eye to ensure correct assignment of exonic boundaries. This approach
confirmed the computationally derived exon number and structure of Tarm1 gene in
human and mouse and identified putative splice variants.
The analysis of murine ESTs and cDNA revealed a six-exon organisation with a combined
sequence length of 867 bp (Fig. 3.2A). The analysis also suggested there may exist a
putative protein coding splice variant lacking exon 5 (Clone 5), which encodes a 22
amino-acid stem region. ESTs BY748165, BY178134, BY210189 and BY189575 lack
exon 2 which destroys a portion of the signal peptide and would most likely result in an
aberrant protein translocation along the secretory pathway.
Tarm1 coding sequence gives rise to a protein of 288 amino acids, which contains a
hydrophobic signal peptide split between exons 1 and 2; two Ig-like domains encoded
by exon 3 and 4, respectively; a stem, exon 5-encoded low complexity polypeptide
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Figure 3.2: Analysis of mouse Tarm1 gene exon structure and alternative splicing.
The analysis was performed by aligning mouse Tarm1 full-length clone and EST se-
quences to the reference genomic DNA. Full-length Tarm1 transcripts were amplified
by PCR from mouse bone marrow mRNA using primer pair specific to the exons 1 and
6. EST sequences were obtained by searching the NCBI EST database with Tarm1
cDNA sequence. The data showed a six-exon organisation and suggested the existence
of one splice variant lacking exon 5.
separating the proximal Ig-like fold and the transmembrane domain; a short cytoplasmic
tail following the transmembrane region is encoded within exon 6 (Fig. 3.2B).
The human TARM1 resembles closely its murine ortholog both in sequence and exon
structure. However, human TARM1 lacks the region homologous to exon 5 (the stem)
present in its murine counterpart and is thus comprised of a total of five exons (Fig. 3.3A).
Analysis of human TARM1 full-length transcripts identified a splice variant which, like
murine Tarm1, would result in an incomplete signal peptide due to the lack of exon
2. Additionally, an alternative exon 1 is located within the intronic region upstream
of exon 2 and encodes a non-canonical lysine-rich signal peptide MKERKKKERK-
ERKRKKERN (AK301730).
Both Ig-like domains of TARM1 contain two characteristic conserved cysteines in iden-
tical positions. The predicted TM region contains a conserved arginine, often seen in
activating receptors, where it serves as an association site for ITAM-bearing signalling
adaptors such as FcεRγ chain.
Six kb upstream of TARM1 on human chromosome 19 is a closely related VSTM1
gene (also known as SIRL-1 ) with a 10-exon structure. I analysed full-length cDNA










Exon number 2 3 4 51
AK301730




SP Ig-like domainC C
TMIg-like domainC C
Tail




Figure 3.3: Analysis of human TARM1 gene exon organisation and alternative splic-
ing. The analysis was performed by aligning human TARM1 full-length clone and EST
sequences to the reference genomic DNA. Full-length TARM1 transcripts were ampli-
fied by PCR from human spleen mRNA (purchased from Clontech) using primer pair
specific to the exons 1 and 5. EST sequences were obtained by searching the NCBI EST
database with TARM1 cDNA sequence. The data showed a five-exon organisation and
an alternatively spliced transcript containing a non-canonical signal peptide.
clones and VSTM-1 transcripts contained in the NCBI EST database (Fig. 3.4A) and
found that several possible SIRL-1 isoforms could exist. Particularly interesting was the
isoform lacking exon 6 which encodes the TM region and which suggested the existence
of a soluble form of SIRL-1 receptor.
At the time this work was performed (2009) there were no published studies describing
the VSTM-1 gene. In 2010, Steevels et al. reported the identification and characterisa-
tion of VSTM1 (Steevels, Lebbink, et al. 2010), which they named signal inhibitory
receptor on leukocytes-1 (SIRL-1). In 2012 Guo et al. published a more detailed
transcriptional profiling of human VSTM1 splice variants confirming the existence of
a soluble isoform expressed predominantly within immune tissues such as bone marrow,
spleen, lymph node and thymus (X. Guo et al. 2012).
SIRL-1 cDNA encodes a 236 amino-acid protein, which, in contrast to TARM1, con-
tains a single Ig-V domain and lacks the conserved arginine within its TM. Instead, a
long cytoplasmic tail contains two ITIMs, implying inhibitory potential through SHP-
1 recruitment (L. Meyaard 2008; Marco Colonna, Navarro, et al. 1997; Burshtyn et al.
1996). The single Ig-V domain of SIRL-1 is closely related to the membrane distal Ig-like
domain of TARM1 sharing 58.1% amino acid similarity and 48.4% identity.
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Figure 3.4: Alignment of human SIRL-1 full-length clone and EST sequences to the
reference genomic DNA. Full-length SIRL-1 transcripts were amplified by PCR from
human spleen RNA (purchased from Clontech) using primer pair specific to the 3’ and 5’
UTR. EST sequences were obtained by searching the NCBI EST database with SIRL-1
cDNA sequence.
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Figure 3.5: Mouse chromosome 7 with annotation of the predicted Sirl-1 (Vstm1 )
ORF and Tarm1 gene. Genome build 38, MGI Mouse genome browser.
The ORF of the putative murine Sirl-1 gene (XM 001475796) can be computationally
deduced and is located, as expected, approximately 6 kb upstream of the Tarm1 gene
(Fig 3.5). It encodes a single Ig-like domain and the amino-acid sequence of the extra-
cellular portion bears similarity to human SIRL-1. Similarly, the rat genome contains
a closely related gene sequence (XM 002728681) in the syntenic region on Chr 1 just
upstream of Tarm1. The alignment of this predicted rat Sirl-1 transcript to the mouse
genomic sequence produces a high similarity (over 85% nucleotide identity) match to the
region of the predicted mouse Sirl-1 ORF. However, in contrast to SIRL-1 in human, it
is unclear whether the murine or rat orthologs are functional. It appears that the ITIM-
bearing cytoplasmic tail found in human SIRL-1 is not encoded within either mouse or
rat ORFs. Instead, their cytoplasmic tails are short and do not seem to be evolution-
arily conserved. Moreover, neither mouse nor rat putative Sirl-1 genes show evidence
of transcriptional activity as the NCBI database lacks mRNAs or ESTs that originate
from these genes. It is thus likely that both mouse and rat Sirl-1 are pseudogenes.





























Figure 3.6: To scale comparison of TARM1 genomic region of mammals. Frame-
work genes CACNG6 (black arrow on the left) and TFPT (black arrow on the right)
were used to identify Tarm1 genomic regions in bushbaby, dog, cat, elephant, rabbit,
mouse, rat and platypus. Amino-acid sequences of predicted ORFs and annotated genes
encoded between the framework genes were aligned to the known human and mouse
TARM1 and OSCAR protein sequences. Phylogenetic tree was then constructed to infer
orthology to SIRL-1, TARM1 and Tarm2. Arrows indicate the gene coding orientation.
Orthologs are color-coded.
The genomic distance between Tarm1 and Oscar genes is approximately 60 Kbp in
the mouse LRC (reference sequence NT 039413.7), which is considerably larger than the
corresponding region between human genes (∼ 17 Kbp) and could potentially contain ad-
ditional unannotated TARM1 related genes. I performed a more detailed computational
analysis of this genomic region in human, mouse and rat using nucleotide alignment of
TARM1 transcript to the genomic sequence in these species. This approach identified
a TARM1 related gene in mouse (Gm3144) and rat (RGD1564272), but not human,
encoded directly downstream of Tarm1 that I have termed Tarm-2.
The position of Tarm-2.
BLASTn alignment of the rat predicted Tarm-2 ORF to the whole mouse genomic se-
quence returns mouse Tarm-2 ORF with over 80% nucleotide identity. Phylogenetic
analysis of Tarm-2 predicted protein sequence places it closer to TARM1 than any
other Tarm1 -related gene suggesting a potential gene duplication event (see next sec-
tion Fig. 3.9).
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Bearing in mind the species-specific differences in Tarm1 -related gene number and con-
servation, it was of interest to investigate this family in other mammalian lineages. Using
two evolutionarily conserved genes, CACNG6 and TFPT, as framework genes, I iden-
tified the genomic region encoding OSCAR and TARM1 in elephant, rabbit, dog, cat,
bushbaby and platypus (Fig. 3.6). Genscan (Burge and Karlin 1997) was used to pre-
dict the location and intron-exon structure of unannotated Tarm1 -related genes encoded
within this genomic region. The translated peptide sequence of each predicted ORF was
used as a query in NCBI tBLASTn (Altschul et al. 1997) search of non-redundant trans-
lated nucleotide sequences database for matches to annotated and predicted genes across
all species. The positions and order of the predicted ORFs together with phylogenetic
analysis of the encoded proteins were used to infer orthology to VSTM1, TARM1 and
Tarm2.
Oscar and Tarm1 -related sequences appear early in mammalian evolution as evidenced
by their presence in the platypus genome. Interestingly, the genomes of bushbaby, dog
and cat contain Tarm1 -like gene located in close proximity to Tarm1 but encoded in the
opposite orientation (Fig. 3.6). An additional Tarm1 -like gene is encoded downstream
of Tarm1 in dog and cat. This suggests that the Tarm1 region may have undergone
an expansion by inverse duplication in the common ancestor of early primates and
carnivores with a subsequent contraction in hominoids, which eliminated all but one
of the TARM1 genes. In lagomorphs (rabbit) this genomic region has undergone a
contraction, which completely eliminated the Tarm1 locus.
A more detailed computational analysis of the human and mouse TARM1 amino-acid se-
quences was performed to map the boundaries of all structural domains in order to facili-
tate molecular cloning and further phylogenetic analysis. Signal peptide cleavage site was
predicted with SignalP (Petersen et al. 2011) (available here: www.cbs.dtu.dk/services/SignalP)
to lie between the positions 16 and 17 in TARM1 of both species (Fig. 3.7). Amino-acid
alignment of human and mouse TARM1 orthologs shows an extensive residue conser-
vation with 47% sequence identity and 62% sequence similarity (Fig. 3.8). Conserved
cysteines of TARM1 Ig-like domains are separated by 47 residues in the first domain
(membrane distal) and by 49 residues in the second domain (membrane proximal) of
both orthologs. In order to determine the type and the span of the domains, Pfam-A
database (http://pfam.sanger.ac.uk) of HMM-profiles representing protein domain fam-
ilies was searched with TARM1 amino-acid sequence. HMM-based analysis established
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Figure 3.7: Prediction of TARM1 signal peptide cleavage site. Full-length amino-acid
sequence of mouse and human TARM1 was analysed on SignalP 4.0 server(Petersen
et al. 2011). A) Mouse Tarm1, B) Human TARM1
hOLT-2 MIPKLLSLLCFRLCVGQGDTRGDGSLPKPSLSAWPSSVVPANSNVTLRCWTPARGV
mOLT-2 MISRLLSLLCLRLCVGQTDIPENGSPPKPSLSAWPSTVLPTKSHVTMQCKSPTPSK
** :******:****** * :** **********:*:*::*.**::* :*: . 
hOLT-2 RKGGIILESPKPLDSTEGAAEFHLNNLKVRNAGEYCCCEYYRKASPHILSQRSDVLL
mOLT-2 KKEGFALNSVKPYNLTEETADFHFTDLRQNDGGHYTCEYYSKWPHDTPSHPSNALF
:* *: *:* ** : ** :*:**:.:*: .:.*.****** * . *: *:.*
hOLT-2 GHLSKPFLRTYQRGTVTAGGRVTLQCQKRDQLFVPIMFALLKAGTPSPIQLQSPAG
mOLT-2 GYLPQPSFQAHHRGTVTAGSKVTLQCQKAGSVLGPVKFALLKVGHSTPVQTRSSTG
*:* :* :::::*******.:******* .:: *: *****.* :*:* :* :
hOLT-2 FSLVDVTAGDAGNYSCMYYQTKSPFWASEPSDQLEILVT----------------
mOLT-2 FSLQNVTARDSGEYSCVYYQAKAPYRASGPSNLLEISVIDNHLPQDLAASTFPPQL
*** :*** *:*:***:***:*:*: ** **: *** * 
hOLT-2 -VPPGTTSSNYSLGNFVRLGLAAVIVVIMGAFLVEAWYSRNVSPGESEAFKPE
mOLT-2 PKTPGTMTEGYTVDNLIRVGVAAAILLIVGGFLVEAWHSERLSPNKPW-----






2 MIPKLLSLLCFRLCVGQGDTR D SLPKPSLSAW SVVPAN N TLRCWTPA GVSFVL
2 MISRLLSLLC RLCVGQTDIPENGSP KPSLSAW TVLPTKSHVTMQCKSPTPS YFIL
** :** **: *  :* *** * : : ::*.*  :  . *
2 RKGGIILESPKP D TEGAAEFHLNNLKVR AGEYTCEYYRKASPHILSQRSDVLLLLVT
2 KKEGFALNSVKPY LTEETADFHF DLRQNDGGHYTCEYYSKWPHDTPSHPSNALFLLVT
:* *: *:* **  *  :*: :.:*: .:. .**** *  . *: *:. * **
2 GHLSKPFLRTYQRGTVTAG R LQCQKRD LFVPIMFALLKAGTPSPIQLQ AGKEID
2 GYLPQPSFQAHHRGTVTAGSK LQCQKAGSVLGPVKFALLKVGHSTP QTRSSTGMV D
*:* :* :: :****** .: **  .:: *: *** *.  : : :* *
2 FSLVDVTAGDAGNYSCMYYQTKSPFWASE SDQL ILVT------
2 FSLQNVTARDSGEYSCVYYQAKAP R SG SNLLEI VIDNHLPQ LAASTFPPQL ATS
*** :*  * : * * : : *  *: *  *
2 -VPPGTTSSNYSLGNFVR LAAVIVVIMGAFLVEAWYSRNVSPGESEAFKPE
2 PKTPGTMTEGY VDNLIR GVAAAILLIVGGF VEAWHSERLSPNKPW-----






Figure 3.8: Amino-acid sequence alignment of human (h) and mouse (m) TARM1
orthologs. Structural protein domains are labeled above the alignement. Grey-shaded
amino-acids are encoded at exonic splice junctions. Conserved cysteines that form
the Ig-fold intra-chain disulfide bridge are in bold font. Transmembrane region is un-
derscored and contains a conserved arginine (highlighted) predicted to mediate FcRγ
association.
the boundaries of both domains and identified them as belonging to the Ig 2 family
(PF13895) with E-values of 2e-10 and 2.9e-09 (hTARM1), 4e-09 and 1.3e-10 (mTARM1)
for domain one and two respectively. The first domain spans 92 residues (28-119) and
the second 94 residues (125-218) in both orthologs (Fig. 3.8)






























Figure 3.9: Phylogenetic tree constructed using amino acid sequences of the ex-
tracellular portions of LRC-encoded proteins. Amino acid sequences were aligned with
Clustalw and the phylogenetic tree was constructed using the Neighbor-Joining method
(Saitou and Masatoshi Nei 1987). The percentage of replicate trees in which the asso-
ciated taxa clustered together in the bootstrap test (100 replicates) are shown next to
the branches (Felsenstein 1985). The evolutionary distances were computed using the
p-distance method (M. Nei and S. Kumar 2000) reflecting the number of amino acid
differences per site. All positions containing gaps and missing data were not included
in the analysis. The analysis was performed in MEGA5 (Tamura et al. 2011).
3.2 Phylogenetic analysis
SIRL-1 and TARM1 are members of the broad immunoglobulin superfamily (IgSF) and
are evolutionarily related to other members of the LRC. However, within this set of
genes TARM1 and SIRL-1 are most closely related to OSCAR. A neighbour-joining
(NJ) phylogenetic tree constructed from the multiple protein sequence alignment of
the extracellular portions of human and mouse LRC genes places TARM1, SIRL-1 and
OSCAR into a well-defined clade with a high bootstrap value (Fig. 3.9).
The majority of the LRC-encoded receptors are composed of two or more Ig-like domains,
each encoded within a separate exon. This arrangement facilitates gene evolution by
the exchange of encoded domains through exon shuffling. Indeed, exon shuffling was
demonstrated to underlie the emergence of new KIR genes in hominoids (Rajalingam,
Parham, and Abi-Rached 2004). In order to account for potential exon duplication
and shuffling events, multiple sequence alignment of TARM1-related genes and other
LRC members was repeated using amino-acid sequences of each Ig-like fold separately.
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This approach produced a clear grouping of the first and the second domains of TARM1-
related proteins into separate clades. SIRL-1, which has a single Ig-like domain, grouped
with the domain-1 clade of TARM1 (Fig. 3.10). Although OSCAR Ig-domain sequences
did not group within the TARM1 clades, OSCAR Ig1 and OSCAR Ig2 formed sister
clades to the respective Ig-clades of TARM1-related genes.































































































Figure 3.10: Phylogenetic tree constructed using amino acid sequences of the Ig-like
domains of LRC-encoded proteins. Ig-like domain amino acid sequences were aligned in
Clustalw and the phylogenetic tree was constructed using the Neighbor-Joining method
(Saitou and Masatoshi Nei 1987). The percentage of replicate trees in which the asso-
ciated taxa clustered together in the bootstrap test (100 replicates) are shown next to
the branches (Felsenstein 1985). The evolutionary distances were computed using the
p-distance method (M. Nei and S. Kumar 2000) reflecting the number of amino acid
differences per site. All positions containing gaps and missing data were not included
in the analysis. The analysis was performed in MEGA5 (Tamura et al. 2011).
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3.3 Summary
The LRC encodes sets of paired activating and inhibitory receptors that modulate the
function of classical innate and adaptive immune cells, such as NK, CTL and myeloid
cells in addition to non-classical immune cells, such as platelets and osteoclasts. This
chapter described the comparative genomics and evolutionary characterisation of two
novel paired OSCAR-related genes, Vstm1 and Tarm1, encoded on the centromeric
boundary of the human and mouse LRC regions.
Mouse and human Tarm1 genes encode proteins belonging to the immunoglobulin su-
perfamily. Their extracellular portions are comprised of two Ig-like domains and are well
conserved both in sequence and exon structure. The transmembrane regions contain a
conserved arginine, often seen in activating receptors where it serves as an association
site for ITAM-bearing signalling adaptors such as FcεRγ. An additional, Tarm1 -related
gene, which I termed Tarm2 is encoded just downstream of Tarm1 in mouse, rat and
elephant but is not present in human.
Human SIRL-1, in contrast to TARM1, contains only a single Ig-like domain and lacks
the conserved arginine within its TM. Instead, a long cytoplasmic tail contains two
ITIMs, implying inhibitory potential through SHP-1 recruitment. Murine Sirl-1 is not
conserved as only a partial ORF, lacking the inhibitory cytoplasmic tail, is found with
no evidence of transcriptional activity.
This disparity in gene conservation and number between human and mouse extends
to several mammalian orders studied. I analysed the genomic region of Tarm1 -related
genes in Primates (human and bushbaby), Carnivora (cat and dog), Rodentia (mouse
and rat), Lagomorpha (rabbit), Proboscidea (elephant) and Monotremata (platypus).
Based on this analysis, it appears that the earliest mammalian OSCAR-related sequence
is found in platypus and is orthologous to Tarm1. Further, the comparison of Tarm1
genomic region showed evidence of its expansion and contraction resulting in the birth
and death of the members of Tarm1 family in different mammalian orders. In early
primates (represented here by the bushbaby) and the genomes of cat and dog, but
not human, Tarm1 seems to have undergone rounds of duplication events including an
inverse duplication giving rise to two additional Tarm1 -like genes.
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This duplication event does not however explain the emergence of SIRL-1 which contains
a single Ig-like domain and a long cytoplasmic tail with inhibitory ITIMs. To investigate
a potential acquisition of the inhibitory tail from another LRC-encoded gene through
exon shuffling, BLAST search was performed with the SIRL-1 tail amino-acid sequence.
The search did not identify any significant hits other than SIRL-1 orthologs. A more in-
depth analysis would thus be required to establish the origins of SIRL-1. Interestingly,
the single Ig domain of SIRL-1 clusters with high confidence values with the Ig1 domains
of human and mouse TARM1 and TARM2 proteins indicating common evolutionary
origin.
The clustering of gene families within the LRC suggests a common ancestral relationship
and a closely linked functional role as has been demonstrated for KIRs and LILRs. It
is likely that SIRL-1 and TARM1 evolved to function antagonistically in primates and
other mammals with functional SIRL-1 and TARM1 proteins. The lack of conservation
of Sirl-1 gene in rodents may be due to the differential cell and tissue distribution
of its activating counterparts Tarm1 and Oscar. OSCAR is expressed on osteoclasts in
human and mouse where it plays a central role in the regulation of osteoclastogenesis (A.
Barrow, N. Raynal, et al. 2011). In human, but not mouse, OSCAR is also expressed on
monocytes, neutrophils, macrophages and DCs where it modulates innate and adaptive
immune responses (Merck, Gaillard, Scuiller, et al. 2006; Merck, Gaillard, Gorman, et al.
2004). In order to study TARM1 protein cell and tissue distribution, monoclonal anti-
human and -mouse TARM1 antibodies had to be developed. The next chapter describes
the development and characterisation of these reagents.
Chapter 4
Generation and validation of
anti-TARM1 monoclonal
antibodies
At the onset of this project, the TARM1 gene was a newly identified and as yet an
uncharacterised member of the LRC. This presented a particular challenge as new im-
munological tools, such as monoclonal antibodies, had to be developed and validated in
order to permit further characterisation and functional analysis of TARM1 protein.
This chapter describes the development of reagents that enabled me to undertake further
characterisation of TARM1 receptor expression and function.
4.1 Generation and characterisation of monoclonal anti-
bodies against mouse and human TARM1
Multiple approaches are available for generating monoclonal antibodies, each with its
own advantages and drawbacks. Characterisation of TARM1 required antibodies that
would be suitable for a wide range of immunological techniques where the antibodies
would recognise both linear and conformational epitopes, such as in Western blot and
flow cytometry respectively.
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I decided to develop a chimeric TARM1 protein comprised of TARM1 ectodomain fused
to the Fc region of human IgG1 for use as an immunogen. This approach provided a dual
advantage, both enabling the generation of a large number of monoclonal antibodies to
a variety of TARM1 epitopes and provided a fusion protein tool which could be used in
its own right to study functional aspects of TARM1 receptor and its putative ligand.
Soluble fusion proteins composed of the constant region of human or murine IgG1 fused to
the extracellular portion of a protein of interest are used extensively in both research and
therapeutic applications. A number of receptor ligand interactions have been identified
using such soluble Fc fusions (Latchman, McKay, and Reiser 1998).
Besides the apparent advantage of producing a secreted form of an otherwise trans-
membrane protein, the presence of an Fc portion confers additional valuable properties
to the fusion protein. It acts as a tag, allowing easy visualisation in the absence of
monoclonal antibodies against the protein of interest. The Fc portion also makes it
possible to purify the fusion proteins using standard chromatography with protein A or
G columns. Moreover, due to the natural propensity of the IgG heavy chain constant
region to dimerise, Fc fusion proteins form homodimers that display higher avidity for
their ligand than monomeric forms.
Thus, construction of TARM1 fusion proteins equipped me with a valuable tool to study
TARM1 protein function as well as to serve as an immunogen for generating a panel of
monoclonal anti-TARM1 antibodies. This section describes how TARM1 fusion proteins
were generated, expressed, purified and validated.
4.1.1 Cloning of TARM1 into Signal pIG vector.
Using bioinformatics tools such as protein secondary structure prediction, domain identi-
fication and multiple sequence alignment with other LRC-encoded proteins, I established
the amino acid sequence of the two Ig-like folds of TARM1 and the membrane proximal
”stem” region to be between the following amino acids: mouse QTDIPE...GYTVDN
and human QGDTRG...NYSLGN. Next, the DNA sequence encoding this extracellu-
lar portion was amplified by PCR introducing restriction enzyme sites compatible with
the multiple cloning site of the Signal pIG plus vector. A detailed cloning procedure
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Sig pigplus




extracellular region Xa IgG1 Fc tail
Figure 4.1: Schematic representation of TARM1-Fc construct. TARM1 sequence
encoding two Ig-like domains and the stem region was cloned into Sig pIG plus vector
placing TARM1 extracellular portion downstream of CD33 signal peptide and upstream
of human IgG1 C region. The resulting construct is under control of two promoters T7
and CMV. A factor Xa site is encoded within the vector sequence between TARM1 and
IgG1 Fc tail.
is described in Materials and Methods section. Briefly, TARM1 amplicons were di-
gested, purified and ligated into a linearised Signal pIG plus vector. Ligation products
were transformed into competent E. coli DH5α cells. The resulting construct is under
transcriptional control of a dual promoter T7 and CMV allowing for vector expression
in both bacterial and mammalian cells respectively. The construct places TARM1 se-
quence downstream of the CD33 signal peptide, ensuring efficient protein secretion, and
is followed by a human IgG1 Fc region (Fig. 4.1). A factor Xa site is included in the vec-
tor sequence between TARM1 and IgG1 Fc tail which, if necessary, permits enzymatic
removal of the Fc portion from the fusion protein.
The sequences of human and mouse TARM1 Signal pIG plus constructs were validated
by sequencing and transfected into Hek293 cells for a large-scale protein secretion as
described next.
4.1.2 Expression, purification and validation of human and mouse TARM1
Fc proteins
Hek293 cells were chosen for the expression of TARM1 Fc fusion proteins. Initially,
transient transfections were performed in a 6-well format, and cell culture medium was
collected to confirm the presence of secreted fusion proteins by Western blot using anti-
human IgG1 Fc-specific antibody. As mentioned earlier, Fc fusion proteins tend to form
covalently-linked dimers; it was, therefore, important to establish whether:









hTARM1 mTARM1 hTARM1 mTARM1
Figure 4.2: Western blot analysis of TARM1 Fc fusion-containing supernatants. Con-
fluent Hek293 cells stably expressing human (h) or mouse (m) TARM1 Fc fusion pro-
teins were grown for 5 days. Supernatants were collected and cell debris removed by
centrifugation. 10 µl of 20 times concentrated supernatants were treated as indicated
and analysed by Western blot. The PVDF membranes were probed with anti-human
IgG1 Fc-specific antibody conjugated to HRP.
1) Human and mouse TARM1 Fc fusion proteins were efficiently expressed as soluble
molecules
2) formed dimers, remained as monomers or were expressed as a mixture of the two, and
3) whether any potential dimerisation was mediated by covalent bonds
Fusion protein-containing cell culture supernatants were concentrated 20 times and anal-
ysed by Western blot following different treatments. The supernatants were either re-
duced with dithiothreitol (DTT) or left untreated, with or without concomitant heat
treatment in the presence of sodium dodecyl sulfate (SDS). Figure 4.2 (left panel)
shows that a complete reduction of the disulphide bridges (samples with DTT and heat
treatment) resulted in a single band of approximately 70 kDa for human TARM1 Fc
fusion protein and 90 kDa for mouse. In the absence of DTT and heat treatment (right
panel) the bulk of both human and mouse TARM1 Fc fusion proteins were expressed
as dimers. However, heat treatment alone caused partial dissociation of the dimers into
monomers (non-reduced plus heat treatment) indicating that some of the dimerisation is
not mediated by covalent linkage between the Fc domains.
These results confirmed that both human and mouse TARM1 Fc fusion proteins were
indeed secreted predominantly as covalently linked dimers enabling me to move on to
a large-scale protein expression and purification. To this end, Hek293 cells were trans-
fected with TARM1 Fc constructs and grown under neomycin selection until stable cell
lines were established for each fusion construct. Following selection, stably transfected
cells were expanded and seeded into triple-bottom tissue culture flasks. Cell culture
supernatants were collected over the course of 3 weeks and fusion proteins were purified
on protein-A columns.
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To test the purification efficiency and the Fc fusion protein quality, samples of the col-
umn flow-through from each purification step were denatured, reduced and separated
on a 10% polyacrylamide gel. Protein bands were visualised with Coomassie stain Fig-
ure 4.3A. The lane containing the cell culture supernatant (sup) prior to the purification
contains bands corresponding to protein constituents of the cell culture medium, with
the most abundant being BSA (∼ 66 kDa). In the first and second column washes (lanes
w1 and w2) the irrelevant proteins were removed. The final eluted TARM1 Fc fusion
fraction (eluate) displayed the expected size.
Next, the integrity and stability of the purified fusion proteins was examined by Western
blot after two rounds of freeze-thaw cycles. Samples were either treated under reduc-
ing or non-reducing conditions with or without heating and analysed by Western blot.
The membrane was probed with HRP-conjugated anti-human IgG1 Fc specific anti-
body (Fig. 4.3B). Under non-reducing conditions (right panel) both mouse and human
TARM1-Fc fusion proteins were present as dimers, although heat-treatment caused a
small fraction of the dimers, not linked covalently, to dissociate into monomers (lanes 1
and 3 ). Hence, purified TARM1-Fc fusions retained their integrity and exhibited good
stability under storage conditions (1 mg/ml in Tris-neutralised elution buffer, pH7.5, at
-80 ℃) even after repeated freeze-thaw cycles. This made them suitable for use as im-
munogens for development of monoclonal antibodies against human and mouse TARM1
extracellular domains and for further study of TARM1 function.
4.2 Immunisation and characterisation of monoclonal an-
tibodies
All immunisations with TARM1 Fc fusion proteins, cell fusion and the initial enzyme-
linked immunosorbent assay (ELISA)-based antibody screen were performed in collab-
oration with Professor K. Skjødt laboratory as described in Materials and Methods.
I performed further characterisation of two panels of monoclonal antibodies, 31 rat anti-
mouse TARM1 and 91 mouse anti-human TARM1. The performance and specificity of
individual clones were tested by flow cytometry, Western blot and immunofluorescent
microscopy.






































Figure 4.3: TARM1 Fc protein purification and validation. (A) Coomassie stain
of denatured and reduced samples of column flow-through taken at different stages of
TARM1 Fc purification. sup, 20 times concentrated cell culture supernatant; w1, first
wash; w2, second wash; eluate, eluted TARM1 Fc fusion proteins. (B) Western blot
analysis of purified TARM1 Fc fusion proteins after two repeated freeze-thaw cycles.
Human and mouse fusion proteins were stored at -80 ℃ until analysis. Samples were
treated as indicated and analysed by Western blot, ∼40 ng of protein were loaded per
lane. Membranes were probed with anti-human IgG1 Fc specific antibody conjugated
to HRP
To determine the antibody reactivity, I expressed full-length FLAG-tagged human and
mouse TARM1 proteins in Hek293T cells as well as HA-tagged versions were retrovirally
transduced into 2B4 cells. Mouse TARM1-expressing cells were stained with rat anti-
mouse TARM1 monoclonal antibodies; cells transduced with human TARM1 were used
as a negative control. A representative screening panel for flow cytometry using 2B4 cells
is shown in Figure 4.4. Median fluorescence intensity (MFI) of staining normalised to
control MFI was plotted for each clone (see the bar chart). The same strategy was used
to screen anti-human TARM1 monoclonal antibodies using mouse TARM1 expressing
2B4 cells as a negative control.
Hek293T cells transiently transfected with full-length FLAG-tagged TARM1 were screened
with antibodies for use in Western blot. Rat anti-mouse TARM1 clone 13 (mAb13) and
mouse anti-human TARM1 clone 4 (mAb4) were chosen for use in flow cytometry ap-
plications. Clones mAb2 (mouse-specific) and mAb74 (human-specific) performed well
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mAb2 mAb3 mAb5 mAb7mAb6
mAb11 mAb12 mAb13 mAb17mAb15
mAb18 mAb20 mAb25 mAb28mAb26
mAb29 mAb30 mAb33 mAb36mAb35
mAb37 mAb39 mAb40 mAb50mAb42
mAb51 mAb52 mAb53 mAb55mAb54
mAb57 anti-HA mTARM1-HA transfected 
hTARM1-HA transfected 









Figure 4.4: Anti-mouse TARM1 monoclonal antibody screen. 2B4 cells were trans-
duced with HA-tagged human (grey filled histograms) or mouse TARM1 (black line)
and stained with rat anti-mouse TARM1 antibodies. Normalised median fluorescence
intensity (MFI) of staining was compared for all antibody clones. Similar levels of cell-
surface expression of both mouse and human TARM1 was confirmed by staining with
anti-HA antibody.
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ms TARM1 hu TARM1
ms TARM1 hu TARM1
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Figure 4.5: Anti-TARM1 monoclonal antibodies bind specifically to TARM1.
Hek293T cells transiently transfected with TARM1 (open histograms) or mock trans-
fected (filled histograms)were stained with monoclonal anti-mouse TARM1 mAb13 (left
panel) or anti-human TARM1 mAb4 (right panel) and fluorescently labelled secondary
Abs and analysed by flow cytometry. (B)Western blot analysis of the total lysate
from TARM1-transfected cells. Hek293T cells were transfected with full-length Flag-
tagged TARM1 and the specificity of anti-TARM1 Abs was determined by Western
blot. Anti-Flag and anti-TARM1 mAbs detected bands of ∼40 kDa for mouse TARM1
(left panel,mAb2) and ∼34 kDa for human TARM1 (right panel, mAb74). Anti-Flag
Ab failed to detect the higher molecular mass band of both mouse and human TARM1
proteins. No bands were detected in untransfected (neg) cell lysates.
in Western blot (Figure 4.5). Surprisingly, the anti-Flag antibody failed to detect the
higher molecular mass (Mr) band detected by the TARM1-specific antibodies in both
human and mouse blots. This discrepancy may be due to the steric occlusion of the
Flag epitope caused by TARM1 glycosylation and/or tertiary structure.
Next, It was crucial to validate that the anti-TARM1 antibodies were reactive against
both the recombinant and the endogenously expressed protein. The observation that
Tarm1 mRNA was abundant in the mouse bone marrow prompted me to investigate
whether anti-TARM1 antibodies could detect the endogenous TARM1 on the cell surface
of bone marrow-derived dendritic cells (BMDC).
I selected a panel of antibody clones with the highest MFI of TARM1 staining on
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transduced 2B4 cells (as shown in Fig. 4.4. Additionally, it was of interest to establish
whether TARM1 expression on the cell surface of resting BMDC was altered following
their stimulation with LPS. For this purpose, bone marrow cells were isolated from a
C57BL/6 mouse and differentiated into BMDC for 7 days as described in Materials and
Methods. On day 8, cells were stimulated with ultra-pure LPS (100 ng/ml) for 24 h or left
untreated. BMDC were stained for flow cytometric analysis of TARM1 expression with
a panel of selected antibody clones or a Rat IgG2a isotype control antibody. Figure 4.6
shows that selected clones (except mAb18 which was used as a negative control) stained
with high MFI and detected the presence of TARM1 protein on the cell surface of both
resting and LPS-stimulated BMDCs. Comparison of staining MFI for control (PBS)
and LPS-treated cells revealed a strong upregulation of TARM1 cell-surface expression
following LPS-induced BMDC maturation.
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Figure 4.6: Anti-mouse TARM1 monoclonal antibodies detect endogenous protein
expression in resting and LPS-stimulated BMDC. C57BL/6 bone marrow cells were
differentiated into BMDC as described in Materials and Methods. BMDC were plated
into 6-well plates and stimulated with LPS (100 ng/ml) for 24 h or left untreated
(PBS). Following stimulation cells were detached and stained with a panel of selected
anti-mouse TARM1 monoclonal antibodies (black lines) or isotype control (grey filled
histograms). MFI (median) of TARM1 stain was plotted for each antibody clone.




















IF microscopy Flow cytometry
Figure 4.7: Anti-mouse TARM1 monoclonal antibody detects endogenous expression
of TARM1 in LPS-stimulated BMM by immunofluorescent microscopy. Representative
image from a screening panel of anti-mouse TARM1-specific antibodies. BMM were
differentiated as described in Materials and Methods, stimulated with 100 ng/ml ultra-
pure LPS for 24 h or left untreated. Cells were fixed with 2% PFA and stained with a
panel of anti-mouse TARM1-specific antibodies or isotype control.
To screen anti-mouse TARM1-specific antibodies for suitability in immunofluorescent
(IF) microscopy I used in vitro differentiated BMM that were treated with LPS (100
ng/ml) or left untreated for 24 h. Cells were differentiated for 6 days as described in
Materials and Methods, detached from culture dishes and transferred into wells with
sterile microscopy glass cover slips, allowed to attach for 6 h and stimulated with 100
ng/ml ultra-pure LPS for 24 h or left untreated. Cells were fixed with 2% PFA and
stained with a panel of anti-mouse TARM1 specific antibodies or isotype control. Rep-
resentative staining of mAb53 is shown in Figure 4.7. TARM1-specific antibody clones
2, 13, 20, 28, 29, 30 and 53 performed equally well in this assay. The IF microscopy
staining of BMM showed that only LPS-treated cells expressed TARM1 protein. This
was also confirmed by flow cytometric staining of BMM using mAb53 (Fig. 4.7 histogram
overlays) and other clones.
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4.3 Summary
To characterise the endogenous TARM1 protein expression specific antibodies were de-
veloped. I created soluble human and mouse TARM1 fusion proteins consisting of the
TARM1 ectodomain fused to the human IgG1 Fc domain to serve as immunogens. Two
panels of monoclonal anti-mouse and -human TARM1 antibodies were raised and char-
acterised for use in flow cytometry, Western blot and IF microscopy.
Many antibody clones performed well in the assays tested. I selected the following
clones for further use in this work. Antibody clones mAb13, mAb53 (both rat anti-
mouse TARM1) and mAb4 (mouse anti-human TARM1) stained TARM1-transfected
and primary cells, as determined by flow cytometry. Clones mAb2 (rat anti-mouse
TARM1) and mAb74 (mouse anti-human TARM1) detected Flag-tagged TARM1 in
transfected cell lysates by Western blot. mAb53 performed well both in IF microscopy
and in flow cytometry of primary cells.




The vast majority of transmembrane proteins undergo post-translational modifications
(PTM) that can have an impact on protein structure, stability and biological function.
Glycosylation is amongst the most widespread modifications, affecting an estimated 70%
of all eukaryotic proteins (Apweiler, Hermjakob, and Sharon 1999). Disruption of the
normal glycosylation pattern has been implicated in a number of autoimmune conditions
(Doyle and Mamula 2001). Thus, prediction of the glycosylation sites with a subsequent
experimental validation is an important part of the characterisation of novel proteins as
well as protein engineering.
Four main categories of glycosylation are defined according to the type of the bond
formed between the sugar and the amino-acid. These are N-linked, O-linked, C-mannosylation
and glyco-phosphatidylinositol (GPI) anchor attachments.
• N-glycosylation is achieved through the addition of oligosaccharides to the amino
group of an asparagine. This process occurs co-translationally within the endoplasmic
reticulum and affects protein folding.
• O-linked glycosylation, on the other hand, is not restricted to a single subcellular
compartment and involves the modification of the hydroxyl group of a serine or a thre-
onine (Reviewed in (Blom et al. 2004)).
• In C-mannosylation, a single α-mannopyranose is attached to the tryptophan residue
via a C-C linkage (Hofsteenge et al. 1994).
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hOLT-2 MIPKLLSLLCFRLCVGQGDTRGDGSLPKPSLSAWPSSVVPANSNVTLRCWTPARGV
mOLT-2 MISRLLSLLCLRLCVGQTDIPENGSPPKPSLSAWPSTVLPTKSHVTMQCKSPTPSK
** :******:****** * :** **********:*:*::*.**::* :*: . 
hOLT-2 RKGGIILESPKPLDSTEGAAEFHLNNLKVRNAGEYCCCEYYRKASPHILSQRSDVLL
mOLT-2 KKEGFALNSVKPYNLTEETADFHFTDLRQNDGGHYTCEYYSKWPHDTPSHPSNALF
:* *: *:* ** : ** :*:**:.:*: .:.*.****** * . *: *:.*
hOLT-2 GHLSKPFLRTYQRGTVTAGGRVTLQCQKRDQLFVPIMFALLKAGTPSPIQLQSPAG
mOLT-2 GYLPQPSFQAHHRGTVTAGSKVTLQCQKAGSVLGPVKFALLKVGHSTPVQTRSSTG
*:* :* :::::*******.:******* .:: *: *****.* :*:* :* :
hOLT-2 FSLVDVTAGDAGNYSCMYYQTKSPFWASEPSDQLEILVT----------------
mOLT-2 FSLQNVTARDSGEYSCVYYQAKAPYRASGPSNLLEISVIDNHLPQDLAASTFPPQL
*** :*** *:*:***:***:*:*: ** **: *** * 
hOLT-2 -VPPGTTSSNYSLGNFVRLGLAAVIVVIMGAFLVEAWYSRNVSPGESEAFKPE
mOLT-2 PKTPGTMTEGYTVDNLIRVGVAAAILLIVGGFLVEAWHSERLSPNKPW-----






2 MIPKLLSLLCFRLCVGQGDTR D SLPKPSLSAW SVVPAN N TLRCWTPA GVSFVL
2 MISRLLSLLC RLCVGQTDIPENGSP KPSLSAW TVLPTKSHVTMQCKSPTPS YFIL
** :** **: *  :* *** * : : ::*.*  :  . *
2 RKGGIILESPKP D TEGAAEFHLNNLKVR AGEYTCEYYRKASPHILSQRSDVLLLLVT
2 KKEGFALNSVKPY LTEETADFHF DLRQNDGGHYTCEYYSKWPHDTPSHPSNALFLLVT
:* *: *:* **  *  :*: :.:*: .:. .**** *  . *: *:. * **
2 GHLSKPFLRTYQRGTVTAG R LQCQKRD LFVPIMFALLKAGTPSPIQLQ AGKEID
2 GYLPQPSFQAHHRGTVTAGSK LQCQKAGSVLGPVKFALLKVGHSTP QTRSSTGMV D
*:* :* :: :****** .: **  .:: *: *** *.  : : :* *
2 FSLVDVTAGDAGNYSCMYYQTKSPFWASE SDQL ILVT------
2 FSLQNVTARDSGEYSCVYYQAKAP R SG SNLLEI VIDNHLPQ LAASTFPPQL ATS
*** :*  * : * * : : *  *: *  *
2 -VPPGTTSSNYSLGNFVR LAAVIVVIMGAFLVEAWYSRNVSPGESEAFKPE
2 PKTPGTMTEGY VDNLIR GVAAAILLIVGGF VEAWHSERLSPNKPW-----






Figure 5.1: Amino-acid sequence alignment of human and mouse TARM1 orthologs
showing predicted structural elements and post-translational modification sites. Struc-
tural protein domains are labeled above the alignment. Grey-shaded amino-acids are
encoded at exonic splice junctions. Conserved cysteines that form the Ig-fold intra-
chain disulfide bridge are in bold font. The transmembrane region is underscored. As-
paragines predicted to be glycosylated are enclosed in black rectangles. O-glycosylated
sites are marked by grey rectangles
Some eukaryotic cell-surface proteins undergo GPI-modification at their carboxyl ter-
minus which anchors them to the cell membrane. This modification requires a prior
proteolytic cleavage of a C-terminal propeptide.
PTM sites can be predicted with various degrees of confidence, and recent advances in
the development of computational protein analysis tools as well as the growing body of
experimentally validated protein structures and post-translational modifications allowed
refinement of such predictions. The sequon Asn-Xaa-Ser/Thr (where Xaa is any amino
acid except Pro) was identified as a prerequisite sequence for the N-glycosylation. Such
consensus was however more difficult to infer for GPI-anchors and O-glycosylation (Blom
et al. 2004). Instead, the analysis of validated modification sites revealed the importance
of sequence composition and the amino acid properties surrounding the sites of these
types of glycosylation (B. Eisenhaber, Bork, and F. Eisenhaber 2001).
This chapter describes computational and experimental approaches used to characterise
TARM1 protein PTMs.




































Figure 5.2: Western blot analysis of TARM1 glycosylation. Left panel : detection of
FLAG-tagged full-length human TARM1 protein in total lysate of transfected Hek293T
(+) and untransfected cells (-) with anti-FLAG antibody. Center and Right panels:
total cell lysates of TARM1 transfected Hek293T cells were either left untreated (Un-
treated), mock treated (Mock) or treated with EndoH (center panel) or PNGase (right
panel). The membrane was probed with anti-TARM1 mAb.
5.1 TARM1 is glycosylated
Several freely available prediction tools were used to analyse the protein sequences
of human and mouse TARM1. Computational analysis identified two putative N-
glycosylation sites (Fig. 5.1) in each sequence (NetNglyc v1.0 software (Gupta, Jung,
and Brunak 2004)). In addition to the predicted N-glycosylation sites, human TARM1 is
also predicted to have two O-glycosylation sites (NetOglyc v4.0 (Steentoft et al. 2013)).
No C-mannosylation (NetCglyc v1.0 (Julenius 2007)) or GPI-anchor sites were found
(big-PI predictor v.3 (B. Eisenhaber, Bork, and F. Eisenhaber 2001)) for either protein.
Experimental validation of the glycosylation state of proteins relies on the fact that
variations in the composition of the oligosaccharides and the saturation of the pre-
dicted attachment sites affects the total protein mass and its mobility through the SDS-
polyacrylamide gel. Thus, the analysis of the mobility shift following protein treatment
with specific glycosidases allows such characterisation.
Peptide-N-glycosidase F (PNGaseF) is widely used to assess the N-glycosylation state.
PNGaseF treatment results in the cleavage of the glycosidic bond between the asparagine
and high mannose, hybrid or complex N-glycans. In contrast to PNGase, endoglycosi-
dase H (Endo H) is unable to cleave off N-linked complex glycans synthesised during
the transit through Golgi. This feature is useful when distinguishing between early and
late protein trafficking.
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I performed a deglycosylation study to validate the occupancy of the predicted glycan
attachment sites in the human TARM1 and to establish the dominant protein form
recognised by the anti-TARM1 monoclonal antibody used for Western blot assays.
To that end, Hek293T cells were transiently transfected with a FLAG-tagged full-length
human TARM1 and total cell lysates were treated with either PNGaseF, EndoH or mock
treated as described in the Materials and Methods section. Following the treatment, the
protein mobility shift was examined by SDS-PAGE (Fig. 5.2).
Immunobloting using the anti-FLAG antibody or the monoclonal anti-TARM1 antibody
showed a band of ∼34 kDa which was ∼4 kDa larger than the predicted 29.5 kDa for
the unglycosylated TARM1 form. The anti-TARM1 mAb, but not the anti-FLAG mAb,
also bound to a higher molecular mass (Mr) product that migrated as a broad band of
∼37-40 kDa. Conversely, the anti-FLAG mAb, but not the anti-TARM1 mAb recognised
a low Mr band of ∼30 kDa, which could represent a degradation product.
The treatment with Endo H resulted in a conversion of the 34 kDa band, but not the
high Mr band, to ∼30 kDa product (Fig. 5.2, centre panel). This suggests that the
main protein species recognised by both the anti-FLAG and the anti-TARM1 mAb is
the early, Endo H sensitive form. The treatment with PNGase F resulted in all TARM1
migrating at ∼30 kDa, which represents the fully deglycosylated form (Fig. 5.2, right
panel).
These observations show that TARM1 protein is N-glycosylated and is recognised by the
monoclonal anti-TARM1 antibody irrespective of its glycosylation state. The product
migrating at an apparent Mr of ∼30 kDa represents the fully deglycosylated protein as
predicted by theoretical mass calculation. The early TARM1 polypeptide residing within
the ER as indicated by the EndoH sensitivity and running at an apparent Mr of ∼34
kDa was the predominant protein species recognised by the anti-TARM1 antibody. The
fully glycosylated, EndoH resistant protein, exhibiting a broad molecular weight range,
most likely represents different extents or branching of sugar moieties with differential
effect on the total glycoprotein mass. The discrepancy between the staining of the
predominant product and its fully deglycosylated form suggests that the anti-TARM1
mAb may have a lower affinity for the deglycosylated polypeptide. However, I can not
rule out that the discrepancy could also be due to a partial degradation of TARM1
protein during the deglycosylation reaction.
Chapter 5. TARM1 protein characterisation 73
The results suggest that ∼10 kDa oligosaccharide is added to TARM1 protein when it
is expressed in Hek293T cells. The oligosaccharide size and composition is often cell-
specific and can differ in primary cells from that observed here.
Since the treatment with PNGaseF resulted in the band running at an apparent Mr of
a fully deglycosylated TARM1, it is likely that the predicted O-glycosylation sites are
not occupied. I therefore did not proceed with the O-glycosidase treatment.
5.2 TARM1 associates with ITAM adapter FcRγ chain
As mentioned previously, a conserved arginine residue is embedded at position 3 within
the TM of mouse and human TARM1. The transmembrane arginine is also present in
TARM1 homolog OSCAR where it mediates the association with the FcRγ resulting
in an increased receptor cell surface expression and transduction of activating signals
(Merck, Gaillard, Gorman, et al. 2004). Signalling adapters have been shown to associate
preferentially with either arginine or lysine embedded within the TM of the associating
receptor. For instance, the majority of receptors known to associate with DAP12 bear
a transmembrane lysine. However, a transmembrane arginine is a hallmark of an FcRγ
and CD3ζ associating receptor. Mutagenesis experiments that substitute arginine for
lysine or vice versa cause a dramatic reduction in the association efficiency (Feng, Call,
and Wucherpfennig 2006). Such preferential assembly is dictated by several structural
features of both the adapters and the associating receptors. Among these is the relative
position of the pairing acidic and basic residues within the membrane-spanning domains
of the assembling partners. All FcRγ associating receptors bear an arginine at position 3
in the N-terminal portion of the membrane-spanning segment which is well aligned with
the aspartic acid of the FcRγ dimer. On the contrary, the aspartic acid in DAP10 and
DAP12 are positioned towards the centre of the transmembrane segment aligning with
the basic residue of the interacting receptor (Feng, Call, and Wucherpfennig 2006; Feng,
Garrity, et al. 2005). Nevertheless, a cell-specific adapter association promiscuity was
demonstrated for some immune receptors with implications for their biological functions
(Nakahashi et al. 2007; Gilfillan et al. 2002; Diefenbach et al. 2002).




























Figure 5.3: TARM1 co-immunoprecipitates with ITAM-containing adapter FcRγ.
Hek293 cells stably expressing HA-tagged adapters DAP10, DAP12, FcRγ and parental
adapter-negative cells (neg) were transiently transfected with full-length TARM1.
Aliquots of whole lysates were analysed by Western blot with anti-HA antibody (top
panel). TARM1 was then immunoprecipitated with monoclonal anti-TARM1 antibody
and the complex was analysed by Western blot (bottom panel) with anti-HA antibody
to detect the co-precipitated adapter.
To establish whether TARM1 associates with an ITAM-containing adapter, I used
Hek293 cell-lines stably expressing haemagglutinin (HA) epitope-tagged FcRγ (HA-
FcRγ) chain, DAP12 (HA-DAP12) and CD3ζ (HA-CD3ζ) adapters. Each cell-line was
transiently transfected with a full-length N-terminally FLAG-tagged human TARM1.
I used the monoclonal anti-TARM1 antibody to co-immunoprecipitate the TARM1-
adapter complex from cell lysates.
Immunoblotting of the complexes with an anti-HA antibody, recognising the associated
ITAM-adapter, revealed that only FcRγ co-immunoprecipitated with TARM1 (Fig. 5.3).
These data demonstrate that TARM1 can stably associate with the ITAM adapter FcRγ
consistent with activating function (Nakajima et al. 1999; A. Barrow, N. Raynal, et al.
2011; Lewis L Lanier et al. 1998; Merck, Gaillard, Gorman, et al. 2004).
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5.3 Summary
In this chapter I provided evidence that human TARM1 is post-translationally modified
by N-glycosylation as demonstrated by changes in the protein mobility shift through
SDS-polyacrylamide gel following treatment with N-glycosidases. The monoclonal anti-
TARM1 antibody clone chosen for use in immunoblotting applications recognises pre-
dominantly the fully glycosylated protein but is also capable of reacting with a deglyco-
sylated form, albeit with lower affinity.
The cytoplasmic tails of human and mouse TARM1 are short and devoid of signalling
motifs, a common feature of many immunoreceptors that associate with an ITAM-
containing adaptor for signal transduction. In a co-immunoprecipitation experiment,
where human TARM1 was transiently expressed in Hek293 cells stably expressing adapters
DAP10, DAP12 and FcRγ, TARM1 associated with the FcRγ adapter.
Classically, ITAM-bearing adapters were thought to trigger activating signalling cas-
cades initiated by the phosphorylation of tyrosine residues within the ITAM by the
Src family protein tyrosine kinases (Iwashima et al. 1994) resulting in the activation
of a number of well-characterised effector pathways. However, a growing number of
studies have challenged this paradigm in the recent decade. For instance, signalling
through DAP12 has been shown to inhibit TLR-mediated responses in macrophages
(J. A. Hamerman, Tchao, et al. 2005). Similarly, the pairing of the FcRγ with FcαRI
results in the inhibition of IgG-mediated activation of myeloid cells (Pasquier et al.
2005). It was therefore important to perform functional characterisation of TARM1 in
order to determine the effects of its ligation on the responses of TARM1+ cells. The
antagonistic action of ITAM-bearing adaptors on TLR signalling is particularly relevant
in this case as TARM1 expression is upregulated following TLR4 ligation.
In the following chapter I describe the expression profile of TARM1 in primary cells,
the impact of TLR ligation on the TARM1 expression and identify the main TARM1-
expressing cell subset in vivo.
Chapter 6
TARM1 expression profiling
6.1 TARM1 mRNA is expressed at similar sites in human
and mouse
In order to gain insight into the transcriptional activity of human and mouse TARM1
genes in primary tissues, I performed a PCR-based screen of a commercially available
human total RNA tissue panel and a total murine RNA tissue panel I prepared in-house
using a C57BL/6 mouse. For screening, cDNA was synthesised by reverse transcription
and examined for the presence of TARM1 transcript using specific primers amplifying a
full-length coding region of TARM1 (Fig. 6.1).
Human and mouse tissues showed an overlapping pattern of TARM1 expression, with
the transcript detectable in the lung, spleen, testis and thymus of both species. In
mouse, TARM1 transcript was highly enriched within the bone marrow and, although,
human bone marrow was not present on the panel, human fetal liver had a high TARM1
expression. Numerous studies investigating fetal hepatic cell composition report the
presence of a large number of stem and progenitor cells similar to those found within
the bone marrow. Human adult liver also contained TARM1 transcript, albeit at a lower
level; this is in contrast to murine adult liver which lacked TARM1 expression. Inter-
estingly, both human and murine lung showed a strong expression of TARM1 mRNA,
which could be due to the presence of a large number of resident myeloid cells. Lymph
node, present on the mouse tissue panel, but absent from the human panel, had a low
level of TARM1 mRNA.
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Figure 6.1: RT-PCR analysis of the expression of full-length TARM1 mRNA in human
and mouse tissues. PCR was performed on cDNA synthesised from total tissue RNA
obtained from (A) Human Total RNA Master Panel II, CloneTech, (B) Mouse tissue
RNA panel produced in-house. TARM1 specific primers amplified full-length coding
region transcript (top panel). Gapdh was used as a reference gene (bottom panel). ntc,
no template control
All visible bands were excised from the gel and the PCR products were sequenced to
validate amplicon identity. A secondary, lower-weight band visible in some tissues was
a PCR artefact.
6.2 TLR signalling induces TARM1 expression on bone-
marrow derived DC and Macrophages
Since treatment of BMDCs with the TLR4 agonist LPS induced upregulation of cell sur-
face TARM1 expression, I screened a panel of TLR agonists for their ability to stimulate
TARM1 expression. To this end, C57BL/6 bone-marrow was differentiated as described
in Materials and Methods into BMDCs and macrophages (BMM) and treated with TLR
agonists for 24 h. TARM1 cell-surface expression was then analysed by flow cytometry.
As shown in Figure 6.2, signalling through several TLRs induced an increase in cell-
surface expression of TARM1 to varying degrees. The maximal TARM1 induction in
both BMM and BMDC was achieved following stimulation with LPS, a TLR4 agonist.
LPS-induced cell-surface expression of TARM1 was confirmed in BMM by immunoflu-
orescence microscopy (Fig. 6.3A). PCR analysis of LPS-stimulated BMM and BMDC
(Fig. 6.3B) also showed a strong upregulation of TARM1 mRNA expression, indicating
that the increase in TARM1 cell-surface expression could be due to an increase in the
de novo mRNA synthesis.


















































































































Figure 6.2: Flow cytometric analysis of TARM1 expression on BMDC (panel A) and
BMM (panel B) following TLR stimulation. C57BL/6 bone marrow was differentiated
into BMM and BMDC as described in Materials and Methods. Cells were stimulated
with a panel of TLR agonists for 24 h and stained with anti-TARM1 monoclonal an-
tibody or isotype control. Anti-CD11c (BMDC) and anti-CD11b (BMM) were used
to assess the differentiation efficiency. MFI (median) of TARM1 staining was plotted
for each TLR agonist. Dead cells, defined as 7-AAD+ were excluded. The data is
representative of at least 4 experiments showing comparable results.
6.3 TARM1 expression in vivo is restricted to the granu-
locytic cell lineage.
RT-PCR analysis of mouse tissues showed that the Tarm1 mRNA was enriched in the
bone marrow. Weaker bands were also visible in other tissues including lung, spleen,
lymph nodes and thymus. In order to determine whether the presence of Tarm1 tran-
script correlated with cell-surface protein expression in ex vivo samples, I analysed sev-
eral tissues from healthy C57BL/6 mice by flow cytometry (Fig. 6.4A).
Cell-surface Tarm1 was expressed only in the bone marrow, and not in other tissues,
which correlated with the high level of Tarm1 transcript detected at this site. Closer
inspection of Tarm1 cell-surface expression in the bone marrow revealed that only the
FschiSschi cell population, consistent with granulocyte/monocyte precursors, was posi-
tive for TARM1 (Fig. 6.4B).
























Figure 6.3: (A) Immunofluorescence microscopy of TARM1 expression on LPS-
treated BMM. Following stimulation (24 h, LPS 100 ng/ml), cells were fixed with
2% PFA and co-stained with anti-TARM1 monoclonal antibody (red) and I-Ab (green).
(B) PCR analysis of TARM1 mRNA expression in BMDC and BMM. Following stimu-
lation, total RNA was extracted and reverse transcribed. Primers amplifying full-length
TARM1 transcript were used. Gapdh served as a reference gene.
I also assessed TARM1 protein expression in key human lymphoid tissues (kindly pro-
vided by Dr. Kourosh Saeb-Parsy) including bone marrow, spleen and lymph nodes.
Only spleen was present on the human total RNA panel. RT-PCR analysis showed a
weak TARM1 band in this tissue. As shown in Figure 6.5 TARM1 protein could be
detected on the cell surface of granulocytes, identified by characteristic FschiSschi pa-
rameters and positive staining for CD16. Both BM and splenic CD16+ granulocytes
expressed TARM1, although the BM population had a higher density of TARM1 recep-
tor as indicated by the higher MFI of positive staining. Granulocytes were present at
a very low frequency in the lymph node sample. TARM1 expression was not detected
on CD3+ T cells or CD19+ B cells. Some CD14+ monocytes in the BM and spleen
expressed a low level of cell-surface TARM1.











Figure 6.4: Flow cytometric analy-
sis of TARM1 cell-surface expression
in murine tissues. C57BL/6 mice were
sacrificed at 8-10 weeks and total cell
populations of bone marrow (BM),
peritoneal exudate (PEC), spleen and
mesenteric lymph nodes (MLN) were
stained with anti-TARM1 mAb13 or
rat IgG2b isotype control for analysis
by flow cytometry. (A) In healthy ani-
mals TARM1 expression is restricted to
the bone marrow. The data is reprisen-
tative of at least 3 independent ex-
periments. (B) Within the bone mar-
row TARM1 expression is restricted to
the high FSC:SSC cell population char-




















Figure 6.5: TARM1 is expressed on the cell surface of human granulocytes. Human
bone marrow (BM), spleen (SP) and lymph nodes (LN) were stained with anti-TARM1
mAb4 or mouse IgG1 isotype control and cell lineage markers for analysis by flow
cytometry. For data analysis dead cells were excluded using Zombie Aqua (Biolegend)
viability dye. Numbers on plots indicate percentages of cells within gates.
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6.4 Summary
RT-PCR analysis of a panel of human and murine tissues showed an overlapping pattern
of TARM1 expression in both species. The transcript was detected in human and mouse
lung, spleen, testis and thymus. In mouse, Tarm1 mRNA was also abundant within
the bone marrow and, although human bone marrow was not present on the panel,
flow cytometric analysis of this tissue showed a high expression of TARM1 protein.
TARM1 was predominantly expressed within the granulocytic compartment defined by
the characteristic FschiSschi phenotype and positive staining for CD16. Some CD14
monocytes expressed a low level of TARM1 protein while CD3+ T cells and CD19+ B
cells were TARM1-. Bone marrow cells with a CD16-/lo phenotype were also TARM1+
and most likely represent a myeloid precursor population that has not yet acquired CD16
expression associated with maturation.
A similar expression pattern was seen in mouse tissues by flow cytometry. TARM1
cell-surface expression was restricted to the bone marrow, where TARM1+ cells made
up 20% to 30% of the total bone marrow population. This number was as high as 59%
within the FschiSschi cell population, characteristic of granulocytes and granulomono-
cytic precursors.
The expression of TARM1 predominantly in lymphoid tissue suggested that it could be
closely associated with immune cell function. Although TARM1 transcript was found in
tissues of non-lymphoid origin such as lung and liver, these sites harbour large resident
populations of specialised immune cells.
Bearing the above in mind, I examined TARM1 cell-surface expression on mouse BMDC
and BMM stimulated with a panel of TLR agonists. This revealed that TARM1 is
expressed on the surface of in vitro-derived resting BMDC (but not resting BMM) and
that TARM1 expression was sensitive to TLR ligation (Fig. 6.2). While the majority
of TLR agonists were able to induce TARM1 cell-surface expression, TLR4 (LPS, 100
ng/ml) was most effective. This observation pointed to a potential role of TARM1 in
the innate immune responses to gram-negative bacteria.
Consequently, it was of interest to investigate TARM1 protein expression in the context
of in vivo immune responses triggered following LPS treatment or bacterial infection, as




7.1 Intraperitoneal administration of LPS induces TARM1
expression in bone-marrow and homing of TARM1+
cells to the site of injection
As described in chapter 6, in healthy animals, constitutive expression of TARM1 was
found within the bone marrow but not in the periphery. TARM1 expression was re-
stricted to the bone marrow cell population identified by the Fscint/hiSschi profile, char-
acteristic of the granulo-monocytic lineage. Further, in vitro differentiated BMM and
BMDC could be induced to express high levels of TARM1 following the treatment
with TLR agonists, among which LPS produced the highest response. This observa-
tion prompted me to investigate whether a localised LPS administration in vivo would
result in a similar upregulation of TARM1 and whether the response would be confined
to the site of injection or induce a systemic TARM1 expression.
To that end, C57BL/6 mice were injected intraperitoneally (ip) with a low dose (3µg per
mouse) of ultra-pure LPS. TARM1 expression was analysed by flow cytometry in the
bone marrow and at the peripheral immune sites 24 h post-treatment. As previously
observed, PBS control animals showed a constitutive TARM1 expression on granulo-
monocytic population within the bone marrow but not at the peripheral sites (Fig. 7.1A).
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Figure 7.1: Flow cytometric analysis of TARM1 cell-surface expression in mouse
tissues following intraperitoneal LPS administration. C57BL/6 mice were injected ip
with either PBS or ultra-pure LPS (3 µg per mouse, Invivogen) and analysed 24 h
later. (A) Total cell populations of bone marrow (BM), peritoneal exudate cells (PEC),
spleen and mesenteric lymph nodes (MLN) were stained with anti-TARM1 mAb13 or
isotype control for analysis by flow cytometry. Histograms represent total live cells. (B)
Flow cytometric analysis of TARM1 cell-surface expression on peritoneal exudate cells
(PECs). Histograms represent live cells within individual SSC:Fsc gates as indicated.
Conversely, LPS administration resulted in a strong upregulation of TARM1 cell surface
expression in the bone marrow, and the appearance of a small TARM1+ population
in the peritoneal exudate cells (PECs). Other sites (spleen, liver and MLN) remained
TARM1- 24 h post-treatment (Fig. 7.1A).
Closer examination of the PECs of control animals showed that they did not con-
tain a clearly defined Fscint/hiSschi granulocyte population and consequently had ∼1%
TARM1+ cells. Following LPS administration, a clear Fscint/hiSschi population repre-
senting ∼16% of the total PECs could be observed and was comprised of predominantly
TARM1+ cells (Fig. 7.1B). The accumulation of the Fscint/hiSschi population at the
























Figure 7.2: Flow cytometric analysis of TARM1 cell-surface expression in mouse bone
marrow following intraperitoneal LPS administration. C57BL/6 mice were injected ip
with either PBS or ultra-pure LPS (3 µg/mouse, Invivogen) and sacrificed 24 h later.
BM cells were stained with anti-TARM1 mAb13 or isotype control. Histograms repre-
sent live cells within individual Fsc:Ssc gates as indicated. Inset: cytospin preparation
of FACS-sorted and differentially stained TARM1+ cells from the BM of LPS treated
animals. BM - bone marrow. Promyelocytes (red arrows), mature neutrophils (black
arrows).
site of injection was most likely the result of cell mobilisation from the bone marrow in
response to the LPS-induced pro-inflammatory signals.
To examine the cellular morphology of TARM1+ cells, the bone marrow of LPS treated
animals was FACS sorted gating on the TARM1 marker. Sorted cells were spun onto
microscope slides and differentially stained with Diff-Qiuck (inset Fig. 7.2). Cytospins
revealed that TARM1 is expressed on a heterogeneous mixture of cells showing ring-
shaped and hypersegmented nuclei characteristic of promyelocytes (red arrows) and
mature neutrophils (black arrows), respectively (Cuenca et al. 2011).
The role of neutrophils as first responders, capable of rapid homing to the sites of im-
mune challenge, is well established. Moreover, numerous studies describe the expansion
of immature CD11b+Gr-1+ cells with ring-shaped nuclei in the bone marrow and their
homing to the lymphoid tissues during inflammatory processes (Brudecki et al. 2012; De-
lano et al. 2007). Pathological conditions where such expansion was documented range
from cancer to tissue damage and sepsis where these cells acquire immunoregulatory
properties and function as a part of the heterogeneous myeloid-derived suppressor cell










Figure 7.3: TARM1 cell-surface expression is upregulated on CD11b+Gr1+ cells in
the BM following intraperitoneal LPS administration. C57BL/6 mice were injected
ip with either PBS or ultra-pure LPS (3 µg/mouse, Invivogen) and the expression of
TARM1, Gr1 and CD11b was examined by flow cytometry 24 h later.
(MDSC) population. Hestdal et al. demonstrated that Gr-1 is not restricted to a single
cell lineage and that the level of Gr-1 expression correlates with the maturation stage of
the myeloid cells ranging from Gr-1neg/lo immature progenitors and myelocytes, to Gr-1hi
differentiated neutrophils (Hestdal et al. 1991). The anti-Gr-1 antibody RB6-8C5, which
was extensively used to identify neutrophils and perform cell depletion in vivo, was later
shown to bind epitopes present on Ly6G and Ly6C cell-surface proteins (T. Fleming,
M. Fleming, and Malek 1993). Characterisation of the cell surface expression pattern of
these antigens showed that Ly6G is expressed predominantly on mature neutrophils and
correlates with granulocyte maturation stage, whereas Ly6C expression is not restricted
to neutrophils but has a wider cellular distribution including dendritic cells, subpopula-
tions of lymphocytes and monocytes (T. Fleming, M. Fleming, and Malek 1993). Bone
marrow monocytes as well as extravasated monocytes have been shown to express high
levels of Ly6C (Sunderkötter et al. 2004) and, along with other cell-surface markers,
this antigen is now widely used to identify the monocytic lineage. I initially used the
Gr-1 antibody in combination with CD11b to determine whether the phenotype of the
LPS-expanded TARM1+ cells in the bone marrow and the peritoneum was in line with
the phenotype of CD11b+Gr-1+ cell population with regulatory properties described by
earlier studies.
Indeed, all TARM1+ cells were also positive for CD11b and Gr-1 (Fig. 7.3). The bone
marrow of healthy animals also contained a population of CD11b+Gr1+ cells that ex-
pressed a lower level of TARM1. Several studies demonstrated that the CD11b+Gr1+
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cells in healthy animals lack the immunoregulatory capacity of CD11b+Gr1+ expanded
during inflammatory responses suggesting that the presence of inflammatory mediators
and growth factors accompanying inflammation are required by this cell population for
the functional transition to MDSCs (Delano et al. 2007; Sander et al. 2010).
The dramatic upregulation of TARM1 on CD11b+Gr1+ in response to inflammatory
signals is intriguing. To gain a greater insight into the identity of TARM1+ cells and
to compare their phenotype under steady-state condition of health to that during an
inflammatory response, I performed a flow cytometric characterisation of tissues using
Ly6G and Ly6C specific antibodies and prototypical cell-surface markers of myeloid and
lymphoid lineages. C57BL/6 mice were administered LPS or PBS ip, as previously, and
the bone marrow cells and PECs were analysed by flow cytometry 24 h later.
The results confirmed that the TARM1+ population within the bone marrow belonged
to the granulo-monocytic subset with CD11b+Ly6G+Ly6C+ phenotype and was neg-
ative for classical T cell, B cell and DC markers CD3, CD19 and CD11c, respectively
(Fig. 7.4A). TARM1+ cells in the bone marrow of control animals were predominantly
CD11b+Ly6GhiLy6Cint with a ∼17% also expressing MHC class II (MHC-II). LPS
administration induced an upregulation of TARM1 expression and expansion of the
TARM1+ population size, as was observed in previous experiments (Fig. 7.4A).
The high expression of the CD11b and Ly6G antigens on TARM1+ cells in the bone
marrow of healthy controls suggested they most likely represented mature neutrophils.
On the contrary, under the conditions of inflammatory response following LPS admin-
istration, an expansion of the TARM1+ population was accompanied by a markedly
reduced expression of the Ly6G antigen, indicating a shift towards a more immature
myeloid phenotype.
This shift was even more apparent in the peritoneal exudate cells of LPS treated mice.
Two distinct TARM1+ populations that differed in their Fsc profile, the expression of
Ly6G, Ly6C and MHC-II were observed. These populations were gated separately based
on their Fsc characteristics during flow cytometric analysis. Gate 1 - TARM1+Fscint, and
gate 2 - TARM1+Fschi (Fig. 7.4B). Lineage marker analysis of these two subgroups re-
vealed that only the Fschi population (gate 2) was MHC-II+, co-expressed CD11b, high
levels of Ly6C and low Ly6G (CD11b+Ly6ChiLy6GloMHC-II+). The TARM1+Fscint
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subpopulation (gate 1) did not express MHC-II and was CD11b+Ly6CintLy6GhiMHC-
II-. These phenotypic characteristics are consistent with the granulocytic origin of
the population in gate 1, and monocytic origin of the population in gate 2. Since
the total TARM1+ population did not express CD11c in either the bone marrow or
the peritoneum, MHC-II expression is unlikely to be due to the presence of DCs and
macrophages. The MHC-II+ cells resembled what has been termed ”inflammatory mono-
cytes”. These cells are rapidly recruited to the sites of inflammation where they give rise
to pro-inflammatory DCs and macrophages (Geissmann et al. 2010; Serbina and Pamer
2006).
In the experiments described here I used a model of a mild peritonitis where the en-
dotoxicosis was induced with a low dose of LPS (0.15 mg/kg, whereas LD50 dose is
1–25 mg/kg (Fink 2014)). Even at this dose profound changes in TARM1 expression
and TARM1+ cells were observed 24 h following the injection. Since this response was
mediated through TLR4 ligation and did not recapitulate the complexity of the immune
response mediated by live infection, it was of interest to investigate the fate of TARM1+


























































Figure 7.4: Flow cytometric characterisation of TARM1+ population in mouse bone marrow and peritoneal exudate cells following intraperitoneal
administration of LPS. C57BL/6 mice were injected ip with either PBS or ultra-pure LPS (3 µg/mouse, Invivogen) and sacrificed 24 h later. (A)
BM and (B) PECs were isolated and stained with anti TARM1 mAb13 and cell lineage markers. BM - bone marrow, PECs - peritoneal exudate
cells
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7.2 Systemic challenge of C57BL/6 mice with Salmonella
typhimurium results in accumulation of TARM1+ in
multiple organs
It is well established that neutrophils are instrumental in the control of murine salmonel-
losis. I used a live-attenuated vaccine strain of Salmonella enterica serovar Typhimurium
(S. Typhimurium) SL3261 in a systemic challenge of C57BL/6 mice. High inoculum of
this strain was well-tolerated by C57BL/6 as was previously established by Dr. P Mas-
troeni (private communication). Four groups of three mice were injected with 1 × 106
CFU or PBS directly into the tail vein and euthanised at 1, 2, 3 and 4 weeks post
infection.
Flow cytometric analysis of the spleen revealed an accumulation of TARM1+ cells up to
week 3 and a decline at week 4 (Fig. 7.5). This pattern followed closely the dynamics
of the infection progression and resolution. The accumulation of TARM1+ cells in
the spleens of mice at 2 wpi was confirmed by confocal microscopy of tissue sections
(Fig. 7.6). A clear TARM1 staining was observed in the tissues of infected mice at this
time point, whereas the tissue of vehicle (PBS) treated animals displayed virtually no
positive staining. This is consistent with the FACS data showing approximately 10%
increase in TARM1+ cells in the spleens of infected mice at 2 wpi. Although TARM1+
cells were observed in clusters, severe splenomegaly with disruption of tissue architecture




























































Figure 7.5: Percentage of TARM1+ cells in the total (A) bone marrow and (B)
spleen of S. typhimurium infected mice at indicated time points following infection.
Each time point is representative of 3 mice. The experiment was repeated twice with
similar outcomes.
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PBS control Salmonella 2 wpi
DAPITARM1 DAPITARM1
Figure 7.6: Confocal microscopy of TARM1 expression in the mouse spleen 2 weeks
following Salmonella infection. Spleen fragments were harvested into 4% paraformalde-
hyde and fixed for 24 h, paraffin-embedded and stored until analysis. Microscopy sec-
tions were deparaffinised, and heat-induced epitope retrieval was perfomed in citrate
buffer pH 5.5. Sections were stained with anti-TARM1 mAb53 (Green) and DAPI.
Tarm1






Figure 7.7: RT-PCR analysis of Tarm1 mRNA expression in total splenocytes of S.
typhimurium infected and control animals. Spleens were harvested at the indicated
time points following infection and 30 mg fragments were stored at -80 ℃ in RNA-later
(Qiagen). For analysis cDNA was generated from total RNA using oligo-d(T) primers.
Full-length TARM1 transcript was amplified using primers specific to exon 1 and 6.
Gapdh served as a reference gene. RT-, reverse transcriptase negative control; ntc, no
template control
PCR analysis performed on the total RNA obtained from the same tissue showed a clear
pattern of Tarm1 gene upregulation with a peak at 1-2 wpi, which mirrored the accumu-
lation and subsequent decline of TARM1+ cells over the course of infection (Fig. 7.7).
PCR analysis was also performed on samples obtained at 8 wpi, when the infection
was fully resolved, and showed a return to the pre-infection level of Tarm1 expression
(data not shown). The RT-PCR data was corroborated by a quantitative analysis of
Tarm1 gene expression in the spleen using quantitative PCR (qPCR). For this purpose,
I designed and validated Tarm1 specific qPCR primers. The amplification efficiency
and the dynamic range were determined over a range of 2-fold template dilutions and
compared to those obtained for the reference gene Gapdh (Fig. 7.8A). Tarm1 primer
specificity was determined by the melting curve analysis of the amplification product.
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Figure 7.8: (A)Validation of Tarm1 primer pair amplifications efficiency and qPCR
analysis of the Tarm1 gene expression in mouse spleens following S. typhimurium infec-
tion. (B) qPCR was performed on cDNA generated from total spleen RNA as described
for RT-PCR. Tarm1 primers spanning the splice junction of exons 5 and 6 were used.
The results showed a peak of Tarm1 gene expression at 1 wpi reaching ∼22 fold increase
over uninfected control (Fig. 7.8B).
The phenotype of TARM1+ cells under the inflammatory conditions of intraperitoneal
in vivo LPS administration distinguished two populations differing in their expres-
sion of Ly6C and Ly6G antigens, namely, CD11b+Ly6CintLy6Ghi and CD11b+Ly6Chi
Ly6Glo. Therefore, I studied the differences in TARM1 cell-surface expression within the
CD11b+Ly6C+ and CD11b+Ly6G+ cell subsets in the bone marrow and spleen through-
out the infection time-course. The TARM1 expression was analysed on subpopulations
expressing varying levels of Ly6C and Ly6G antigens.
In the bone marrow, two CD11b+Ly6C+ subsets could be discerned based on the expres-
sion level of these markers (Fig. 7.9, left panel). In control mice, the CD11b+Ly6Chi pop-
ulation was underrepresented (gate 2, left panel) and expressed little TARM1, whereas
CD11b+Ly6Cint cells comprised the predominant TARM1+ population. At 1 wpi, as the
infection became established, an accumulation of the CD11b+Ly6Chi population with
a concomitant increase in the cell-surface expression of TARM1 was observed. TARM1
expression peaked between week 1 and 2 post-infection on both CD11b+Ly6Chi and
CD11b+Ly6Cint cell subsets and declined at 4 wpi.
Similarly, CD11b+Ly6G+ cells could be divided into distinct subpopulations based on
their expression level of the Ly6G antigen (Fig. 7.9, right panel). TARM1 expression in
control animals was observed predominantly on the Ly6Ghi population that represented
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the majority of all CD11b+Ly6G+ cells (gate 4, right panel). However, a reduction in
the abundance of this population and the accumulation of Ly6G-/lo/int cells was observed
following the infection. This shift is most likely indicative of the altered granulopoiesis
leading to the accumulation of Ly6G-/lo myeloid precursors to replace the rapidly de-
pleted pool of mature Ly6Ghi granulocytes. At 1 wpi, high TARM1 expression was
evident on all CD11b+Ly6G+ cells irrespective of their maturation stage. This trend
reversed noticeably by 3 wpi when the CD11b+Ly6Gneg cells decreased in abundance
and lost the expression of TARM1. CD11b+Ly6Ghi mature granulocytes maintained
high TARM1 expression throughout weeks 1-3, whereafter the expression returned to a
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Figure 7.9: Flow cytometric characterisation of TARM1 expression in mouse bone marrow cells following iv administration of S. typhimurium.
C57BL/6 mice were injected iv with either PBS or S. typhimurium strain SL3261 and sacrificed at the indicated time points. Cells were isolated
and stained with anti TARM1 mAb13 and cell lineage markers.
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A very similar trend was observed in the spleen (Fig. 7.10). As was mentioned ear-
lier, TARM1+ cells represent ∼1% of the total splenocytes in healthy animals. This
is well-correlated with a similarly low abundance of CD11b+Ly6C+Ly6G+ cells out-
side of the bone marrow under steady-state conditions. As the infection progressed,
an accumulation of CD11b+Ly6C+ granulocytes in the spleen was observed following
similar dynamics to that in the bone marrow, both in the relative cell abundance and
the expression of TARM1 (Fig. 7.10, left panel). The influx of granulocytes into the
spleen over the course of infection could be seen by flow cytometry as the increase in
the frequency of larger, more granular cells characterised as Sscint/hiFschi.
At the peak of infection, between weeks 1-2, the predominant cell subset was CD11b+Ly6Gint
(Fig. 7.10, gate 3), whereafter cells with higher Ly6G expression (gate 4) began to ac-
cumulate. It appears that in the spleen, TARM1 expression correlated with the level of
Ly6G expression with a peak at 1-2 wpi.
Although the lineage markers I used to study TARM1+ cells identified them as mature
(CD11b+Ly6Ghi) and immature (CD11b+Ly6Glo/int) neutrophils, a more detailed char-
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Figure 7.10: Flow cytometric characterisation of TARM1 expression in mouse splenocytes following iv administration of S. typhimurium. C57BL/6
mice were injected iv with either PBS or S. typhimurium strain SL3261 and sacrificed at the indicated time points. Cells were isolated and stained
with anti-TARM1 mAb13 and cell lineage markers.















































Figure 7.11: TARM1+ cells upregulate PD-L1 expression 24 h following Salmonella
infection. C57BL/6 mice were injected iv with either PBS or S. typhimurium strain
SL3261 and sacrificed 24 h later. TARM1 and PD-L1 expression were examined by
flow cytometry on splenocytes and BM.
A number of studies emerged over the past decade uncovering neutrophil functions
previously not associated with cells of the innate immune system. For instance, IFN-
γ stimulated neutrophils acquire the ability to suppress T cell proliferation through
upregulation of PD-L1 (Kleijn et al. 2013). Neutrophils were shown to suppress Th1
responses during intracellular Brucella infection (Barquero-Calvo et al. 2013). High
levels of PD-L1 were also found on the peripheral blood neutrophils in patients with
an active tuberculosis (McNab et al. 2011). With this in mind, I characterised PD-
L1 expression on TARM1+ cells in the BM and spleen of mice following Salmonella
infection. Majority of the TARM1+ cells in the bone marrow and spleen expressed PD-
L1 24 h following infection (Fig. 7.11). The finding that TARM1+ cells upregulate the
expression of PD-L1 suggested they may exert a suppressive immune effect.
7.2.1 Human circulating neutrophils express TARM1
I also examined TARM1 cell-surface expression in human peripheral blood. Similarly to
mice, human TARM1 was detected on circulating granulocytes, but the expression varied
greatly among donors (Fig. 7.12A). To confirm TARM1 expression on granulocytes, I
prepared a neutrophil-enriched cell fraction by Ficoll density centrifugation of peripheral
blood obtained from a donor with high TARM1 expression (∼ 93% purity) and analysed
the lysate by Western blot. The neutrophil-depleted fraction was used as a control. A
clear TARM1-specific band was detected in the lysate of neutrophil-enriched fraction
but not in the neutrophil-depleted mononuclear cell lysate (Fig. 7.12B). These results
are inline with the results of flow cytometric analysis of TARM1 expression in human












































Figure 7.12: TARM1 is expressed on the surface of human peripheral blood gran-
ulocytes. (A) Flow cytometry of whole human blood. Human peripheral blood was
collected from healthy donors (n=15) and red blood cells were removed by sedimenta-
tion using HetaSep (Stemcell Technologies). TARM1 expression was analysed by flow
cytometry. Only granulocytes were positive for TARM1. Representative plots from sev-
eral donors are shown. The values for median fluorescence intensity staining of TARM1
were normalised to isotype control value for each donor. (B) Western blot. TARM1
protein is detected in purified neutrophils but not in neutrophil-depleted mononuclear
cell fraction. Neutrophils were isolated by Ficoll density centrifugation. Purity was
assessed by microscopy of neutrophil cytospins (right panel) and was routinely above
90%. +, hTARM1 transfected Hek293T cells; −, Hek293T transfected with a control
construct; Ne, neutrophils; Mo, neutrophil-depleted mononuclear cell fraction. (left
panel) Cytospin preparation of purified neutrophils.
tissues shown in Chapter 6, Figure 6.5, page 80, where cell-surface TARM1 was detected
in CD16+ neutrophils in the bone marrow and spleen and CD16lo/- immature myelocytes
in the bone marrow.
These results show that under conditions of health, TARM1 expression is found pre-
dominantly in the bone marrow CD11b+Ly6C+Ly6G+ mature neutrophils and myelo-
cytes. Increased TARM1 expression and homing of TARM1+ cells to peripheral sites
is strongly associated with inflammation. Similarly to mice, human TARM1 appears to
be restricted to the granulocytic population suggesting conservation of function.
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7.3 Summary
The data, showing that high levels of cell-surface expression of TARM1 could be induced
in vitro on BMM and BMDC by treatment with TLR agonists, prompted me to inves-
tigate whether an in vivo, localised administration of TLR4 agonist LPS or a systemic
bacterial challenge would elicit similar effects on TARM1 expression and shed light on
its cell distribution in the context of acute or sustained inflammatory responses. To
address these questions, I used a mouse model of sterile peritonitis induced with a low
dose of LPS administered ip and a systemic challenge with an attenuated vaccine strain
of S. typhimurium SL3261.
Sterile peritonitis was induced with ip administration of LPS (3 µg) and a BM, spleen,
liver, lymph nodes and PECs were analysed by flow cytometry 24 h later. The data
showed that LPS treatment induced a rapid and robust upregulation of TARM1 cell-
surface expression in the BM, expansion of the TARM1+ population size and its migra-
tion to the peritoneum. Morphological examination of cytospins prepared from TARM1+
cells sorted from the BM of LPS treated animals showed that they comprised a hetero-
geneous mixture of myeloid precursors with ring-shaped nuclei and mature neutrophils.
Flow cytometric characterisation of TARM1+ cells using prototypical markers of gran-
ulocytes, DCs and lymphocytes showed that in control animals TARM1 expression was
low and restricted to the BM cells with a phenotype of mature neutrophils
CD11b+Ly6GhiLy6C+. Whereas the inflammatory response 24 h following LPS admin-
istration was accompanied by a decrease in the expression of Ly6G antigen, indicating
a shift towards a more immature myeloid phenotype among TARM1+ cells.
An increased frequency of myeloid precursors in the bone marrow and peripheral sites is
sometimes observed during inflammation as a consequence of its modulatory effect on the
myelopoiesis (Terashima et al. 1996). Acute infection or other inflammatory processes
where the reserves of mature granulocytes are rapidly mobilised from the bone marrow
and the circulation to the sites of inflammation trigger an accelerated proliferation of
bone marrow granulocytic precursors to replenish the rapidly consumed mature cells in a
process referred to as demand-adapted or emergency granulopoiesis (Manz and Boettcher
2014; Takizawa, Boettcher, and Manz 2012; Boettcher et al. 2012).The extent of the
myelopoietic proliferation is governed by the nature and the severity of the pathology
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and the combination of hematopoietic growth factors. Of particular interest for this
work is the association of an increase in TARM1 expression on neutrophil precursors
and mature neutrophils during inflammation. Boettcher et al. demonstrated that ip
administration LPS (two doses of 35 µg) mimics the acute conditions necessary to initiate
emergency granulopoiesis (Boettcher et al. 2012). Although the dose of LPS I used was
twenty times lower than in the study by Boettcher et al, the induction of a modest shift
towards an increased frequency of Ly6Glo neutrophil precursors could be observed.
The TARM1+ cells infiltrating the peritoneum of LPS treated animals were composed
of two distinct populations that differed in their expression of Ly6G, Ly6C and MHC-II
markers and were CD11b+Ly6ChiLy6GloMHC-II+ monocytic and
CD11b+Ly6CintLy6GhiMHC-II- granulocytic phenotypes. Since both populations lacked
CD11c, the expression of MHC-II was unlikely due to the presence of DCs or macrophages.
Instead, low or absent Ly6G with high levels of Ly6C and MHC-II is a hallmark of inflam-
matory monocytes that have been implicated in both pro-inflammatory and suppressive
processes (Geissmann et al. 2010; Serbina and Pamer 2006). These cells were described
to rapidly migrate to sites of inflammation where they gave rise to DCs and macrophages
(Geissmann et al. 2010; Serbina and Pamer 2006)
Since LPS-induced sterile peritonitis did not recapitulate the complexity and duration
of the immune response mediated by live infection, it was of interest to determine the
fate of TARM1+ cells during systemic bacterial challenge.
Mice were challenged with an attenuated vaccine strain of Salmonella typhimurium
via tail vein. Flow cytometric analysis showed that TARM1 expression followed the
infection dynamics peaking at the height of infection between weeks 1 and 2. In the
bone marrow TARM1 expression was strongly upregulated on mature granulocytes and
immature myeloid cells. An influx of TARM1+ cells expressing different levels of Ly6C
and Ly6G antigens was observed in the spleens of infected mice. These cells persisted
in the spleen for the duration of the infection and maintained elevated expression of
cell-surface TARM1.
A growing number of studies show that perturbations in myelopoiesis seen during in-
flammation and cancer lead to the emergence of so called myeloid-derived suppressor
cells (MDSC), a heterogeneous population of myeloid precursors with a potent T cell
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suppressive function (Cuenca et al. 2011; Delano et al. 2007). Historically, this popula-
tion in mice was identified by the co-expression of CD11b and Gr-1 antigens. However,
as discussed earlier, anti Gr-1 antibody recognises epitopes on both Ly6C and Ly6G
antigens with a wide cell distribution. High expression of Ly6C with low or absent
Ly6G is a hallmark of inflammatory monocytes which have been shown to exert either
pro-inflammatory or immunosuppressive effects (Geissmann et al. 2010; Serbina and
Pamer 2006). High expression of Ly6G with low or no expression of Ly6C identifies
granulocytic cells such as mature neutrophils and granulocyte precursors.
Although terminally differentiated neutrophils are only a small fraction of MDSCs, a
large body of work suggests that both human and mouse neutrophils can be induced
to acquire APC-like phenotype in vitro or under pathological conditions in vivo where
they exert immunoregulatory effects on T cells often resulting in the suppression of Th1
responses (Rodriguez et al. 2009; Gosselin et al. 1993; Alemán et al. 2005; Ostanin
et al. 2012; Abdallah et al. 2011). In patients with acute infectious disease or cancer
granulocytic MDSCs have been shown to release arginase-I into the circulation result-
ing in the depletion of L-arginine and the impairment of T cell function (Darcy et al.
2014; Rodriguez et al. 2009). Secretion of IL-10 (X. Zhang et al. 2009) and PD-L1 (Mc-
Nab et al. 2011) expression during bacterial infections were also proposed as regulatory
mechanisms employed by neutrophils. Interestingly, TARM1+ cells expressed PD-L1
(Fig. 7.11) 24 h following infection. This points to a potential role of TARM1+ cells in
the control of inflammation in the models used here.
MDSCs were first characterised in tumour-bearing mice and their prominent role in
tumour immune evasion has since been well-established. A growing body of evidence
suggests that MDSCs are also induced in a broad range of pathological conditions in-
cluding tissue damage (Noel et al. 2011) and microbial sepsis (Delano et al. 2007) where
their role may be to protect against severe hyperinflammatory response. Delano et al
reported that polymicrobial sepsis induced an expansion of immature Gr-1+CD11b+
cells and their accumulation in the spleens of infected mice. The authors suggested that
this population had an important host-protective anti-inflammatory function (Delano
et al. 2007). Indeed, Brudecki et al. also observed a progressive expansion of Gr-
1+CD11b+ population and accumulation of immature myeloid cells with ring-shaped
nuclei in mice with CLP-induced polymicrobial sepsis (Brudecki et al. 2012). Using
adoptive MDSC transfers the authors demonstrated that the function of this population
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during severe sepsis depended on the context in which it expanded. MDSCs derived
from day 3 early septic mice were proinflammatory, whereas MDSCs isolated from day
12 late septic mice were immunosuppressive, and, when transferred to recipient animals,
improved survival during early septic hyperinflammation (Brudecki et al. 2012). Derive
et al, confirmed that during polymicrobial sepsis mainly the granulocytic MDSC subset
(CD11b+Ly6GhiLy6Clo) accumulated progressively in the spleens of septic mice and had
differential responses to TLR4 and IL6 stimulation depending on the time following the
onset of sepsis Derive et al. 2012.
Much of the earlier work performed on murine neutrophils and MDSCs defined them
as CD11b+Gr1+ which does not accurately reflect the true identity of these cell sub-
sets.Therefore, studies using the Gr-1 antibody should be interpreted with caution.
Unique markers are needed to facilitate a more sensitive and reliable means of discrim-
ination between different components of the regulatory cell subsets. The identification
of TARM1 offers an intriguing possibility of being a marker of activated regulatory
cells. However, a more detailed phenotyping strategy and functional analysis must be
employed for a reliable characterisation of the nature of TARM1+ cells.
It was of great interest to explore whether TARM1 protein itself had a regulatory po-
tential. Next chapter describes the characterisation of TARM1 functional effects on T




secretion by macrophages and
neutrophils and inhibits T cell
proliferation
An outstanding question that remains to be answered is whether the TARM1 trans-
membrane protein can function as a bona fide ‘receptor’ either by binding to an as yet
unidentified extracellular ligand or by transducing intracellular signals that modulate
the function of TARM1-expressing cells.
To gain insight into whether TARM1 can communicate with the extracellular environ-
ment, I generated TARM1-2B4-NFAT-GFP reporter cells which were used to search for
TARM1 ligand. To evaluate whether TARM1 can bind to a cellular ligand, I exam-
ined the effects of the recombinant TARM1 extracellular domain on T cell activation
and proliferation in vitro by generating soluble mouse and human fusion proteins com-
prised of the extracellular portion of TARM1 fused to the human IgG1 Fc. Finally,
to evaluate whether TARM1 protein could transduce intracellular signals, I stimulated
BMM and neutrophils with an anti-TARM1 mAb in the presence or absence of various
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TLR ligands, to determine whether TARM1 stimulation could modulate the function of
TARM1-expressing cells.
8.1 Generation and validation of TARM1-2B4 reporter lines
I used a widely adopted 2B4-NFAT-GFP reporter system to screen for a physiological
ligand for TARM1. The murine T cell hybridoma 2B4 carries a stably transduced GFP
gene under the control of a nuclear factor of activated T cells (NFAT) transcriptional
response element and was therefore chosen to generate TARM1 reporter cells. Thus,
cross-linking of an ITAM receptor in 2B4-NFAT-GFP reporter cell-line will result in
NFAT activation and translocation to the nucleus and induction of GFP expression.
This system provides a sensitive and convenient flow cytometry-based assay for a high-
throughput screening of cells to identify candidates expressing physiological ligands for
the assayed receptor (H. Arase et al. 2002).
TARM1 requires association with the FcRγ adaptor in order to signal. This adaptor is
not expressed in the mouse 2B4-NFAT-GFP reporter cells. It was therefore necessary
to circumvent the requirement of TARM1 for FcRγ association in this reporter system.
Signalling through the T cell receptor complex culminates in NFAT activation and the
2B4 T cell hybridoma contains all the necessary Src-family kinases and downstream
signalling molecules required for this purpose. CD3ζ contains three ITAM motifs and
can thus serve as a strong trigger for the downstream signalling cascade culminating
in NFAT activation. Therefore, in order to eliminate the need for a signalling adaptor
molecule and to improve the sensitivity of the system for TARM1 cross-linking, the
extracellular portion of the TARM1 receptor was fused to the intracellular portion of
the human CD3ζ, as shown in Fig. 8.1.
Cloning strategy and generation of a stable TARM1 reporter cell line. The
ectodomains of mouse and human TARM1 were first cloned into pDisplay vector (mouse
TARM1 BamHI-GQTDIP...EGYTVD-SalI; human TARM1 BamHI-GDTRGD...
TSSNYSLG-SalI). Next, the region of pDisplay containing the TARM1 sequence flanked
by the Igκ signal peptide and HA-tag at the 5’ end and Myc-tag and platelet-derived
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ITAM  ITAM  ITAM
PDGFR TMTARM1 MycHAIgk SP CD3ζ tail
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Figure 8.1: Schematic respresentation of TARM1-CD3ζ chimeric construct. Igκ SP -
murine Igκ-chain signal peptide, HA - hemagglutinin A epitope tag, Myc - myc epitope
tag, PDGFR TM - platelet-derived growth factor receptor transmembrane domain,
CD3ζ - the ITAM-containing intracellular portion of CD3ζ.
growth factor receptor transmembrane domain (PDGFR-TM) at the 3’ end was sub-
cloned into pMXs-puro retroviral vector containing human CD3ζ tail (using EcoRV-
XhoI restriction sites). The resulting construct encoded, in the 5’ to 3’ orientation, Igκ
signal peptide, HA-tag, TARM1 ectodomain, Myc-tag, PDGFR TM and human CD3ζ
tail (Fig. 8.1). 2B4-NFAT-GFP cells were transduced with TARM1 retroviral constructs
and grown under pyromycin selection until stable lines (TARM1-2B4) were established
(∼ 3 weeks). To determine whether TARM1-2B4 cells could respond to TARM1 ligation,
cells were cultured in the presence of plate-bound anti-HA antibody and were analysed
by flow cytometry 24 h later. Using this method of TARM1 stimulation, over 70% of
human and mouse TARM1-2B4 reporter cells, but not parental cells, became GFP+
indicating that TARM1 NFAT-GFP reporter cells were suitable for screening different
cell-lines for the presence of TARM1 ligands.
8.1.1 Screen for human TARM1 ligands
To search for a physiological ligand for human TARM1, I used the human TARM1 2B4
GFP reporter cells to screen common human cell lines representing different lineages
such as fibroblasts, neuronal cells, myeloid and lymphoid cells. During the initial screen
of cell lines, TARM1 reporter cells, but not control RAET1L reporter cell line or parental
2B4 cells, responded with a moderate GFP induction (39% GFP+ cells) only to primary
human dermal fibroblast (HDF) (representative plots are shown in Figure 8.2A).
In order to minimise the heterogeneity in TARM1 2B4 reporter cell responses, the top
10% of responding cells were single-cell sorted and cultured until clonal TARM1 GFP
reporter cell lines were established. Next, I tested the response strength of the individual
TARM1 2B4 reporter cell clones to HDF (representative clones are shown in Figure 8.2B)
and identified clone B4 as the best responder showing over 90% GFP+ cells after over
night coculture. Clone B4 was chosen for further coculture experiments.
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I screened a panel of cell lines using TARM1 2B4 reporter cell clone B4 and confirmed
that HDF cells were capable of stimulating a robust GFP response (Fig. 8.2C). In addi-
tion, both Jurkat and primary mouse CD4+ T cells were able to induce GFP response in
TARM1 2B4 reporter cells (Fig. 8.2D). Interestingly, both HDF and, to a lesser extent,
chicken fibroblast cell line RSV-B4 triggered GFP production in TARM1 reporter cells
suggesting that the putative ligand may be conserved across species.
TARM1 is encoded in close proximity to and is phylogenetically related to a collagen-
binding receptor OSCAR (A. Barrow, N. Raynal, et al. 2011). Fibroblasts synthesise
components of the extracellular matrix including collagen. Therefore I used a human
TARM1-Fc fusion protein to assay for collagen-binding activity using a library of triple-
helical collagens I-V described previously (A. Barrow, N. Raynal, et al. 2011). No specific
binding of human TARM1-Fc fusion could be detected in ELISA assay. TARM1-Fc
fusion protein also failed to show binding to HDF cells in flow cytometric assay suggesting
that the interaction of TARM1 with its putative ligand may be of low affinity making
it unsuitable for use in flow cytometric assays.
8.2 TARM1-Fc inhibits T cell activation and proliferation
in vitro
Next I investigated the potential functional role of the interaction of TARM1 receptor
with a putative ligand expressed on T cells. Our group and others (I. A. Smith et al.
2010) have previously used chimeric Fc fusion proteins to study immunomodulatory
activity of several receptors in in vitro T cell proliferation assays. I used this system to
examine the effects of TARM1 Fc fusion protein on anti-CD3 anti-CD28 induced T cell
activation and proliferation in vitro.
Purified primary mouse CD4+ T cells were labelled with CFSE and activated for 72
h with plate-bound anti-CD3 (clone 145-2C11) and anti-CD28 (clone 37.51) antibodies
in the presence of plate-bound mouse TARM1-Fc fusion protein or control Fc fusion
proteins. No proliferation was observed as measured by CFSE dilution when TARM1-
Fc was present in the wells (Fig. 8.3).
Although the CFSE dilution assay provided information about the effect of TARM1-
Fc on T cell proliferation, this technique does not allow to assess T cell activation. T
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Figure 8.2: TARM1-2B4-NFAT-GFP reporter cells detect a putative TARM1 ligand
expressed on fibroblasts and T cells. The reporter cells expressed chimeric receptor
composed of the ectodomain of human TARM1 and the CD3ζ cytoplasmic region.
(A) Bulk human TARM1 2B4 reporter cells or control RAET1L 2B4 reporter cell line
and parental (untransduced) 2B4 cells were cocultured overnight with human dermal
fibroblasts (HDF) and GFP induction in reporter cells was assayed by flow cytometry.
(B) Representative plots showing differences in GFP induction by TARM1 2B4 reporter
single cell clones following over night coculture with HDF. Hek293 was used as a control
target cell line. Inset in the top right corner indicates clone number. Clone B4 showed
the highest GFP response. (C) Coculture of TARM1 2B4 clone B4 and control parental
2B4 with a panel of target cell lines. (D) Coculture of TARM1 2B4 clone B4 and control
parental 2B4 with Jurkat cell line and primary mouse CD4+ T cells. The % of GFP+
cells is shown above the gate.






















































Figure 8.3: TARM1-Fc inhibits T cell proliferation. Primary mouse CD4+ T cells
were isolated immunomagnetically by positive selection. Cells were labelled with CFSE
and activated with plate-bound anti-CD3 (clone 145-2C11) and anti-CD28 (clone 37.51)
antibodies in the presence of either plate-bound mouse TARM1-Fc fusion protein or
control human IgG1 or control fusion proteins mouse GpVI-Fc and mouse LairI-Fc.
CFSE dilution was analysed by flow cytometry after 72 h of culture. FIlled histograms
indicate non-activated cells. Open histograms are T cells activated in the presence of
Fc fusion proteins as indicated.
cells that do not enter S-phase following CD3 and CD28 cross-linking may still become
activated and ready to participate in the immune response.
I wished to establish whether in addition to the inhibition of T cell proliferation TARM1
also suppressed T cell activation. Since cell activation and proliferation is accompanied
by an increase in cellular metabolism, I used a tetrazolium dye MTT as a redox indicator
in a metabolic proliferation assay. MTT assay allows multiple measurements to be made
throughout the course of cell stimulation and enables the study of T cell activation
dynamics. Another hallmark of lymphocyte activation is the secretion of IL-2 and the
upregulation of IL-2 receptor alpha chain (CD25) and a C-type lectin CD69. CD69 in
particular is rapidly induced by TCR/CD3 engagement, and can be detected on the cell
surface of activated T cells within 2-3 hours following stimulation (Testi, Phillips, and
LEWIS L Lanier 1989). Therefore the use of a metabolic MTT assay, analysis of IL-2
secretion in combination with flow cytometric analysis of cell surface expression of CD25
and CD69 allow for an accurate determination of T cell activation independent of the
proliferative status (Caruso et al. 1997).
I repeated the experiment in which purified primary mouse CD4+ T cells were activated
as described above in the presence of plate-bound TARM1-Fc fusion protein or hIgG1
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for 90 h and analysed CFSE dilution by flow cytometry. No proliferation was observed
in the presence of TARM1-Fc fusion protein (Fig. 8.4A). MTT assay performed at 0 h,
20 h, 40 h and 80 h time points showed a stark inhibition of T cell metabolic activity
(Fig. 8.4B) in the presence of TARM1-Fc. ELISA assay of IL-2 secretion performed
20 h following activation showed a significant inhibition of secretion in the presence of
TARM1-Fc fusion protein (Fig. 8.4D). No inhibition was observed where human IgG1
was used instead of TARM1-Fc.
The inhibition of T cell response by TARM1- Fc fusion protein could not be attributed to
cytotoxicity as TARM1-Fc had no impact on T cell viability (Fig. 8.4C) as determined
by staining with AnnexinV and PI at 90 h of culture. Viable cells were defined as
AnnexinV-PI-. The decrease in live cell number in the presence of TARM1-Fc fusion
protein was most likely due to the inhibition of T cell activation.
To analyse the effects of TARM1 on the activation of T cells using CD69 and CD25
expression as markers of activation I wished to minimise the impact of cell isolation
procedure. Therefore I used a negative immunomagnetic selection method to obtain
a total splenic T cell population comprised of both CD4+ and CD8+ cells. Cells were
activated with plate-bound α-CD3 antibody, as described above, in the presence of plate-
bound TARM1-Fc or hIgG1 for 3 days. T cell stimulation in the presence of TARM1
resulted in a marked reduction in the frequency of CD69+CD25+ double-positive cells
(Fig. 8.5, left panel) and the total cell-surface expression of CD69 and CD25 (Fig. 8.5,
right panel). The suppression of T cell activation was observed across wide anti-CD3
antibody concentrations (Fig 8.6)
These data indicate that, at least in vitro, TARM1 exerts a suppressive effect on both
T cell activation and proliferative T cell responses.
8.3 TARM1 costimulates proinflammatory cytokine secre-
tion in BMMs and primary neutrophils
In Chapter 6 I showed that TARM1 expression is upregulated on BMM, BMDC and
neutrophils in response to TLR stimulation. ITAM adaptor-associated receptors such as
OSCAR and TREM-1 have been shown to synergise with TLR signalling. Ligation of ei-
ther OSCAR (Merck, Gaillard, Scuiller, et al. 2006) or TREM1 (Bouchon, Dietrich, and












































































































































Figure 8.4: TARM1 inhibits CD4+ T cell activation and
proliferation in vitro. (A) CFSE dilution assay. CD4+
T cells isolated by positive selection from the spleens and
lymph nodes of NOD mice (n=5) were labelled with CFSE
and stimulated with plate bound anti-CD3 (1 µg/ml) and
anti-CD28 (0.25 µg/ml) antibodies in the presence of ei-
ther plate bound TARM1-Fc (10 µg/ml) or control human
IgG1 (10 µg/ml). Proliferation was determined by CFSE
dilution after 90 h of culture. Percent of proliferating cells
was determined by gating on cells that divided at least
once. Statistical analysis was performed using two-tailed t
test, where ∗ ∗ ∗ corresponds to p<0.0001. (B) Metabolic
MTT assay. CD4+ T cells were isolated by negative se-
lection from spleens of NOD mice (n=4) and activated
with plate bound anti-CD3 (1 µg/ml) in the presence of
either plate bound TARM1-Fc (10 µg/ml) or control hu-
man IgG1 (10 µg/ml). T cell activation and proliferation
was determined at 0 h, 20 h, 40 h and 80 h of culture.
(C) TARM1-Fc does not affect T cell viability. T cell via-
bility was determined by flow cytometry using AnnexinV
and PI at 90 h of culture. AnnexinV-PI- cells were consid-
ered viable. (D) TARM1-Fc suppresses IL-2 secretion by
activated CD4+ T cells




























Figure 8.5: TARM1 inhibits upregulation of activation markers CD25 and CD69 by
stimulated T cells in vitro. T cells were isolated by negative selection from spleens of
C57BL/6 mice (n=3) and activated with plate-bound anti-CD3 antibody (1 µg/ml) in
the presence of either plate bound TARM1-Fc (10 µg/ml) or control human IgG1 (10
µg/ml). The plots show percentage of CD25+CD69+ double-positive T cells (left) and
representative histograms of CD69 (top) and CD25 (bottom) expression in the presence
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Figure 8.6: TARM1 inhibits upregulation of activation markers CD25 and CD69
by stimulated T cells in vitro across wide anti-CD3 antibody concentrations. Pan-T
cells were isolated immunomagnetically by negative selection from spleens of C57BL/6
mice (n=2) and activated for 3 days with the indicated concentrations of anti-CD3
antibody in the presence of plate-bound TARM1-Fc (10 µg/ml) or human IgG1 control.
Expression of activation markers was analysed by flow cytometry. The plot shows
percentages of CD25+CD69+ double-positive T cells.
Marco Colonna 2000; Bouchon, Facchetti, et al. 2001) on monocytes and neutrophils was
shown to mediate the secretion of proinflammatory cytokines. Co-ligation of these re-
ceptors in the presence of TLR agonists, particularly LPS, was demonstrated to enhance
TLR-dependent cytokine secretion and the downstream proinflammatory responses of
myeloid cells (A. D. Barrow et al. 2015; Merck, Gaillard, Scuiller, et al. 2006; Bouchon,
Facchetti, et al. 2001). Neutrophils and monocytes that infiltrate human tissues during
bacterial infections as well as peritoneal neutrophils of patients with bacterial sepsis and
mice with experimental LPS-induced shock express high levels of TREM1 (Bouchon,
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Facchetti, et al. 2001). Therefore, the synergistic action of TREM1 and TLRs was im-
plicated in the morbidity of bacterial sepsis (Bouchon, Facchetti, et al. 2001). This was
supported by the finding that the blockade of TREM1 in mice reduced the mortality
from LPS-induced shock (Bouchon, Facchetti, et al. 2001). Because TARM1 expression
was also upregulated by TLR ligands, particularly LPS, I examined whether TARM1 lig-
ation in the presence or absence of TLR agonists in vitro could modulate the secretion of
proinflammatory cytokines by BMMs and neutrophils. For this experiment, neutrophils
were isolated from mouse BM by FACS. It was shown that mouse BM contains large
quantities of mature, functionally competent neutrophils that respond to stimulation in
a comparable manner to the peripheral blood neutrophils (Boxio et al. 2004). To assess
the effects of TARM1 cross-linking, BMMs and primary mouse BM neutrophils were
cultured in tissue culture plates coated with either TARM1-specific antibody or isotype
control (Fig. 8.7). Cross-linking of TARM1 in the absence of TLR agonists did not
stimulate cytokine secretion by either BMMs or neutrophils. However, the concomitant
stimulation of TARM1 and TLR-1/2, -3, -4, and -7 enhanced secretion of the proin-
flammatory cytokines TNF-α and IL-6 by BMMs (Fig. 8.7A). Similarly, stimulation of
TARM1 together with TLR4 enhanced the secretion of TNF-α and IL-6 by neutrophils
(Fig. 8.7B). These results show that TARM1 stimulation cooperates with TLR signalling
to enhance the secretion of proinflammatory cytokines by macrophages and neutrophils
and may play a role in the modulation of cellular responses to pro-inflammatory stimuli.








































































































Figure 8.7: TARM1 costimulates the secretion of proinflammatory cytokines by
macrophages and neutrophils in a TLR-dependent manner. Concentrations of TNF-a or
IL-6 in supernatants derived from (A) BMMs or (B) primary neutrophil cultures stim-
ulated with either immobilised anti-TARM1 (TARM1) specific antibody or rat IgG2a
isotype control (Iso), with or without agonists for TLR-1/2, -3, -4, and -7. ***p ≤
0.001, ****p ≤ 0.0001.
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8.4 Summary
In this chapter I described the generation, validation and use of the TARM1-2B4-NFAT-
GFP reporter system to identify cells expressing a putative extracellular ligand for
TARM1. A screen of a panel of cell lines showed that T cells and fibroblasts induced
a robust GFP response in the TARM1 2B4 reporter cells suggesting that T cells and
fibroblasts may express the ligand for TARM1 receptor.
Next I examined the effects of TARM1 binding to its putative ligand on T cells. I used an
immobilised recombinant TARM1 Fc fusion protein in combination with anti-CD3/anti-
CD28 stimulation to evaluate the activation and proliferation of T cells. The expression
of activation markers CD25 and CD69, IL-2 secretion as well as the metabolic activity of
stimulated T cells were markedly reduced in the presence of TARM1-Fc fusion protein.
In addition, T cell proliferation was also significantly suppressed by TARM1 Fc fusion
protein.
Finally, I evaluated whether TARM1 protein could act as a receptor by transducing
intracellular signals to modulate the function of TARM1-expressing cells such as neu-
trophils and BMM. Cross-linking of TARM1 in the presence of TLR-1/2, -3, -4, and
-7 agonists resulted in enhanced pro-inflammatory response of BMM and neutrophils
evidenced by an increased secretion of TNF-α and IL-6. Interestingly, these cytokines
are critical for the induction and expansion of CD11b+Gr1+ MDSCs in the BM and
their subsequent migration to the periphery (Marigo et al. 2010; Bunt et al. 2007; Sade-
Feldman et al. 2013). In humans, the role of IL-6 in the context of multiple pathologies,
particularly cancer, has attracted a lot of interest in recent years. Chronic inflammation
is now widely accepted as one of the factors facilitating tumour development (Atsumi
et al. 2014; Park et al. 2010) and elevated levels of IL-6 have been found in patients
with a variety of tumours such as prostate, ovarian (Berek et al. 1991) and breast cancer
(Sansone et al. 2007) and is a prognostic factor for poor outcome (Scambia et al. 1995;
Nakashima et al. 2000; Michalaki et al. 2004).
The direct role of IL-6 in tumour progression is complex due to its pleiotropic effects on
both tumour cells and the immune compartment where it can signal in both paracrine
and autocrine manner. In mouse model of obesity-induced hepatocellular carcinoma,
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enhanced production of IL-6 and TNF was shown to lead to the activation of the onco-
genic transcription factor STAT3, whereas ablation of the IL-6 gene prevented tumour
development (Park et al. 2010). In a different model tumour-derived exosomes were
demonstrated to induce STAT3-dependent immunosuppressive function in mouse and
human MDSCs in a TLR2-dependent manner through an autocrine production of IL-6
(Chalmin et al. 2010).
Collectively, these results show that TARM1 functions as a bona fide receptor by binding
to an as yet unidentified extracellular ligand expressed on fibroblasts and T cells and
signalling bidirectionally to inhibit T cell responses while transducing an activating in-
tracellular signal to TARM1-expressing myeloid cells enhancing their responses following
stimulation with TLR agonists.
These data also provide tentative support to the hypothesis proposed in chapter 7 sug-
gesting that mature neutrophils and immature myeloid cells, that could be part of the
MDSC population, upregulate TARM1 following a pro-inflammatory stimulus, migrate
to the peripheral sites where TARM1 may act as a co-regulatory receptor controlling T
cell activation while potentiating the production of IL-6 and TNF-α by myeloid cells.
Extensive functional analysis of TARM1+ cells will be required to establish whether its
expression is indeed associated with regulatory cells such as MDSCs and to determine
the role of TARM1 in their function.
Chapter 9
Discussion
In this work I describe the characterisation of a novel receptor TARM1 encoded within
the leukocyte receptor complex (LRC). My investigation into TARM1 pursued a number
of aims starting with the verification of TARM1 status as a bona fide gene and placing
it within the current phylogenetic and evolutionary context. A further line of research
examined TARM1 protein structure, biochemistry and function including TARM1 post-
translational modifications, association with signalling adaptor proteins, gene expression
profile in vivo and establishing whether TARM1 is a functional receptor capable of
modulating cellular immune responses.
I used computational methods and analyses to examine the genomic organisation and
sequence of the human and mouse TARM1 orthologs; I showed that in both species
TARM1 is extensively conserved in sequence and exon structure and encodes two Ig-like
folds identifying it as a member of the broader IgSF. Similarly to the activating members
of the LRC, TARM1 has a short cytoplasmic tail and encodes a conserved arginine in
its TM, where it may serve as an association site for ITAM-bearing signalling adaptors
such as FcRγ.
Phylogenetic analysis of translated amino acid sequence of the extracellular portion of
TARM1 showed that it is related to other members of the LRC, particularly OSCAR and
SIRL-1. In human, TARM1 shares the highest sequence similarity with the inhibitory
receptor SIRL-1 (Steevels, Lebbink, et al. 2010) (VSTM-1 gene) encoded adjacent to
TARM1. In mouse and rat, Sirl-1 is a pseudogene with no evidence of transcriptional
activity.
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Gene duplication and exon shuffling are among the mechanisms that may have con-
tributed to the evolution of the LRC (A. Barrow and J. Trowsdale 2008). Phylogenetic
analysis of individual Ig-like domains of human and mouse LRC members showed that
the first Ig-like domain of TARM1 in both species clusters with high confidence with
the single Ig-like domain of human SIRL-1 suggesting a common evolutionary origin.
A prominent theme among the LRC-encoded gene families is the clustering of closely
related genes encoding receptors with opposing functions, as exemplified by the acti-
vating and inhibitory KIR and LILR genes. It is possible that SIRL-1 and TARM1
have a common ancestral relationship and have evolved to function antagonistically in
primates.
The genomic location of TARM1 on the centromeric boundary of the LRC in human and
mouse as well as its extensive conservation in mice and humans warranted further analy-
sis of TARM1 phylogenetics and evolution. I identified and analysed the genomic region
of TARM1 in several mammalian orders (Primates, Carnivora, Rodentia, Lagomorpha,
Proboscida and Monotrema) using conserved framework genes. The data indicated that
TARM1 appeared early in mammalian evolution, as evidenced by its presence in the
platypus, and has undergone rounds of expansion and contraction resulting in the birth
and death of the members of the Tarm1 family in different mammalian orders. In
early primates (represented here by the bushbaby) and in the genomes of Carnivora
(cat and dog), Tarm1 has undergone rounds of duplication events, including an inverse
duplication, giving rise to two additional Tarm1 genes.
To enable further characterisation of TARM1 protein, I developed secreted human and
mouse TARM1-Fc fusion proteins to serve as immunogens for the generation of mono-
clonal anti-TARM1 antibodies and to facilitate the study of TARM1 function. I char-
acterised two panels of mAbs against human and mouse TARM1 receptors and selected
several clones optimised for use in flow cytometry and Western blot.
I used the newly characterised monoclonal antibodies to show that TARM1 could be
immunoprecipitated with an ITAM-bearing adaptor FcRγ suggesting it may function as
an activating receptor on TARM1-bearing cells.
RT-PCR screening of mouse and human tissues showed that TARM1 transcript was
highly enriched in the BM. Flow cytometric analysis of mouse BM and other tis-
sues including spleen, PECs, liver and lymph nodes showed that in healthy animals
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TARM1 cell-surface expression was indeed restricted to the BM. Detailed analysis of
the TARM1+ cells showed that they had a prototypical phenotype of granulocytes
CD11b+Ly6G+Ly6C+. Of the total BM granulocytes, over 59% were TARM1+. In
healthy animals, no TARM1 expression was found in the spleen, PECs, liver or lymph
nodes, which could be explained by a low frequency of granulocytes (≤ 1%) in these
tissues in the steady state.
I examined TARM1 cell-surface expression in human BM, spleen, mesenteric lymph
nodes and peripheral blood. The pattern of human TARM1 expression resembled closely
that observed in mouse suggesting evolutionary conservation of TARM1 function. As in
mice, cell-surface TARM1 expression in human tissues was detected predominnatly in the
cell population having the characteristic granulomonocytic phenotype of FSChiSSCint-hi
and CD16+CD3-CD19-. In the BM TARM1 expression was also observed on myeloid
precursor cells that were CD16-CD3-CD19-. A proportion of CD14+ monocytes in the
BM and spleen also had a low-level TARM1 expression.
TARM1 expression could also be detected on mouse BM-derived DCs but not macrophages.
The expression could be strongly upregulated in BMDC and induced in BMM by treat-
ment with TLR agonists. The TLR4 ligand LPS was particularly effective at inducing
high levels of TARM1 transcript and sell-surface receptor expression. Such robust in-
duction points to a potential role for TARM1 in modulating the innate immune response
to gram-negative bacteria.
I explored this hypothesis by studying TARM1 induction in the context of a localised
endotoxin-induced inflammatory response. Intraperitoneal administration of a low-
dose LPS induced a strong upregulation of cell surface TARM1 expression by BM
CD11b+Ly6G+Ly6C+ cells and their migration to the peritoneum. I examined the
morphology of FACS sorted, differentially stained TARM1+ BM cells. This popula-
tion consisted of cells showing ring-shaped or hypersegmented nuclei characteristic of
promyelocytes and mature neutrophils, respectively (Cuenca et al. 2011).
Interestingly, more than 50% of TARM1+ cells that migrated to the peritoneum ex-
pressed MHC II and had a CD11b+Ly6ChiLy6Glo phenotype but lacked the DC/-
macrophage marker CD11c. Given the rapid recruitment to the peritoneum following
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LPS injection, the CD11b+Ly6ChiLy6GloMHC II+TARM1+ cells likely represented in-
flammatory monocytes. These cells were shown to rapidly migrate to sites of inflamma-
tion, where they could give rise to proinflammatory DCs and macrophages (Henderson
et al. 2003) or exert immunosuppressive effects (Geissmann et al. 2010; Serbina and
Pamer 2006; Ribechini et al. 2017; Gallina et al. 2006). It is still poorly understood
what factors govern whether monocytes develop to augment inflammatory responses or
become monocytic suppressor cells. Several studies demonstrated that the progression
towards the immunosuppressive function, often observed during cancer development or
chronic infection, takes place in several stages. Ribechini et al. described a two-stage
process that ”licenses” murine Ly6Chi and human CD14+ monocytes to acquire sup-
pressor functions. This process is initiated by the release of GM-CSF in the absence
of strong activating signals such as IFNγ resulting in structural changes in the IFNγR
pathway. Subsequent exposure of licensed monocytes to IFNγ alone or in combination
with LPS stabilises the expression of inducible nitric oxide synthase (iNOS) in mouse
and indoleamine 2,3-dioxygenase (IDO) in human monocytes leading to their conversion
into suppressor cells (Ribechini et al. 2017). Conversely, in the context of acute inflam-
mation such as sepsis, the presence of pathogen-derived strong activating signals such
as TLR agonists results in classic activation of myeloid cells (Ribechini et al. 2017).
In the model of LPS-induced sterile inflammation, the immune response is mediated
through TLR4 ligation and does not recapitulate all of the complex features of a live
bacterial infection. It was therefore of interest to study the induction of TARM1 expres-
sion and the distribution pattern of TARM1+ cells during systemic bacterial challenge.
I used a live-attenuated vaccine strain of Salmonella in a systemic challenge of C57BL/6
mice. Flow cytometric analysis showed that TARM1 expression followed the infection
dynamics peaking at the height of infection between weeks 1 and 2. In the bone mar-
row TARM1 expression was strongly upregulated on mature granulocytes and immature
myeloid cells. An influx of TARM1+ neutrophils and monocytes was observed in the
spleens of infected mice, where they persisted for the duration of the infection and
maintained an elevated expression of cell-surface TARM1.
Further studies are required to determine whether proinflammatory signalling induced
by TLR ligands other than LPS can regulate human TARM1 cell-surface expression to
the same extent and to determine TARM1 cell and tissue distribution in the context of
human pathologies such as sepsis. The proinflammatory environment has been shown
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to increase neutrophil lifespan (Brach, Gruss, Herrmann, et al. 1992; Colotta et al.
1992), and since TARM1 expression is upregulated by neutrophils in the context of
inflammatory responses, it would be of interest to investigate whether an increased
TARM1 expression (TARMhi) could be the hallmark of neutrophils with enhanced in
vivo lifespans.
Interestingly, the expression of a closely related SIRL-1 receptor in human is also re-
stricted to neutrophils and monocytes, where it plays a role in the negative regulation
of the oxidative burst (Steevels, Avondt, et al. 2013) and can prevent the pathogenic
release of neutrophil extracellular traps in cells from systemic lupus erythematosus pa-
tients (Van Avondt et al. 2013).
The amino acid sequence of the single IgV domain of SIRL-1 is ∼48% identical to the first
Ig-like domain of TARM1. However, owing to its two ITIMs, SIRL-1 exerts inhibitory
effects on neutrophil function (Steevels, Avondt, et al. 2013; Van Avondt et al. 2013),
whereas TARM1 associates with ITAM-bearing adaptor FcRγ, suggesting an activating
function (Daëron et al. 2008). To test the TARM1 signalling potential, I assessed the
outcome of TARM1 crosslinking on FACS sorted mouse BM neutrophils and BMM.
Indeed, TARM1 engagement enhanced the secretion of proinflammatory cytokines by
BMMs and BM neutrophils stimulated with TLR ligands, such as LPS. This supports
the hypothesis that TARM1 functions as a co-stimulatory receptor on immune cells
and is a paired receptor of the inhibitory SIRL-1 receptor. The integration of opposing
signals delivered by TARM1-SIRL1 axis may be essential for balancing of the innate and
adaptive immune cell responses.
A large body of work suggests that both human and mouse neutrophils can be activated
by, and may exert immunoregulatory effects on, T cells (Gosselin et al. 1993; Abdallah
et al. 2011; Alemán et al. 2005; Iking-Konert et al. 2005; Ostanin et al. 2012). Notably,
T cells from the synovial fluid of rheumatoid arthritis patients were shown to activate
neutrophils at the site of inflammation (Iking-Konert et al. 2005). In patients with
renal cell carcinoma, neutrophils were shown to suppress T cell responses through the
release of L-arginine metabolising enzyme arginase I (Rodriguez et al. 2009). Pillay
et al. described a population of human neutrophils that suppress T-cell proliferation
during acute systemic inflammation induced by endotoxin challenge. The inhibition
required cell-contact established via the neutrophil-expressed integrin Mac-1 and was
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mediated by the release of hydrogen peroxide into the immunological synapse formed
with T cells (Pillay et al. 2012). In murine models, the secretion of IL-10 (X. Zhang
et al. 2009; Boari et al. 2012; Doz et al. 2013; Ocuin et al. 2011) and the expression of
programmed death ligand 1 (McNab et al. 2011; Kleijn et al. 2013) have been proposed as
the major components of the immunosuppressive mechanisms employed by neutrophils
during bacterial, fungal and parasitic infections. These suppressive neutrophils have
been shown to attenuate inflammatory monocytes during septic peritonitis (Ocuin et al.
2011), control the inflammatory response of dendritic cells, macrophages, and T cells
(Pillay et al. 2012). In contrast to murine neutrophils, there is no consensus on whether
human neutrophils are capable of IL-10 production and the literature abounds with
conflicting reports (De Santo et al. 2010; Davey et al. 2011). The contradictions could
be related to differences in neutrophil purification methods and experimental conditions.
A recent study showed that a monocyte contamination of less than 1% in preparations
of human neutrophils could be responsible for the bulk of IL-10 secretion (Calzetti et
al. 2017). It was proposed that human neutrophils are incapable of IL-10 production
due to an inactive chromatin configuration at the IL-10 locus (Tamassia et al. 2013).
However, recently it was shown that IL-10 secretion by human neutrophils could be
induced following their direct cell-contact with LPS-treated Treg cells or exposure to
exogenous IL-10. These conditions contributed to chromatin reorganisation at the IL-10
locus enabling gene expression (Lewkowicz et al. 2016).
TARM1 is expressed at high levels on neutrophils during inflammation. Therefore, I ex-
plored whether it could be involved in the neutrophil-mediated T cell regulation. I used
a recombinant TARM1-Fc fusion protein to study T cell responses in vitro. I demon-
strated that the TARM1 receptor ectodomain was capable, at least in vitro, of potently
inhibiting CD3/CD28-induced CD4+ and CD8+ T cell activation and proliferation. I
also demonstrated that TARM1 protein could function as a bona fide receptor by trans-
ducing intracellular signals to modulate the function of TARM1-expressing cells such as
neutrophils and BMM. Cross-linking of TARM1 in the presence of TLR-1/2, -3, -4, and
-7 agonists resulted in enhanced proinflammatory response of BMM and neutrophils as
evidenced by an increased secretion of TNF-α and IL-6. Although these results are en-
couraging, great caution should be exercised in making any inferences about the function
of TARM1 in vivo. The high avidity of recombinant TARM1 Fc fusion protein may not
be physiological and the use of monoclonal antibody as a surrogate ligand to cross-link


















Figure 9.1: Model for TARM1-mediated
bi-directional signalling in the immune sys-
tem. TARM1 receptor signalling syner-
gises with specific inflammatory stimuli, e.g.
TLR agonists, such as Pam3CK4 (TLR1/2),
Poly I:C (TLR3), LPS (TLR4) or Im-
iquimod (TLR7), to enhance the secretion
of proinflammatory cytokines, such as TNF-
α and IL-6, by TARM1-expressing cells.
Conversely, engagement of the TARM1
ectodomain with an as yet unidentified lig-
and (Ligand X) expressed on T cells results
in the inhibition of T cell activation and pro-
liferation.
TARM1 may lead to artificial cellular responses. Further experiments to determine the
TARM1 ligand will be required to confirm these data.
Bearing in mind that TARM1 cell surface expression was rapidly upregulated by neu-
trophils and inflammatory monocytes in vivo during immune challenge, and TARM1+
cells homed to the sites of inflammation, TARM1 may represent a previously uncharac-
terised negative regulator of T cell activation expressed by neutrophils and inflammatory
monocytes, macrophages, and DCs to modulate the early stages of T cell responses while
transducing an activating intracellular signal to TARM1-expressing myeloid cells enhanc-
ing their responses following stimulation with TLR agonists. A schematic depiction of
this model is shown in Figure 9.1. Bidirectional signalling has been previously demon-
strated between myeloid cells and innate lymphocytes, such as NK cells, as exemplified
by the interaction between AICL and NKp80 (Welte et al. 2006). Similarly to TARM1,
the cell surface expression of AICL is also regulated by TLR ligands. The AICL/NKp80
bidirectional signalling interaction resulted in the activation of both NK cells and mono-
cytes, respectively. A TARM1 knock-out mouse or in vivo TARM1 blocking experiments
will be required to truly determine the validity of this model.
In mouse model of S. Typhimurium infection used in this work, TARM1 expression
was also observed on cells showing a classical phenotype of MDSCs (ring-shaped nuclei,
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Figure 9.2: TARM1 is expressed on MDSC-like cells that infiltrate spleen and tumour
mass. Flow cytometric analysis of the expression of TARM1, CD11b, Ly6G, Ly6C and
CD11c on cells from OT1 tumour-bearing and control mice. TARM1 gate was set
relative to isotype control. BM - bone marrow, SP - spleen, Tu - tumour
CD11b+Gr1+). I wanted to explore whether TARM1 expression was indeed associated
with suppressive myeloid cells. The accumulation of MDSCs in tumour-bearing mice
and cancer patients is well-documented in the literature (Youn et al. 2008; Ostrand-
Rosenberg and Sinha 2009).
Therefore, I conducted a preliminary flow cytometric analysis of TARM1 expression
in OT1 mice carrying a T cell-lineage restricted oncogenic gene fusion nucleophosmin -
anaplastic lymphoma kinase (Malcolm et al. 2016) (ex vivo samples were kindly provided
by Dr. CJ Fairbairn). These animals develop spontaneous lymphomas histopathologi-
cally mimicking human anaplastic large cell lymphoma (ALCL) (Malcolm et al. 2016).
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Flow cytometric staining of BM, spleen and the tumour mass showed an expansion of
cells bearing G-MDSC phenotype (CD11b+Ly6GhiLy6Cint) in the BM and their infil-
tration into the spleen and the tumour mass in line with earlier studies. Interestingly,
the majority of TARM1+ cells expressed the G-MDSC phenotype and were present in
the tumour mass Fig. 9.2.
The extent of neutrophilic infiltration in human tumours as well as high neutrophil-
lymphocyte ratio in the blood were identified as the most powerful immunologic predic-
tors of poor prognostic outcome in human oncology (Jensen et al. 2009; Y.-W. Li et al.
2011; Donskov and Maase 2006; Shen et al. 2014). As I described in the Introduction
(page 19), the role of neutrophils in tumourigenesis is complex and multifaceted and their
function changes as tumours evolve (Mishalian et al. 2013). Evidence that emerged from
mouse models suggests that tumour associated neutrophils (TANs) undergo a switch
from a cytotoxic to an immunosuppressive phenotype as the tumour transitions from
early to late stages (Fridlender et al. 2009; Eruslanov et al. 2014; Mishalian et al. 2013).
It is still unclear whether the paradigm of N1 cytotoxic neutrophils and N2 immuno-
suppressive pro-tumourigenic neutrophils applies to human pathologies (Fridlender et
al. 2009). Eruslanov et al. found that early-stage human lung tumours were infiltrated
with APC-like hybrid TANs that could augment or directly stimulate antigen-dependent
and independent memory and effector T cell responses, and capture and cross-present
tumour antigens (Eruslanov et al. 2014; Eruslanov 2017). The authors observed that
TANs present in larger tumours had a diminished ability to stimulate T cells suggesting
that neutrophils undergo a phenotypic and functional switch as the tumour progresses.
The majority of data on human cancers was obtained from late-stage tumours and
describes pro-tumourigenic functions of TANs. For example, neutrophils have been
implicated in promoting tumour angiogenesis and invasiveness by induction of VEGF
expression and the release of matrix metalloproteinases (Ardi et al. 2007; Kuang, Zhao,
Wu, et al. 2011; Shamamian et al. 2001).
These findings warrant further research into the role of TARM1 on neutrophils and
present the exciting possibility of using TARM1 (or its ligand) as a pharmaceutical target
to regulate or selectively deplete TARM1-expressing cells such as MDSCs and activated
neutrophils or to control T cell responses by targeting TARM1 ligand. This approach
would be highly relevant in numerous pathologies caused by excessive or aberrant T cell
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activation such as in autoimmune and inflammatory conditions or pathological MDSC-
mediated T cell suppression as observed in cancer patients.
The identification of the inhibitory TARM1 ligand expressed on T cells will be a crucial
next step that could help shed light on as yet uncharacterised mechanisms of T cell
regulation.
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